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Tumour development is defined as a process in which cells constantly accumulate genetic 
mutations and epigenetic alterations. However, there is growing evidence that the tumour 
microenvironment including the extracellular matrix (ECM) also affects cancer cells survival, 
proliferation, growth, invasion and metastasis through cell-ECM interaction, cytokines, and 
growth factors. In addition, it is suggested that cancer cells rely on extracellular proteins 
during starvation, which is often observed in the tumour microenvironment due to elevated 
tumour growth rate and limited blood supply. Nonetheless, the role of ECM internalisation in 
cancer metabolism and regulatory mechanisms of this process have not been addressed in 
detail yet. Here we explored the role of ECM trafficking in terms of controlling breast cancer 
growth and survival. Our data demonstrate that the mechanisms through which cell-ECM 
interaction affects cancer cell growth varies by different starvation conditions. Under amino 
acid (AA) depletion, the presence of ECM could partially rescue the growth of invasive breast 
cancer cells (MDA-MB-231). Breast cancer cells were able to internalize and degrade collagen 
I and Matrigel under AA deficiency. In addition, inhibition of ECM uptake prevented cell 
growth under starvation. Our data show that presence of collagen I and Matrigel promotes 
cellular anabolic activity under AA starvation conditions by inducing mTORC1 activity. Mass-
spectrometry data from AA starved cells on ECMs demonstrated significant increase in AA 
content as well as the upregulation of different metabolic pathways including phenylalanine 
and tyrosine metabolism, potentially increasing energy content of cells via fumarate 
formation. The data under non-essential AA (NEAA) starvation was also consistent to the AA 
starvation as cells required ECM internalization to rescue their growth. Monitoring candidate 
genes participating in ECM trafficking revealed three genes, RIN3, MAKP8IP3 and AP3D1 
potentially having important role in trafficking of the ECM to the lysosome since their lack of 
function had adverse impact on invasive breast cancer cell growth under the NEAA deficiency. 
Under Glucose (Glc) starvation, MDA-MB-231 showed higher growth rate on ECM compared 
to the plastic. They could internalize ECM followed by lysosomal degradation. However, lack 
of ECM uptake did not oppose their growth. Whereas inhibition of focal adhesion kinase (FAK) 
activity substantially reduced their growth rate. Presence of ECM also enhanced mTORC1 
activity in Glc starved cells. In contrast, ECM did not change metabolic content of cells after 
six days of Glc depletion. Thus, it is possible that the presence of ECM can trigger signalling 
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pathways downstream of FAK inducing mTORC1 activity and cell growth. These findings lead 
to the conclusion that the presence of ECM could facilitate cancer cells growth/survival in 
nutrient deficient conditions via various mechanisms. There are different types of tumours 
that are surrounded by a dense and fibrotic stroma including breast, lung, pancreatic, and 
colon tumours. Therefore, the findings of this study could potentially be generalised to other 
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Chapter 1: Introduction 
1.1 Hallmarks of cancer 
 
Cancer cells are characterised by ten common traits causing their transformation to 
tumorigenic and finally malignant cells. These traits are called “Hallmarks of cancer” 
permitting these cells to survive, proliferate and migrate at different levels of cancer 
progression (Figure 1.1) (Hanahan and Weinberg, 2011). 
 
 
Figure 1.1. Hallmarks of Cancer. Hallmarks of Cancer are ten biological capabilities cells acquire during 
tumour development. Genome instability and tumour promoting inflammation are two hallmarks that 
enable cancer cells to obtain rest of the characteristics including evading growth suppressors, avoiding 
immune destruction, enabling replicative mortality, activating invasion and metastasis, inducing 
angiogenesis, resisting cell death, deregulating cellular energetics, and sustaining proliferative 
signalling (Figure is adapted from (Hanahan and Weinberg, 2011)).  
 
Two of these hallmarks enabling cancer cells to acquire rest of the characteristics are: 
1. Genome instability/mutation. Susceptibility of cells to mutagenic compounds, defects 
in DNA maintenance machinery, as well as deficiency in the system that monitor 
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genome integrity result in genome instability and mutation (Jackson and Bartek, 2009, 
Negrini et al., 2010).   
2. Tumour promoting inflammation. Even though inflammation in the tumour 
microenvironment was interpreted as a sign of immune system attack to the 
neoplastic cells, it has a very paradoxical activity in favour of tumours. Inflammation 
is managed by immune cells around the tumour releasing mitogenic molecules, pro-
angiogenic factors and enzymes that modify extracellular matrix (ECM) to promote 
cancer cells’ metastasis and invasion. Therefore, inflammation could facilitate the 
emergence of other features of cancer cells (DeNardo et al., 2010, Grivennikov et al., 
2010, Hanahan and Weinberg, 2011).  
In addition to genomic changes, the property of microenvironment around the tumours 
enables cancer cells to obtain the tumorigenic characteristics being briefly explained in the 
following sections. 
1.1.1 Sustaining proliferative signalling. 
One of the main features that discriminate cancer cells from normal cells is their ability of 
continuous proliferation and ultimately destruction of the tissue architecture. Cancer cells go 
through continuous proliferation by different mechanisms. Some of them constantly release 
growth factors (GFs) and benefit from autocrine growth stimulation. Some cancer cells 
release signalling molecules that induce normal stroma cells to release GFs in their micro-
environment.  They could also benefit from over-expression of their GF receptors making 
them over-sensitive to signalling molecules. In addition, there might be some structural 
alteration in the receptors that keep them constantly triggered (Hanahan and Weinberg, 
2011, Bhowmick et al., 2004, Cheng et al., 2008). The tumour micro-environment (TME) also 
plays a critical role in terms of cancer cell proliferation. Angiogenesis in the TME provides a 
route for cancer cells to receive blood-born mitogenic GFs. It also facilitates the transfer and 
infiltration of specific types of leukocytes releasing different types of growth mediators 
including histamine, interleukins (ILs), heparins, transforming growth factor-β (TGF-β), 
epidermal growth factor (EGF) and fibroblast growth factor (FGF). These growth mediators 
induce the proliferation and division of neoplastic and normal cells in the vicinity of the TME. 
Infiltrated leukocytes also release proteolytic enzymes modifying ECM to make the mitogenic 
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factors more available (Balkwill et al., 2005, Lu et al., 2011). Cancer associated fibroblast cells 
(CAFs) are also in charge of releasing various types of growth mediators such as EGF, insulin-
like growth factor -1(IGF-1) and FGFs. Therefore, alongside gene mutation in cancer cells, the 
TME also provides a pro-proliferative environment for them (Hanahan and Coussens, 2012).   
1.1.2 Evading growth suppressors 
 Cancer cells stop the function of genes called tumour suppressor genes negatively regulating 
cell proliferation. Two most important tumour suppressor genes are retinoblastoma-
associated (RB) and TP53. RB works as a cell cycle gatekeeper and inhibits G1 to S transition 
based on mostly external growth-inhibitory signals. While TP53 perceives different 
abnormalities and stresses inside the cell and stops cell proliferation or induces cell apoptosis 
based on the intensity of the damages (Hanahan and Weinberg, 2011). Another mechanism 
that in normal cells regulates proliferation is ‘contact inhibition’. Contact inhibition stops cell 
proliferation when cells make a confluent monolayer. Even though contact inhibition was 
firstly found as an in vitro mechanism, it could be generalized to in vivo (Stramer and Mayor, 
2017). Different mechanisms have been suggested for contact inhibition. For example, a 
tumour suppressor gene (NF2) triggers contact inhibition through coupling transmembrane 
tyrosine kinase receptors with cell surface adhesion molecules to increase cell-cell 
attachment and limit the access of GFs to their receptors (Curto et al., 2007, Okada et al., 
2005).  
1.1.3 Resisting cell death 
Mammalian cells are exposed to different disturbances inside the cell or in their 
microenvironment inducing signalling pathways that result in cell death. There are different 
types of cell death. Apoptosis is a programmed cell death which is highly regulated. There are 
biochemical events happening during apoptosis that result in cell death including cytoplasm 
shrinkage, nuclear fragmentation, and chromatin condensation that all accumulate in the 
apoptosis body being absorbed by other cells in their neighbourhood. Apoptosis could occur 
in response to DNA damage or depletion of survival factor signalling (Galluzzi et al., 2018). To 
avoid apoptosis, cancer cells upregulate anti-apoptotic, and survival signalling factors or 
downregulate pro-apoptotic proteins. In addition, loss of function for tumour suppressor 
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genes like TP53 cause disruption in sensing DNA damage and skipping apoptosis (Adams and 
Cory, 2007, Hanahan and Weinberg, 2011, Junttila and Evan, 2009, Lowe et al., 2004). 
Autophagic cell death is another type of death that happens when cells remove dysfunctional 
organelle through autophagosome fuse with lysosome. Autophagy can be a pro or anti 
tumorigenic process. In some types of cancer cells, autophagy is used as a cell death 
mechanism. Prolonged autophagy results in excessive degradation and damage of organelles 
and eventually cell death (Mathew et al., 2007). However, in other cancer cells like pancreatic 
cancer cells, the high demand of nutrients in proliferating cells can be met by autophagy, 
through nutrient recycling and protein degradation (Yang et al., 2011). Necrosis is a type of 
cell death that happens due to irreversible cell injury. During necrosis, no phagocytosis or 
lysosomal integration happens. In contrast to autophagy and apoptosis, necrosis works in 
favour of neoplastic cells (Galluzzi and Kroemer, 2008). Debris from necrotic cells could be 
consumed as a source of energy by proliferative cells in their neighbourhood. Necrotic cells 
also release some proinflammatory signals attracting immune cells, which have a tumour 
promoting effect (White et al., 2010). In addition, necrotic cells themselves might release 
some mitogenic factors that induce proliferation (Galluzzi and Kroemer, 2008, Grivennikov et 
al., 2010, White et al., 2010). CAFs could also assist cancer cells to avoid apoptosis. CAFs 
release some pro-survival factors such as IGF-1 and IGF-2. Moreover, they deposit and 
remodel ECMs in a way that they could make survival signals available for the cells in their 
vicinity (Lu et al., 2011).  
1.1.4 Enabling replicative immortality. 
To make a tumour, cancer cells need to cross the barriers against their unlimited proliferation. 
There is different evidence showing that telomeres, a region of hexanucleotide repeats at the 
end of the chromosomes, are involved in cancer cell consistent division. In normal cells, every 
proliferation result in shortening of telomeres. Hence, cells after a limited number of divisions 
enter a senescence phase in which they are still alive but non-proliferative. If telomere 
erosion happens causing genome instability, cells face a crisis phase and die. However, in vitro 
cell culture gives rise to the cells surviving the crisis phase and having non-stopped division. 
These cells are called immortalized. Cancer cells work like immortalized cells. They evade the 
crisis phase and instead keep proliferating. This ability of neoplastic cells is linked to the 
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expression of telomerase enzymes. Telomerase enzyme in immortalized or cancer cells 
protects telomeres from degradation and chromosomal fusion during DNA replication 
resulting in unlimited division and skipping the crisis phase (Blasco, 2005, Hanahan and 
Weinberg, 2011, Shay and Wright, 2000, Prasad et al., 2020).  
1.1.5 Inducing angiogenesis 
In normal tissue, angiogenesis does not happen unless due to wound healing or women’s 
menstrual cycle. However, tumour growth and metastasis are highly dependent on 
angiogenesis. Highly proliferative neoplastic cells need vasculature to receive nutrients and 
oxygen and remove their metabolic wastes. Vasculature formation happens either de novo, 
called vasculogenesis, or through sprouting of pre-existing vessels, called angiogenesis. 
Angiogenesis is stimulated as a response to cancer cells' need for oxygen and nutrients. 
Various types of signalling molecules have been identified as an angiogenesis activator 
including vascular endothelial growth factor (VEGF), TGF-β, FGF and tumour necrosis factors 
(TNF). Both up regulation of angiogenesis factors and down regulation of angiogenesis 
inhibitors are needed for this process (Carmeliet, 2005, Hanahan and Weinberg, 2011, Nishida 
et al., 2006). Even though cellular and molecular procedures are the same in both normal and 
oncogenic angiogenesis, tumour blood vessels are highly branched, leaky, enlarged with 
inconsistent blood flow in the TME (Nagy et al., 2010, Baluk et al., 2005). There is also 
evidence that CAFs are involved in regulating tumours’ angiogenesis. ECMs derived from CAFs 
can sequester signalling molecules and angiogenesis activators.  In addition, introducing ECM 
remodelling enzymes such as MMPs facilitate the accessibility of angiogenic mediators for the 
cancer cells. CAFs themselves are also responsible of producing angiogenesis signalling factors 
such as FGF, VEGF and platelet derived growth factors (PDGF) (Crawford et al., 2009, Kalluri 
and Zeisberg, 2006, Rasanen and Vaheri, 2010).  
1.1.6 Invasion and metastasis  
In the process of metastasis, carcinoma cells go through epithelial mesenchymal transition 
(EMT). During EMT cancer cells lose their adherens junctions (E-cadherin); release protease 
for ECM degradation and achieve fibroblastic morphology. These biological changes allow 
cancer cells to progress through the metastatic cascade composed of local invasion, 
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intravasation, extravasation, formation of micro- and finally macro-tumour in distant organs 
(Berx and van Roy, 2009, Hanahan and Weinberg, 2011, Peinado et al., 2011, Sabeh et al., 
2009, Talmadge and Fidler, 2010). Stroma cells in the TME also facilitate cancer cells invasion. 
Releasing VEGF not only induces angiogenesis, but also its interaction with VEGF receptor 2 
(VEGFR2) on endothelial cells relaxes the tight junction between them. Loose junction induces 
blood leakage and as a result facilitate intravasation of cancer cells (Peinado et al., 2011). The 
same process could happen during cancer cells extravasation. Infiltrating immune cells (IICs) 
also provides different types of proteases for remodelling and degrading ECMs, thus creating 
a path for cell metastasis (Lu et al., 2011). Macrophages also provide chemo-attraction to 
facilitate intravasation through releasing EGF (Qian and Pollard, 2010). CAFs play an important 
role in cell invasion. Providing metastasis path is mainly responsible for CAFs through 
depositing ECMs. In addition, CAFs induce invasion and EMT through releasing signalling 
molecules such as hepatocyte growth factor (HGF) and TGF-β (Chaffer and Weinberg, 2011, 
Hanahan and Coussens, 2012, Kessenbrock et al., 2010).   
1.1.7 Evading immune destruction  
It is believed that the immune system could monitor and destroy cells commencing 
tumorigenic transformation. Cancer cells can develop mechanisms to protect themselves 
from the immune system. There are some studies showing that mice with deficiency in some 
of their immune system components more frequently develop tumours compared to the 
normal mice (Hanahan and Weinberg, 2011, Kim et al., 2007, Teng et al., 2008). It is suggested 
that immunogenic tumours would be eradicated in immunocompetent hosts; while their 
weak immunogenic counterparts are able to hide from the immune system and grow in both 
immunocompetent and immunodeficient hosts (Smyth et al., 2006).  There are also studies 
showing that in some types of cancers like ovarian and colon cancers, infiltration of cytotoxic 
T cells (CTL) and Natural killer (NK) cells into the TME improves the prognosis (Pages et al., 
2010, Nelson, 2008). However, some immunogenic tumours acquire the ability to neutralize 
the immune destructive effect of CTLs or NK cells by releasing immunosuppressive factors like 
TGF-β (Shields et al., 2010, Yang and Weinberg, 2008). CAFs in the TME produce 
immunosuppressive factors such as TGF-β; and induce recruitment of IICs by releasing 
chemokines. IICs use different immunosuppressive mechanisms to neutralize the anti-
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tumorigenic effect of NKs and CTLs. In addition, aberrant angiogenesis cannot provide an 
efficient route toward the tumour for cytotoxic cells such as CTLs and NKs. (Onrust et al., 
1996, Ruffell et al., 2012, Stover et al., 2007).    
Tumours benefit from all cancer hallmarks, plus ‘reprogramming energy metabolism’ 
described in detail in section 1.4. However, each type of cancer shows specific properties 
which should be considered for the development of therapies. In the following section, 
characteristics of breast cancer will be explained in more detail.    
 
1.2 Breast cancer 
1.2.1 Incidence 
Breast cancer is the most common type of cancer among women. In 2012 around 1.7 million 
women were diagnosed with breast cancer with 521,900 deaths worldwide. Between 1980 
to 1990 in western countries the incidence of breast cancer was around 30%. However, due 
to changes in reproduction pattern and availability of diagnostic techniques such as 
mammography, the mortality rate is decreasing or being stabilized (Coughlin, 2019). In 2016, 
in the United Kingdom (UK), 54,960 cases of breast cancer were diagnosed which was 15.2% 
of all the cancers (Excluding non-melanoma skin cancer) diagnosed in the same year (National 
Disease Registration Service, 2020). Studies over a decade in the UK, between 1993-1995 and 
2015-2017 shows that the incidence of breast cancer increased around 23% among women; 
and women aged between 65 to 69 showed the highest increase, 69%. Even though the 
incidence of breast cancer is increasing, the mortality rate has decreased around 19% in 
women over the past decade. The mortality rate between 2015 to 2017 was around 11,400 
per year (Cancer Research UK, 2020). Breast cancer is a very heterogeneous disease, it could 
vary by alteration in oncogene and tumour suppressor genes, hormone and GF receptor 
expression, histological phenotype, molecular biomarkers and the TME. Identifying the 
molecular and cellular characteristics of breast cancer heterogeneity could help to find more 
specific treatment (Turashvili and Brogi, 2017).   
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1.2.2 Breast cancer classification 
Historically, classification of breast cancer was based on the cancer grade and histological 
types. In the grading system three factors are considered including tubule formation, nuclear 
pleomorphism, and mitotic count, which was first established by Bloom and Richardson 
(Bloom and Richardson, 1957). Cells are scored 1-3 for each category based on poor tubular 
formation, high pleomorphism and high mitotic count normalized by microscope field. Based 
on the scoring, cells fall into three categories called grade 1,2 or 3. Grade 1 cells show highest 
differentiation while grade 3 has the lowest differentiation rate. Grading can help to choose 
suitable therapy and predict the outcome (Vuong et al., 2014).  Recently, other factors are 
considered in terms of tumour characteristics and therapy outcome. Expression of hormone 
receptors including oestrogen (ER) and progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) are used to evaluate prognosis and cancer response to some 
endocrine treatments (Vuong et al., 2014). 
1.2.2.1 Molecular classification 
Gene expression analysis of breast cancer cells through cDNA microarray sub-divide them into 
different groups showing various characteristics in terms of expression of different receptors, 
proliferation rate, and their response to various therapies. Gene expression analysis classifies 
breast cancer cells to four different molecular subtypes including luminal A, luminal B, basal 
like and HER-2 enriched. Luminal A and B both are ER positive. However, Luminal B over-
expresses genes associated with proliferation, such as Ki-67. Hence, it is higher grade with 
poorer prognosis compared to luminal A.  HER-2 receptors could be expressed alongside ER 
and PR and these tumours are subcategorized as Luminal B. While HER-2 overexpression with 
ER-/PR- is categorized as HER-2 enriched subtype. Overexpression of HER-2 and genes 
associated with proliferation in HER-2 enriched tumours result in high grade and poor 
outcome. Basal-like groups are named after basal epithelial cells as they have high similarity 
in their gene expression. In addition, they are triple negative and express none of the 
receptors which help them to escape from treatments targeting hormone receptors and HER-
2 (Table 1.1) (Sorlie et al., 2001, Sorlie et al., 2003). Further efforts in terms of classification 
result in addition of two more ER negative breast cancer subtypes including claudin-low 
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tumours which are triple negative and apocrine tumours which are positive for androgen 
receptor (AR) (Prat et al., 2010, Farmer et al., 2005).  




















Luminal B 2-3 ER+ 
PR+ 
HER2+ 
or HER2- with 
high Ki-67 
20% of invasive 
breast cancer, 
higher proliferation 
than luminal A. 
Response to 
endocrine treatment 
not as good as 
luminal A. Worse 
prognosis compared 
to luminal A. 
HER-2 enriched 2-3 ER- 
PR- 
HER2+ 
15% of invasive 







Basal-like  3-3 Triple  
negative 
~15% of invasive 









 Table1.1 Characteristics of major molecular subtype of breast cancer (Vuong et al., 2014, 
Eliyatkin et al., 2015, Tang et al., 2016b). 
 
1.2.2.2 Clinical classification 
Decisions about the best effective way of treatment in breast cancer mainly rely on expression 
of hormone receptors (HR). Endocrine therapy improved the survival rate of patients to at 
least five years. However, the battle against resistance to the therapy, recurrence of the 
disease and triple negative cells is still on.   
1.2.2.2.1 ER positive and HER-2 negative breast cancer 
Around 85% of breast cancer tumours are HR+ expressing ER and or PR. There are two types 
of ER, α and β. ERα is one of the main markers of cancer prognosis. ER is located in either 
plasma membrane or cytoplasm. Binding of oestrogen to ER triggers its translocation to the 
28 
 
nucleus where it binds to the oestrogen responsive element (ERE) of promoters to induce 
downstream gene expression.  This process makes the HR+ cells vulnerable to the ER 
inhibitors such as tamoxifen, that binds to ER and inhibits its proliferative effect; or aromatase 
inhibitors (AIs), that stop aromatase enzyme from catalysing the conversion of androgen into 
oestrogen (Tang et al., 2016b, Burns and Korach, 2012). However, 20% to 30% of the ER+ 
breast cancer will show resistance to the therapy. This resistance could be de novo, primary 
resistance with no previous treatment, or appear over a long time that tumours are being 
exposed to the therapy (Ring and Dowsett, 2004, Nass and Kalinski, 2015, Tang et al., 2016b).  
1.2.2.2.2 HER-2 positive breast cancer 
Around 20% of breast cancer tumours are HER-2+. HER-2 is a tyrosine kinase transmembrane 
receptor. Overexpression of HER-2 receptors make the cancer cells more responsive to the 
GFs including EGF. Therefore, HER-2+ cells are more aggressive and proliferative compared to 
the ER+/HER-2- cells (Pegram et al., 2004, O'Shaughnessy, 2005). On the other hand, HER-2+ 
cells are more susceptible to the HER-2 inhibitors such as monoclonal antibodies including 
trastuzumab and pertuzumab, or tyrosine kinase inhibitors including lapatinib (Tang et al., 
2016b). Trastuzumab mechanism of action is to bind to the extracellular domain of HER-2 and 
inhibit tyrosine kinase activity of the intracellular domain, resulting in changes in the 
transcription of genes linked to cell proliferation and survival. In addition, trastuzumab could 
induce the destruction of cancer cells through immune cell recruitment (Hudis, 2007). Around 
65% of patients being treated by trastuzumab show de novo resistance, and 70% of patients 
with early response to the therapy will develop resistance later (Vu and Claret, 2012). There 
is also an aberrant type of HER-2+ that does not contain the extracellular domain and is 
constitutively active. Presence of this type of HER-2+ is associated usually with 
aggressiveness, poor outcome, and resistance to trastuzumab therapy (Scaltriti et al., 2007, 
Arribas et al., 2011).  
1.2.2.2.3 Triple negative breast cancer 
Around 15% of the population of breast cancer is triple negative (TNBC). TNBC is a type of 
cancer that is HR and HER-2 negative. Therefore, targeting receptors through endocrine 
therapy or HER-2 inhibitors cannot be used as an effective mode of treatment. Patients with 
TNBC suffer from poor prognosis due to high tumour grade, higher rate of recurrence and 
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lack of targeted therapy (Dent et al., 2007, Anders and Carey, 2008). It has been a challenge 
to find markers for TNBC. Androgen receptors are expressed in 40% of TNBC. AR inhibition in 
TNBC decreases tumour growth (Giovannelli et al., 2018). EGF receptor (EGFR) is another 
target as 60% of TNBC express EGFR (Brand et al., 2014). Poly (ADP-ribose) polymerase 
(PARP1) enzyme can also be targeted to induce cell death. PARP1 is associated with molecular 
pathways that result in DNA damage repair. When PARP1 is inhibited, an alternative 
mechanism called homologous recombination is used to repair DNA. Both BRCA1 and BRCA2 
are engaged in this process. BRCA1 mutation is associated with TNBC type of cancer making 
them responsive to PARP1 inhibition and DNA damage accumulation result in cell death 
(Anders and Carey, 2008). Common therapy for TNBC is combination of surgery, radiotherapy, 
and chemotherapy. However, TNBC could become resistant in response to some 
chemotherapy (Perez, 2009).  Therefore, more studies are needed to find specific targets for 
efficient treatment of TNBC.   
1.2.3 Models for study breast cancer 
Evolution of breast cancer as an heterogenous disease is due to different genetic changes 
such as mutation, copy number amplification, rearrangement, and epigenetic alteration. 
Breast cancer progression starts from benign hyperplasia of epithelial cells of mammary 
ducts, developing to atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), DCIS 
with microinvasion and invasive ductal cancer (Figure 1.2). To have a proper model to study 
the stages from normal epithelial to malignant cells, a series of human cell lines, MCF10, are 
used. MCF10-M are mortal epithelial cells taken from a patient with fibrocystic breast. To 
have a stable cell line, two immortalized cell lines, MCF10A (attached cells) and MCF10F 
(floating cells) have been originated from spontaneous immortalization of MCF10-M (Dawson 
et al., 1996, Rhee et al., 2008, So et al., 2012). MCF10A belongs to a Basal-like molecular 
subtype due to the lack of ER, PR and HER2 expression (Soule et al., 1990, Subik et al., 2010). 
MCF10A cells are still categorized as normal due to their inability in making tumours in 
immunodeficient mice, lack of anchorage-independent growth, relying on GFs and hormones 
to grow in the cell culture (Soule et al., 1990). Nonetheless, transfection of MCF10A cells with 
constitutively active HRAS gives rise to cells with benign proliferation (MCF-10AT1 and MCF-
10AT1 kcl2) which generate lesions similar to ADH. MCF-10AT1 cells have a non-invasive 
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derivative, MCF-10DCIS.com cell line, which form lesions like DCIS; and, invasive ones, MCF-
10CA1a (MCF-10CA1h cl2, MCF-10CA1d cl1 and MCF-10CA1a cl1), which are able to make 
invasive ductal carcinomas (Rhee et al., 2008, So et al., 2012).  
 
Figure 1.2. Schematic image of breast cancer progression. Cancer cell growth starts from benign 
hyperplasia of epithelial cells of mammary ducts, then it evolves to atypical ductal hyperplasia, with a 
little abnormality in cell shape, ductal carcinoma in situ with cells showing features of cancer cells. 
And at the end they acquire invasive ductal cancer phenotype. Image is “Created with 
BioRender.com.” 
 
Different genetic changes in proto-oncogenes and tumour suppressor genes induce the 
mentioned transformations. Constitutive activation of HRAS in non-malignant mammary 
epithelial cells gives rise to benign MCF-10AT1, as mentioned above. However, to acquire the 
invasive characteristics of MCF10CA1a cells, further induction of C-Myc, cyclin D and insulin 
like growth factor I receptor (IGF-IR) are needed. These proteins are respectively in charge of 
regulation of cell proliferation, cell cycle, and breast cancer cell growth and survival. Erk1/2, 
Akt, signal transducer and activator of transcription 3 (Stat3), and Pak4 are other signalling 
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molecules highly expressed in the invasive cell line, MCF10CA1a. These are believed to be 
responsible for cell cycle progression and motility through mediating cellular response to 
external signalling factors such as cytokines and GFs (Rhee et al., 2008, So et al., 2012).  
Therefore, MCF10 cell lines can be used as a model to evaluate the activity of different 
signalling pathways and the effect of therapeutics at different stages of cancer progression 
and during their transition from localised to invasive cancer. In addition, working on cell lines 
being categorized as TNBC gives this opportunity to discover specific targets to develop novel 
treatments against this subtype.  
There are other cell lines, including MDA-MB-231, MDA-MB-231-UR, MCF-12A, HBL101, 
HS598T, BT-20, MCF-10F, 468 and BT-48, that fall into Basal-like subtype because of them 
being negative for ER, PR, HER-2 expression while expressing EGFR. All these cell lines can 
facilitate targeting TNBC (Subik et al., 2010). For instance, among these cell lines, MDA-MB-
231 is a very aggressive and metastatic cell line that 100% expresses Ki-67, a proliferation 
marker. MDA-MB-231 cell line was first isolated from pleural effusions from a breast cancer 
patient (Cailleau et al., 1974). Their high proliferation and invasion rate make MDA-MB-231 
cells a desirable model to identify genes participating in metastasis and identify their 
interaction with the TME inside the breast as a primary tumour or distant tissues as a 
secondary tumour (Minn et al., 2005).  
Acquiring cancer properties is not confined to genetic changes. Interaction with stroma cells 
and extracellular proteins facilitate tumour progression as well. Thus, both genetic alteration 
in epithelial cells and the TME can be considered as stimuli for growth, invasion, and 
metastasis (Bergamaschi et al., 2008).   
1.3 The tumour microenvironment  
Tumour development comprises acquiring the fundamental changes in cancer cells, described 
by Hanahan and Weinberg and summarised in section 1.1. Even though these developments 
are direct result of genome instability in cancer cells, host response to these changes results 
in development of tumour tissue consisting of host cells and ECM scaffolds called TME 
(Hanahan and Weinberg, 2011, Hanahan and Coussens, 2012). The TME is composed of non-
malignant cells arranged in a dynamic network of ECM working in mutual close contact with 
cancer cells to promote their malignancy.  The cellular components of the TME comprise cells 
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from the immune system, endothelial cells, pericytes, blood cells, adipocytes, mesenchymal 
stroma cells and fibroblasts. At an early stage of tumour development, the TME negatively 
regulates tumour growth. However, tumours reciprocal interaction with the TME has 
manipulative effect in favour of cancer cells (Maman and Witz, 2018, Zhuang et al., 2019, 
Valkenburg et al., 2018). ECM deposition and remodelling by fibroblasts help cell invasion and 
make the signalling molecules trapped in the ECM available. Endothelial cells and pericytes 
facilitate angiogenesis and metastasis. Adipocytes release GFs and cytokines. Immune cells 
induce EMT and help cancer cells to hide from killer cells and acquired immune surveillance 
(Brown, 2014, Hida et al., 2013, Ruffell and Coussens, 2015, van Beijnum et al., 2015, Choi et 
al., 2018, Kozin et al., 2010). In the past decade, the TME has been considered as an important 
target for the cancer therapy (Turley et al., 2015). 
1.3.1 Cancer associated fibroblasts 
Fibroblasts are spindle-like cells with mesenchymal origin. Fibroblasts are the main source of 
ECM production. However, they are normally quiescent and located in connective tissues 
among ECM fibres. In response to chronic and acute inflammation, wound healing and 
fibrosis, fibroblasts become activated. Activated fibroblasts, known as myofibroblast, are 
morphologically and molecularly different from the quiescent ones (Liu et al., 2019, Kalluri, 
2016).  Activated fibroblasts express myofibroblast markers, α-Smooth muscle actin (αSMA), 
platelet-derived growth factor receptor beta (PDGFRβ) and fibroblast activation protein 
(FAP). They have a stellate shape. They are metabolically active, proliferative, and migratory. 
Once fibroblasts are activated, they release chemokines and cytokines, recruit immune cells, 
produce, and remodel ECM, and provide physical forces to obtain tissue architecture and 
homeostasis (Kalluri, 2016, Poltavets et al., 2018).   
CAFs are the active form of fibroblasts and the most abundant cellular component of the TME. 
Release of GFs such as TGFβ, FGF2 and PDGF from tumour cells induce recruitment of 
fibroblasts and their transformation to CAFs (Nissen et al., 2019). High concentration of CAFs 
in the TME is usually correlated to poor prognosis in different cancers including breast cancer 
(Surowiak et al., 2007, Kellermann et al., 2007). CAFs could also originate from non-fibroblast 
cell types.  Epithelial and endothelial cells can go through mesenchymal transition, adopt 
fibroblast phenotype, and express fibroblast specific protein 1 (Iwano et al., 2002, Zeisberg et 
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al., 2007). It was also shown that exposure of adipose-derived stem cells to conditioned media 
from breast cancer cells containing TGFβ1 differentiate them to CAF (Jotzu et al., 2010). 
Fibrocytes, mesenchymal cells originated from monocytes and mesenchymal stem cells 
originated from the bone marrow could be also recruited in the TME and transformed into 
CAFs (Barth et al., 2002, Jung et al., 2013, Zhu et al., 2014). Compared to activated fibroblasts, 
CAFs express higher amount of myofibroblast markers, and increase synthesis and 
remodelling of collagen and other ECM components (Kalluri and Zeisberg, 2006). CAFs can 
release different types of GFs and pro-inflammatory cytokines to induce angiogenesis and 
recruit more immunosuppressive cells into the tumour niche to affect cancer cell 
proliferation, migration, angiogenesis, and immune surveillance (Ahmadzadeh and 
Rosenberg, 2005, Feig et al., 2013, Nissen et al., 2019). The major job of CAFs in the TME is 
contributing to the synthesis of fibrous tissue (desmoplasia) around the tumour and 
remodelling of the ECM. CAFs increase the release of matrix metalloproteinase (MMPs) and 
lysyl oxidase (LOX) proteins to induce collagen cross-linking, re-alignment, and fibre 
elongation (Pankova et al., 2016, Hanley et al., 2016). Desmoplastic stroma around the tissue 
usually corelate to poor prognosis and severe cancer (Saadi et al., 2010, Surowiak et al., 2007).  
1.3.2 The Extracellular matrix 
ECM is a substantial part of the microenvironment in all tissues. Genome sequencing of 
organisms revealed all the proteins that contribute to the ECM, called ‘matrisome’. 
Matrisome proteins are divided into two different categories. First, the components that 
constitute the ECM called ‘core matrisome’. Second, the proteins that are associated with the 
ECM are called ‘associated matrisome’.  Core matrisome components include around 300 
genes. 35 genes for proteoglycans, 43 genes for collagens and the rest are for glycoproteins 
including fibronectin, laminin, tenascins, thrombospondin etc.  Matrisome associated 
proteins include around 778 genes subcategorized into ECM regulators such as MMPs and 
LOX, ECM affiliated proteins such as galectins and semaphorins, and secreted factors 
including cytokines and GFs (Naba et al., 2012).  
ECM consists of both basement membrane (BM) and interstitial matrix (IM) mainly composed 
of proteins, proteoglycans, glycoproteins, and glycosaminoglycan (Nissen et al., 2019). BM is 
mainly composed of collagen IV, fibronectin, entactin and laminins, which separate epithelial 
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and epithelial cells from IM. Collagen IV keeps the epithelial cell structure intact while laminin 
provides an adhesion site for them (Theocharis et al., 2016). The IM comprises fibrous 
proteins such as fibrillar collagen, glycoproteins (fibronectin and tenascin C) and 
proteoglycans. In most of the tissues, collagen type I and type III are the major components 
of the ECM. ECM components provide tensile strength and chemical cues to keep tissue 
homeostasis through regulating different mechanisms inside and outside the cells such cell 
migration, anchorage, biomechanical forces, and GF signalling induction (Insua-Rodriguez and 
Oskarsson, 2016, Lu et al., 2012). The ECM provides a dynamic environment for cells which 
interact and regulate cells’ behaviour. During tumour formation, recruitment of CAFs with 
their reciprocal interactions with cancer cells totally alter ECM’s dynamics. Breast malignant 
tissues usually show desmoplastic properties with higher amount of fibrillar collagen 
deposition, more ECM remodelling enzymes and alteration in GFs availability providing a pro-
tumorigenic environment (Pankova et al., 2016, Insua-Rodriguez and Oskarsson, 2016).  
1.3.2.1 Collagen 
The main component of the ECM is collagen and 30% of the whole-body protein is composed 
of collagen. Up to this point 28 different types of collagen have been recognized. Even though 
collagens have different structures, they all are made of right-handed triple helix composed 
of three α-chains. These α-chains contain repeating Gly–X–Y triplet. Gly is glycine and X and Y 
could be substituted by any other AAs. However, X and Y are mainly replaced by proline and 
hydroxyproline, respectively. Each triple-helix could be built of three similar or different α-
chains wrapping around the central axis with the glycine face inward of the helix.  The small 
hydrogen atom side chain of glycine causes the inter-chain hydrogen bond and secures the 
triple helix (Okuyama et al., 1981, Bella et al., 1994). Prior to final triple helix formation, 
collagens go through different modification processes such as hydroxylation, glycosylation, 
phosphorylation and cross-linking in the endoplasmic reticulum (ER). The end product of the 
ER, the procollagen, is transported to the Golgi to face the last modifications and self-
assembly to make fibrillar collagen (Figure 1.3) (Gelse et al., 2003, Nissen et al., 2019, 




Figure 1.3. Collagen synthesis steps. In collagen’s α-chains, glycine is in every three residues. 
Following X and Y could be substituted by any other amino acids. Assembly of α-chains followed by 
pro-collagen triple-helix assembly are processed in the ER. Procollagen traffic from the ER to the Golgi 
to go through final modifications. Finally, after pro-collagen secretion to the extracellular area, N and 
C terminal will be cleaved and they will be cross-linked via enzymes located outside the cell. Image is 
“Created with BioRender.com.” 
There are different subcategories of collagens based on their structure. Fibrillar collagen, 
anchoring fibrils, membrane-associated collagens with Interrupted triple-helices (MACITs), 
fibril associated collagens with interrupted triple helices (FACITs) and network forming 
collagen (Table 1.2). The main components of the IM are fibrillar collagen type I, II, III, V, XI, 
XXIV, XXVII and network making collagen VI; while the BM is mainly composed of network 
making collagen type IV and VIII (Table 1.2) (Nissen et al., 2019). As described in Table 1.2, 
collagen composition of both BM and IM could participate in tumour development and 
progression. Pancreatic cancer cells show elevated survival and growth rate in environments 
with elevated deposition of collagen (Armstrong et al., 2004). In line with that, breast cancer 
cells have higher metastasis and invasion rate in environments with high collagen fibrils; and 
cancer progression is significantly induced when mammary glands produce greater amount 
of collagen, laminin, and fibronectin fragments during weaning-induced involution (McDaniel 
et al., 2006, Provenzano et al., 2008). Collagen remodelling enzymes, LOX and MMPs, have a 
pivotal role in modifying collagens in favour of tumour progression (Insua-Rodriguez and 
Oskarsson, 2016).  
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Table 1.2. Different types of collagen participate in IM and BM. 




Fibrillar I Dermis, tandem, 
bone, ligament 
Bone, colorectal, 





II Cartilage, vitreous Chondrosarcoma Death and survival 
III Intestine, lung, liver, 
skin, vascular system 
Colorectal, breast, 
pancreas and Head 









collagen type I and III 
Breast cancer Growth 





placenta, and brain 
Colorectal, HNSCC 
cancer breast, lung, 







Bone, kidney, ovaries, 
muscle, testis, and 
spleen. 
HNSCC Proliferation 
XXVII Cartilage, bone, eye, 
lung, heart, and 
arteries 
NA NA 
Network IV Basement membrane Pancreas cancer Growth and 
migration (Ohlund 
et al., 2009) 
VI cornea, lung, skin, 
adipose, tendon, 
cartilage, skeletal 









VIII Basement membrane, 
heart, kidney, dermis, 
and brain 
Colorectal cancer NA (Willumsen et 
al., 2019) 
  Table 1.2. Description of the distribution of collagens participating in BM and IM in normal 





Even though fibronectin (FN) has one single gene, extended alternative splicing gives rise to 
two major different types, plasma fibronectin and cellular fibronectin (Schwarzbauer et al., 
1983). Plasma FN is released from hepatocytes and located in blood; while cellular fibronectin 
is a component of the ECM found in most of the tissues. FN is composed of two subunits 
linked together by disulphide bonds in their C terminal (Wagner and Hynes, 1979). Each 
subunit is composed of three modules, types I, II and III (Figure 1.4) (Petersen et al., 1983, 
Schwarzbauer and DeSimone, 2011). FN has collagen, fibrin, heparin, and cell binding sites. 
Cell-fibronectin interaction happens through integrin and syndecans (Cell surface receptors) 
and it can regulate cell adhesion, migration, and differentiation (Schwarzbauer and 
DeSimone, 2011, Bowditch et al., 1994). FN can be produced by both cancer cells and CAFs in 
the TME. Upregulation of FN in TME has been linked to invasiveness of cancer cells including 
lung carcinoma and breast cancer. Migratory cells also induce FN production in the 
environment they reside after metastasis by releasing different cytokines (Kaplan et al., 2005, 
Fernandez-Garcia et al., 2014). STAT3 pathway and Mitogen-activated protein kinase (MAPK) 
pathway could be induced through cell-FN interaction, resulting in more invasion and 
metastasis associated with poor prognosis and clinical outcome in breast cancer (Qian et al., 




Figure 1.4. Fibronectin structure. The fibronectin molecule is composed of different binding motifs 
and has specific affinity toward heparin, fibrin, integrin, cells, and intramolecular units that enable 
self-assembly of the molecule. These binding motifs are built by three fibronectin repeats, I, II and III. 




Laminin is a large heterotrimeric protein that is composed of three chains, α, β and γ, that 
join each other in a triple-helical coiled-coil domain to form a cross-shaped configuration. 
Each chain is encoded by an individual gene. Different laminin chains share a common 
structure. They have a globular N-terminal domain (LN domain) followed by a straight LE 
domain. β and γ chain make trimerization happen through their laminin coiled-coil (LCC) 
domain following LE, while α chain C-terminal consists of five laminin globular (LG) domains 
(Figure 1.5) (Theocharis et al., 2016, Timpl and Brown, 1994). Various combinations of laminin 
chains, LAMα1–5, LAMβ1–3, and LAMγ1–3, give rise to 16 different isoforms of laminin 
(Durbeej, 2010). Laminin has different binding regions including, cell, collagen, integrin, 
entactin and dystroglycan binding regions (Aumailley, 2013). Laminin self-binding through LN 
domain or their binding to entactin significantly participate into the BM structure (Willem et 
al., 2002). Laminin also provides proper substrate for migration of epithelial and endothelial 
cells in wound healing and angiogenesis (Willem et al., 2002, Malinda et al., 2008). Laminin 
could have both anti and pro tumorigenic effects. Laminin-111 (LM-111), the main 
component of the BM, has anti-tumorigenic effect by preventing methylation of E-cadherin 
promoter and therefore increasing E-cadherin expression and cell-cell adhesion (Benton et 
al., 2009). In contrast, expression of LM-332 in breast tissue correlates to invasion and 




Figure 1.5. Laminin structure. Laminin is composed of three chains, α-chain, β-chain, and γ-chain 
making a Y shaped structure. Each of these chains contains different binding domains shown in the 
figure. Image is “Created with BioRender.com.” 
 
1.3.3 ECM remodelling in breast cancer 
ECMs are a major component of the TME, and they are in direct contact with tumour cells. 
Tumorigenic phenotypes of cancer cells such as proliferation, migration and dissemination 
depend on both cell genotype and ECM content. It is believed that there are significant 
changes in gene expression related to cell anchorage (cadherin and integrin) and ECM 
remodelling (MMP and Lox) between normal and breast cancer epithelial cells. In breast 
cancer, high breast tissue density, disruption of BM, increase in remodelling enzymes, 
matricellular proteins, and proteoglycans are associated with a shift to more malignant and 





Figure 1.6. Changes in ECM during breast cancer progression. Changes in the composition and 
mechanical properties of ECMs affects transformation from normal mammary epithelial cells to 
malignant cells.  The normal mammary epithelial cells locate around the lumen of the ducts, and they 
are surrounded by basal cells covered by intact BM. Stroma around the normal mammary gland is 
composed of random fibrillar collagen, fibroblasts and immune cells keeping tissue haemostasis. 
During malignancy, the stroma composition changes due to the presence of CAFs and cancer-
associated immune cells. Increase in the amount of fibrillar collagen (I, III and V), hyaluronan, 
fibronectin and lox enzymes increase ECM stiffness promoting tumour invasiveness. Invasion of breast 
cancer cells is concomitant to BM disruption resulting in a decrease in collagen IV and LM-111 and an 
increase in the activity of ECM remodelling enzymes including MMPs, cathepsins and heparinase. 
Besides, during invasion, ECM fibrils undergo higher cross-linking. They are also organised in 
perpendicular orientation toward the lumen to provide the route for cancer cells to migrate (Insua-
Rodriguez and Oskarsson, 2016, Kaushik et al., 2016). Image is “Created with BioRender.com.” 
 
In terms of collagen, in malignant tumours, mRNA expression of procollagen I and III is 
confined to stroma cells and it is higher compared to benign tumours (Kauppila et al., 1998). 
Increase in secretion of collagen I is linked to the higher adhesion, sprouting and invasiveness 
of MDA-MB-231 and MCF7 breast cancer cells (Kim et al., 2014). As MDA-MB-231 are more 
aggressive than MCF7 cells, their injection to mouse mammary gland results in more collagen 
deposition and cross-linking, showing that there is a correlation between rate of 
aggressiveness and ability of modifying the TME (Liverani et al., 2017).  Transplantation of 
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breast cancer tumours in transgenic mice with higher collagen density in the mammary gland 
also showed more proliferation, invasion, and lung metastasis (Provenzano et al., 2008). Both 
in vitro and in vivo (mouse xenograft model) study also revealed that the stroma from 
mammary glands undergoing weaning-induced involution significantly increases breast 
cancer cell, MDA-MB-231, invasion with higher rate of angiogenesis compared to Matrigel or 
stroma from nulliparous mouse. Stroma in weaning-induced regression has higher MMP 
activity, high level of fibrillar collagen and proteolytic fragment of fibronectin and laminin 
(McDaniel et al., 2006).   
FN is a major component of ECM promoting cell differentiation, migration, and dissemination. 
Comparing CAFs derived FN to FN derived from normal fibroblasts (NF) revealed some 
differences. FN derived from CAFs is organized in parallel lines aligned with each other; 
whereas NF-FN is like a mesh. Aligned FN induces cancer cells directional migration through 
αV integrin (Erdogan et al., 2017).  Inhibition of FN expression along with MMPs inhibition 
reduce in vivo metastasis and in vitro migration in breast cancer cells (MDA-MB-231) (Hong 
et al., 2014). However, downregulation of a micro-RNA family, which inhibits malignant 
transformation in CAFs, induced ECM stiffness through increase in FN and LOX expression and 
resulted in poor outcome in breast cancer patients (Tang et al., 2016a). In addition, co-
expression of fibronectin with β1 integrin in breast tumours is linked to low survival rate (Yao 
et al., 2007). 
 Laminin interaction with cancer cells could also regulate their behaviour. LM511 deposited 
by breast cancer stem cells works as an integrin α6β1 ligand to activate TAZ and induce self-
renewal and tumour initiation (Chang et al., 2015). Cleavage of LM-332 by MMP-2 also reveals 
its EGF-like domain which binds to the EGFR of breast epithelial cells (MCF10A) and induces 
their migration (Schenk et al., 2003). 
Major changes in the ECM are mediated by LOXs enzymes or MMPs. Expression of these 
enzymes in CAFs leads to ECM cross-linking, fibre alignment and degradation (Nissen et al., 
2019). CAFs with higher expression of activated fibroblast markers such as αSMA show higher 
LOX expression, resulting in collagen I increased stiffness and eventually higher proliferation 
of breast cancer cells (Cox et al., 2013). In various cancers including breast cancer, LOX is 
overexpressed resulting in changes in ECM directionality, stiffness, and topology (Mohan et 
al., 2020).  Expression of LOX is enhanced in mammary tumours with higher metastasis rate 
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compared to the ones with little invasion. Inhibition of LOX activity decreases stiffness of ECM 
resulting in lower cancer cell intravasation and metastasis in breast cancer (Pickup et al., 
2013). Injection of organoid into the LOX pre-conditioned mammary gland promotes growth 
and invasion of cancer cells through collagen stiffening, which result in focal adhesion 
assembly and PI3K signalling (Levental et al., 2009).  
Invasive phenotype of cancer cells heavily relies on the ability of degrading the ECM. MMPs 
are a proteolytic enzyme family that have a major role in ECM degradation associated with 
metastasis and invasion. Expression of some types of MMPs such as MMP-2, MMP-14, MMP-
9, and tissue inhibitor of metalloproteases (TIMP)-2 in breast cancer is associated with poor 
prognosis and could be used as an indicator for survival rate (Talvensaari-Mattila et al., 1998, 
Tetu et al., 2006, Yousef et al., 2014). Overexpression of MMP-9 is mostly seen in invasive 
breast cancer cells such as triple negative ones and it is tightly correlated with metastasis, 
shorter latency in relapse and lower survival rate after relapse in patients (Yousef et al., 2014). 
The stroma from mammary glands undergoing involution show a high rate of MMP activity in 
addition to high levels of collagen, fibronectin, and laminin deposition. In vivo study on 
weaning-induced involuting mammary glands show that activity elevation for MMP-2 and 
MMP-9 could correlate to their higher rate of liver, kidney, and lung metastasis (McDaniel et 
al., 2006). Early studies show that some MMPs, such as stromelysin-3, are exclusively 
expressed by fibroblasts around breast cancer tumours (Basset et al., 1990). Interaction of 
neoplastic cells with fibroblasts through different signalling molecules including tumour 
necrosis factor-α (TNF-α), PDGF, EGF, basic FGF (bFGF) induce their activation and MMPs 
expression which eventually induce the invasive growth (Basset et al., 1990, Stuelten et al., 
2005). Liberating the fibroblast associated-MMPs is also a mechanism that cancer cells take 
advantage of. Invasive breast cancer cells (MDA-MB-231) induce the release of MMPs such as 
MMP-2 bound to the membrane of normal bone marrow fibroblasts (BMF) and increase ECM 
degradation to facilitate their migration into other tissues (Saad et al., 2002).  
The physical composition of the ECM could regulate different aspects of cellular behaviour 
ranging from proliferation, invasion, growth, metastasis, to another major factor controlling 
cancer progression, which is metabolism.  
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1.3.4 ECM receptors: integrins 
There are different types of cell receptors that mediate the cell-ECM interactions including 
discoidin domain receptor (DDR) family, syndecans, CD44 and integrins (Sainio and 
Jarvelainen, 2020). Integrins are cell adhesion receptors which mainly recognize ECMs and 
cell adhesion proteins as ligands. They are a family of heterodimeric molecules composed of 
two transmembrane subunits, α and β, non-covalently bound together. At least 18 different 
α subunits and 8 β subunits genes have been discovered in mammalians, resulting in 24 
different combinations of αβ heterodimer that can engage various ECM components (Table 
1.3). Each integrin subunit is composed of a large extracellular domain, a single 
transmembrane domain, and a short intracellular domain (Takada et al., 2007). Transition of 
integrins from low affinity and inactive receptors to active receptors with high affinity majorly 
depends on their conformation alteration. Inactivated integrins have a hairpin like structure 
where their ligand binding domain faces toward the membrane. Whereas their active version 
is more extended with the ligand domain facing away from the membrane and exposed to 
ECM (Xiong et al., 2001, Tiwari et al., 2011). Activation of integrins take place through a 
bidirectional signal transportation: ‘inside-out’ and ‘outside-in’ signalling. In inside-out 
signalling, proteins containing a FERM (Four-point-one, Ezrin, Radixin, Moesin) domain such 
as talin and kindilin bind to the integrin intracellular domain and induce receptor extension 
and ECM binding. In outside-in signalling, binding of integrin to ECMs induce recruitment to 
talin of more adaptor proteins in focal adhesion (FA) to strengthen ECM-cytoskeleton 
signalling. In this case, integrins can work as force sensors, transferring forces applied by ECMs 
to cells through FA proteins resulting in triggering different signalling pathways or changes in 
gene expression. On the other hand, forces from cytoskeletons could also be transferred to 
ECM through FAs that allows integrins to pull ECM and sense mechanical cues (Klotzsch et al., 
2009, Maziveyi and Alahari, 2017). Proteins engaging in FA complexes participate in different 
signalling pathways inside the cell. However, tyrosine phosphorylation is the main signalling 
pathway involved in recruiting more proteins to FAs. There are two dominant tyrosine kinases 
participating in FA signalling, FA kinase (FAK) and SRC. Integrin-talin interaction support 
recruitments of FAK. FAK is a non-receptor kinase consisting of two protein binding domain, 
N-terminal FERM domain and C-terminal FAT (Focal adhesion targeting) domain that makes 
it a proper platform for recruitment of other proteins. Integrin-ligand binding results in FAK 
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autophosphorylation providing a SH2 binding domain in FAK to engage with proteins carrying 
SH2 domain including SRC (Maziveyi and Alahari, 2017). Engagement of SRC and FAK leads to 
phosphorylation and recruitment of other proteins such as paxillin and vinculin. Paxilin has a 
leucine and aspartate rich domain that could bind directly to vinculin (Figure 1.7) (Maziveyi 
and Alahari, 2017, Burridge et al., 1992). Vinculin is a tension sensor conveying mechanical 
forces from ECM to the actin filaments (Grashoff et al., 2010). Therefore, FA provides a bi-
directional pathway for the cytoskeleton-ECM interaction. 
 
Figure 1.7. Schematic representation of FA complex formation followed by integrin activation.  
Engagement of integrin with ECM results in integrin clustering and focal adhesion complex 
recruitment cause signal transmission inside the cell and integrin-actin cytoskeleton interaction 
(Maziveyi and Alahari, 2017). Image is “Created with BioRender.com.” 
 
Integrin trafficking has been shown to happen for both active and inactive receptors. Integrins 
can be internalized through different endocytosis pathways including clathrin-dependent 
endocytosis, caveolin-dependent endocytosis, and macropinocytosis (De Franceschi et al., 
2015, Gu et al., 2011). Internalized integrins follow two different pathways: being recycled to 
provide further cell-ECM adhesion or being degraded inside the lysosomes (De Franceschi et 
al., 2015). Discovery of ECM molecules in endocytosis vesicles reveals that there is ECM-
integrin co-endocytosis. In addition, ECM turnover can rely on both remodelling enzymes 
outside the cells and ECM internalization and degradation inside the cell. As an example, 
fibronectin engaged with β1 integrin can go through caveolin-1 dependent endocytosis 
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pathway followed by lysosomal degradation (Sottile and Chandler, 2005). Also, the size of 
fibronectin can affect its endocytosis. Prior to fibronectin endocytosis along with α5β1 
integrin, fibronectin degradation by MMP-14 is critical (Shi and Sottile, 2011).  
 
Table 1.3. ECMs and their integrin receptors.   
Ligands Integrins 
Collagen α10β1, α2β1, α1β1, α11β1, αXβ2 
Fibronectin αIIbβ3, αVβ3, αVβ6, αVβ1, α5β1, α8β1, α4β1, α4β7, 
αDβ2 
Laminin α3β1, α6β1, α6β4, α7β1, α1β1, α2β1, α10β1, α3β1 
 Table 1.3. Integrin-ECM interaction (Humphries et al., 2006, Takada et al., 2007). 
1.3.5 The crosstalk between nutrient signalling and the ECM-integrin 
trafficking.  
Triggering signalling pathways through trafficking of extracellular protein (ECP) bound 
integrin could directly or indirectly affect cell metabolism. Mechanistic target of Rapamycin 
(mTOR) is one of the signalling pathways that could be regulated by integrin trafficking. mTOR 
is a serine-threonine protein kinase forming two independent complexes, mTORC1 and 
mTORC2. mTORC1 signalling pathway activity relies on nutrient and GF availability (Kim et al., 
2013a, Kim et al., 2013b, Zoncu et al., 2011b). Presence of AAs, GFs and other sources of 
energy induce mTORC1 activity. Activation of mTORC1 triggers downstream signalling 
pathways responsible for anabolic processes including nucleotide, lipid, and protein 
synthesis. However, nutrient deficiency restrains the activity of mTORC1 permitting cells to 
use other sources of nutrient acquisition like autophagy (Korolchuk et al., 2011). It has been 
demonstrated that mimicking nutrient deficiency via deactivation of mTORC1 activity could 
effectively increase integrin internalization. Glucose (Glc) depletion induces FN bound α5β1 
integrin translocation from focal adhesions to fibrillar adhesions beneath the nucleus, 
followed by an Arf4-dependent internalization pathway. Transport of FN-bound α5β1 integrin 
to lysosomes eventually leads to mTOR1 recruitment and activation. Activation of mTORC1 
negatively regulates integrin internalization implying that simulating nutrient deficient 
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environments by inhibiting mTORC1 activity results in a higher ligand-bound α5β1 integrin 
endocytosis (Rainero et al., 2015a).  Addition of laminin to the environment where normal 
mammary epithelial cells suffer from serum and GF deficiency increased laminin bound β4 
integrin internalization. After internalization, laminin is conducted to the lysosome where it 
is degraded resulting in higher AA content of the cells. Eventually, the increase in cellular AA 
concentration induces mTORC1 activity to avoid excess uptake of extracellular proteins. 
Studies on mice under dietary restriction also confirmed that mammary epithelial cells have 
a tendency to induce laminin internalization from BM or other types of ECMs during nutrient 
deficiency (Muranen et al., 2017). Therefore, ECM uptake following integrins trafficking under 
nutrient depleted conditions could hypothetically supply a source of nutrients for cells as 
ECMs are rich in AAs and sugars.  
AMP-activated protein kinase (AMPK) is a serine-threonine kinase responding to the nutrient 
availability. AMPK activation blocks any anabolic process of the cells and gives the opportunity 
to the catabolic pathways to provide energy and nutrients for the cells during nutrient 
starvation (Hardie et al., 2012). In fibroblasts, activation of AMPK has inhibitory effect on α5β1 
integrins activity. AMPK activation due to lack of nutrient/energy blocks tensin3 expression. 
Translocation of α5β1 integrins from focal adhesions to fibrillar adhesions is accompanied by 
replacement of talin with tensin. Therefore, AMPK has an inhibitory role for the activation of 
α5β1 integrins in fibroblasts. In AMPK KO mouse embryonic fibroblasts (MEFs), activity of 
α5β1 is increased which directly lead to more fibronectin biogenesis and fibrillar adhesion 
leading to a stiffer environment (Georgiadou et al., 2017).  
Sensing mechanical properties of the microenvironment by integrins could also affect cell 
metabolism. CD98hc is an integrin co-receptor and AA transporter. CD98hc can assess 
mechanical forces from the environment resulting in integrin and RhoA activation to increase 
cell stiffness. It has been shown that interruption in mechanosensing due to C330S mutation 
in CD98hc can disrupt sphingolipid synthesis in fibroblasts. Sphingolipids are types of lipids 
located in the plasma membranes. Sphingolipids have structural functions. In addition, they 
modulate transmembrane protein dynamics. Absence of CD98hc reduces sphingolipid 
availability disrupting translocation and activation of SRC kinase and GEF-H1 which is 
responsible for RhoA activation (Boulter et al., 2018). Therefore, presence of ECP as a source 
of nutrient or biomechanical force can affect cell metabolic status suggesting that 
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experiencing different microenvironments during metastasis can affect cancer cell behaviour 
(Nazemi and Rainero, 2020).   
 
Figure 1.8. Crosstalk between integrin-ECM interaction and nutrient availability. Glucose and serum 
starvation respectively induce fibronectin and laminin bound integrin to be internalized inside the cell 
followed by lysosomal degradation. Besides, extraction of nutrients from ECMs inside the lysosome 
reactivate mTORC1 signalling, blocking further integrin internalization to avoid excess uptake of ECPs. 
Activation of AMPK during starvation, however, blocks tensin expression resulting in integrin 
inactivation. CD98hc activation is due to biomechanical forces from ECMs causing sphingolipid 
production and RhoA activation (Nazemi and Rainero, 2020).    
 
1.4 Metabolism 
1.4.1 Reprogramming energy metabolism 
In normal somatic cells, the presence of intact blood vessels provides adequate oxygen and 
nutrients for the cells. However, nutrient uptake is not triggered simply by the presence of 
nutrients in the surrounding environment. Interaction of cells with soluble GFs and the ECM 
through membrane receptors are required to regulate nutrient consumption (Thompson, 
2011, Grassian et al., 2011). Due to high proliferation rate and inadequate oxygen/blood 
delivery, cancer cells need to optimize their metabolism to acquire the maximum amount of 
nutrients from the environment and to overcome nutrient-poor conditions. Metabolic 
alterations in cancer cells comprise all phases of metabolism in the cells, including nutrient 
uptake, intracellular metabolic pathways, and metabolite dependent gene regulation. The 
main biosynthetic needs of cells are accomplished by Glc and Gln uptake working as carbon 
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building blocks for macromolecules production. They also work as electron transfer 
intermediates in the electron transfer chain in the form of nicotinamide adenine dinucleotide 
(NADH) and reduced flavin adenine dinucleotide (FADH) to help ATP production (Pavlova and 
Thompson, 2016).  
Significantly, enhanced Glc consumption because of metabolic demands of cancer cells was 
first described by Otto Warburg (Warburg et al., 1927). In normal cells, in the presence of 
oxygen, most of the pyruvates enter the tricarboxylic acid (TCA) cycle in mitochondria to 
produce 36 molecules of ATP. In contrast, during hypoxia, differentiated cells use anaerobic 
glycolysis and produce lactate allowing glycolysis to continue with less ATP production. 
However, cancer cells and proliferating cells, regardless of presence of oxygen, use the 
glycolytic pathway, called aerobic glycolysis or Warburg effect (Vander Heiden et al., 2009). 
At that time, Warburg was convinced that cancer cells had a respiration deficiency making 
them rely on glycolysis (Hanahan and Weinberg, 2011, Warburg, 1956). Warburg’s hypothesis 
that the tendency of cancer cells toward aerobic glycolysis was because of inhibition of the 
TCA cycle was proven wrong. Later studies demonstrated that tumour cells have an intact 
mitochondria, and they can use oxidative phosphorylation to meet their ATP needs. In 
addition, some non-cancerous proliferative cells benefit from aerobic glycolysis showing that 
it has some advantage in terms of biosynthesis (Cavalli et al., 1997, Brand et al., 1986).  
Now the question is why neoplastic cells prefer converting pyruvate from glycolysis to lactate 
over feeding to the TCA cycle? Demand of ATP in proliferative cells is just slightly higher than 
quiescent cells. However, their need for precursor molecules and NADPH is significantly 
higher than non-proliferative cells. Glycolysis is a main source for production of precursor 
molecules (Figure 1.10), whereas the TCA cycle focuses on production of ATP and NADH, 
which are negative regulators of glycolysis. Conversion of pyruvate to lactate gives the 
opportunity to cells to decrease ATP accumulation, therefore releasing the ATP-mediated 
inhibition of glycolysis (Pavlova and Thompson, 2016). In addition, even though the number 
of ATP molecules per Glc generated by glycolysis is lower than by the TCA cycle, ATP 
production is faster, which makes glycolysis more profitable for proliferative cells with high 
demands of energy (Pfeiffer et al., 2001).  
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In general, cancer cells might have some preferences over different metabolic pathways in 
different conditions. Each metabolic pathway could be reinforced through different genetic 
or non-genetic changes. In the following sections the basics of each metabolic pathway with 
their alteration due to cancer cells metabolic rewiring will be briefly explained.  
1.4.2 TCA cycle 
The TCA cycle is a cell respiration machinery composed of a series of chemical reactions 
happening in the mitochondrial matrix in the presence of oxygen, providing energy, redox 
balance, and macromolecules (Anderson et al., 2018). The TCA cycle is fed through different 
sources including, Glc, glutamine (Gln), and fatty acid. Since pyruvate made from glycolysis is 
mainly consumed to produce lactate in cancer cells, Gln and fatty acid play a major role to 
replenish TCA cycle intermediates (Figure 1.9) (Described in below sections) (DeBerardinis et 
al., 2007, Eagle, 1955). The main input of the TCA cycle is acetyl-CoA. Acetyl-CoA is obtained 
from pyruvate, fatty acids and different AAs including phenylalanine, tyrosine, leucine, 
isoleucine, and tryptophan. Conversion of Acetyl-CoA to other TCA cycle intermediates trigger 
redox reactions generating reduced NADH and FADH. Later, NADH and FADH along with 
oxygen were consumed in oxidative phosphorylation reactions to form ATP (Akram, 2014). 
In addition to the mutations in cancer cells inducing uptake of Gln, Glc, and other fuel sources 
of the TCA cycle (Described in the sections below), cancer progression has also been shown 
to rely on the derailed function of TCA cycle enzymes.  Succinate dehydrogenase (SDH) 
catalyses the oxidation of succinate to fumarate and participates in TCA cycle and electron 
transport chain in mitochondria. SDH is known as a tumour suppressor gene whose mutation 
results in neoplastic transformation through succinate and ROS accumulation, both resulting 
in hypoxia-inducible factor-1 (HIF-1) induction (Gottlieb and Tomlinson, 2005). Fumarate 
hydratase (FH) catalyses the conversion of fumarate to l-malate and has a role in AA synthesis 
and urea cycle. FH mutation is one of the first germline mutations discovered in adult 
testicular tumours as well as in patients with ovarian mucinous cystadenoma (Ylisaukko-oja 
et al., 2006, Carvajal-Carmona et al., 2006). Isocitrate dehydrogenase (IDH) catalyses 
isocitrate to alpha-ketoglutarate transformation. IDH mutation in acute myeloid leukaemia 
(AML) suppresses hematopoietic cell differentiation (Yen et al., 2017). It is also one of the 
markers of secondary glioblastomas (Ohgaki and Kleihues, 2013).  Overall, TCA cycle 
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dysregulation and accumulation of the intermediate metabolites inside the cells, due to the 
mutation in TCA cycle enzymes, could convey some oncogenic signalling pathways that 
facilitate tumour growth or survival. 
 
Figure 1.9. TCA cycle intermediates. The aim of the TCA cycle is to release energy via oxidation of 
Acetyl-CoA. During this metabolic pathway, consumption of acetate from acetyl-CoA and H2O reduces 
NAD+ to NADH and releases CO2. NADH are fed to the electron transport pathway in the mitochondria 
membrane to produce ATP. Image is “Created with BioRender.com.” 
 
1.4.3 Glycolysis 
Glycolysis is a series of metabolic processes that use one molecule of Glc to generate two 
molecules of pyruvate and two molecules of ATP. In the first phase of glycolytic metabolic 
reactions, consumption of two molecules of ATP fuel the reaction in which Glc is catabolized 
into fructose-1,6-bisphosphate through sequential reactions triggered by different enzymes, 
including hexokinase, phosphor-glucose isomerase, and phosphofructokinase. In the second 
phase of glycolysis, fructose-1,6-bisphosphate is catalysed into two molecules of pyruvate, 
four molecules of ATP and two molecules of NADH. In aerobic conditions, pyruvate is oxidized 
and fed into the TCA cycle through acetyl-CoA to make 36 molecules of ATP, CO2, and H2O. In 
contrast, in anaerobic conditions, pyruvate is catalysed into lactate by the lactate 
dehydrogenase enzyme (LDH) (Figure 1.10) (Pelicano et al., 2006). Even though the main 
product of glycolysis is known as pyruvate, some of glycolysis intermediates could branch off 
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and participate in production of precursors in different pathways, demonstrating why relying 
on glycolysis could be more advantageous for proliferative cells. In the pentose phosphate 
pathway (PPP), partial oxidation of glucose-6-phosphate gives rise to NADPH and ribose-5-
phosphate which is a component of nucleotides (Jiang et al., 2011). Fructose-6-phosphate 
could also branch off and participate in the production of hexosamines (Itkonen et al., 2013, 
Spiro, 2002, Wellen et al., 2010). Dihydroxyacetone phosphate (DHAP) could be converted 
into glycerol-3-phosphate to produce phospholipids. The most well-known of these pathways 
is using 3-phosphoglycerate as a precursor to produce serine and glycine. Pyruvate could also 
be involved in AA metabolism by participating in the production of some non-essential AAs 
(NEAA) including asparagine and aspartate through metabolic pathways mediated by 
different enzymes such as pyruvate-carboxylase and glutamate and oxaloacetate 
transaminases (Figure 1.10 and 1.11) (Pavlova and Thompson, 2016, Locasale et al., 2011, 
Pelicano et al., 2006). 
Considerable increase of both Glc and Gln uptake in cancer cells and their correlation to poor 
prognosis have been studied since the mid-1900s (Som et al., 1980, Warburg et al., 1927, 
Eagle, 1955).  Activation of PI3K/Akt and Ras signalling pathway induce Glc internalization by 
promoting the expression of a Glc transporter, Glut1; and their aberrant activation which 
facilitates constant Glc uptake in cancer cells (Wieman et al., 2007, Murakami et al., 1992). 
Transformation of glucose to glucose-6-phosphate is upregulated in cancer cells due to 
excessive expression of different isoforms of hexokinase (HK). HK could be considered as a 
target for cancer therapy (Ko et al., 2001). Inhibition of HK in breast cancer cells induce 
apoptosis; while in melanoma and leukaemia HK suppression results in lower production of 
ATP (Kwiatkowska et al., 2016, Nakano et al., 2011). Transformation of phosphoenolpyruvate 
to pyruvate in glycolysis is catalysed by pyruvate kinase (PK). There are four isoforms of PK in 
mammals; isoform M2 (PKM2) was shown to be upregulated in different tumours resulting in 
higher metabolism and tumour growth. Targeting PKM2 as a cancer therapy could increase 
the effect of chemotherapy (Shi et al., 2010, Akins et al., 2018). Therefore, higher Glc uptake 
and excessive expression of key glycolytic enzymes can induce tumorigenicity in cancer cells. 
Moreover, degradation of an ECM component, hyaluronan, has been shown to promote 
glycolysis via increasing Glut1 trafficking to the plasma membrane, resulting in higher 
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migration rate in breast cancer cells. Thus, ECMs can also indirectly regulate cancer cells 
metabolic status and invasion (Sullivan et al., 2018).  
 
Figure 1.10. Glycolysis. During glycolysis, glucose is converted to pyruvate and lactate. Cells secrete 
lactate to the extracellular environment. However, pyruvate is fed into the TCA cycle via Acetyl-CoA. 
Some of the glycolysis intermediates are used as a precursor for nucleotide, amino acid, and fatty acid 
synthesis (Figure is adapted from (Baenke, 2012)). Image is “Created with BioRender.com.”.  
 
1.4.4 Glutaminolysis 
Glutamine is the most abundant AA in plasma (Bergstrom et al., 1974). Even though Gln is 
known as a NEAA, proliferative cells such as cancer cells need external sources to meet their 
high demand (Lacey and Wilmore, 1990). Some cells mainly rely on Gln uptake to replenish 
their TCA cycle, which is called Gln anaplerosis, to provide energy. Gln also provides reduced 
nitrogen as a building block of nitrogen-containing compounds including NEAAs, pyrimidine 
and purine nucleotides and glucosamine-6-phosphatase (Nicklin et al., 2009). Glutaminolysis, 
the process of feeding the TCA cycle by Gln, happens through conversion of Gln to glutamate 
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by glutaminase enzymes (GLS1/GLS2). Glutamate can be converted to α-ketoglutarate, one 
of the TCA intermediates, through different pathways. In the process of α-ketoglutarate 
formation, glutamate can be catalysed by glutamate dehydrogenase (GDH) or some 
transaminase enzymes including glutamate–oxaloacetate transaminase (GOT), glutamate–
pyruvate transaminase (GPT), and phosphoserine transaminase (PSAT). Glutamate 
transformation via transaminase results in production of different NEAAs. GOT, PSAT and GPT 
can promote generation of aspartate, serine, and alanine respectively in the process of α-
ketoglutarate formation. Aspartate can be converted to asparagine or be used as a building 
block for nucleotide formation.  α-ketoglutarate can be transformed to citrate and being 
released from mitochondria to the cytoplasm. Citrate could be catalysed to Acetyl-CoA 
working as a precursor of fatty acids and lipids inside the cells. In general, Gln anaplerosis can 
also provide NEAAs and nucleotide precursors to the cells (Yang et al., 2017). Efflux of 
cytoplasmic Gln is also coupled with import of AAs such as leucine, iso-Leucine, tyrosine, 
valine, methionine, tryptophan, and phenylalanine through L-type amino acid transporter 
(LAT1) (Figure 1.11) (Yanagida et al., 2001).   
According to studies on Gln, the oncogenic protein, C-Myc, prompts the transcription of Gln 
transporters, ASCT2 and ASN2, to increase Gln uptake. C-Myc also induces GLS over-
expression in mitochondria increasing Gln metabolism. Inhibition of GLS1 in prostate and 
breast cancer cells decreases their growth rate.  However, tumour suppressor proteins of the 
Rb family, participating in G1 cell cycle checkpoint, negatively regulate Gln consumption 
inside the cell (Wang et al., 2011, Reynolds et al., 2014, Gao et al., 2009, Qie et al., 2014). 
Cancer cell Gln dependency is also linked to their invasiveness. Highly invasive ovarian cancer 
cells need Gln uptake for their growth while low invasive ones are Gln independent. Invasive 
ovarian cancer cells have higher glutaminolysis rate due to elevated expression of GLS and 
GOT enzymes, which has been linked to their poor prognosis (Yang et al., 2014). It has 
previously been shown that the rate of GLS protein is dependent on tumour stage. Higher 
stage and grade of breast cancer cells rely more on Gln. In addition, the amount of GLS is 
significantly higher in cells negative for both ER and PR implying that they rely more on 
external sources of Gln (Demas et al., 2019).  Gln to glutamate conversion is also linked to 
metastasis of breast cancer cells. Presence of glutamate in the TME facilitates invasion. 
Invasive breast cancer cells release glutamate into the environment. Glutamate activates 
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metabotropic glutamate receptors (GRM3) responding to extracellular glutamate. Activation 
of GRM3 stimulates MMP-14 recycling happening via Rab27 GTPase. Recycling of MMP-14 
from late endosome to plasma membrane increases fibrillar collagen degradation, resulting 
in higher invasion (Dornier et al., 2017). Gln addicted cancer cells could easily face Gln 
deprivation due to their high Gln uptake and inadequacy in Gln transport via blood vessels. 
Tumour cells might rely on alternative sources, like ECPs or CAFs, in their microenvironment 
to meet their Gln needs (for more details please refer to section 1.4.6 and 1.4.7)  
1.4.5 Amino acid metabolism 
Amino acids are the main building blocks of protein. The human body can endogenously 
synthesize a group of AAs called NEAAs. However, the rest of the AAs that must be received 
from an exogenous source are called essential AAs (EAAs) (Table 1.4) (Vettore et al., 2020).  



















Changes in the rate of different AA synthesis or consumption in favour of cell survival or 
growth is common in cancer cells. In breast cancer cells, the catabolism of proline via proline 
dehydrogenase (PRODH) is elevated, resulting in higher ATP production and maintenance of 
spheroid growth and metastasis of cancer cells (Elia et al., 2017). ECM stiffness increases 
proline synthesis in lung adenocarcinoma through increase in PYCR1, a key enzyme for proline 
synthesis, resulting in higher proliferation of cells (Guo et al., 2019). Serine synthesis is also 
upregulated in different types of cancer. The enzyme that is responsible for the early stage of 
serine synthesis is 3-phosphoglycerate dehydrogenase (PHGDH). PHGDH upregulation is 
more common in triple-negative breast cancer cells and its high expression is correlated to 
lower survival rate and shorter relapse time (Locasale et al., 2011, Pollari et al., 2011). PHGDH 
expression in glioma cells and cervical cancer is also linked to high tumour grade and lower 
survival rate (Liu et al., 2013, Jing et al., 2013). Serine can also be converted to glycine and 
cysteine. An in vivo study showed that tumour transplants in the mouse mammary gland 
decrease the level of plasma cysteine (Al-Awadi et al., 2008). In addition, hypermethylation 
of cysteine dioxygenase in breast cancer cells induces ROS detoxification and survival (Jeschke 
et al., 2013). Glycine also facilitates cancer cells detoxification via participating in glutathione 
production, which is an essential antioxidant (di Salvo et al., 2013). Cancer cell glycine 
consumption and biosynthesis correlates with their proliferation and metastasis; and breast 
cancer patients with high reliance on glycine show higher mortality rate (Jain et al., 2012).  
In cancer cells, high proliferation rates result in higher metabolic demand. Therefore, they 
rely on external sources to provide NEAAs, a process called NEAAs auxotrophy. NEAAs 
auxotrophy is linked to different mutations in genes expressing NEAA synthesis enzymes. 
Argininosuccinate synthetase (ASS) transfers amino groups from aspartate to synthesize 
arginine from citrulline. In some cancer cells, mutation in ASS genes limits the synthesis of 
arginine (Szlosarek et al., 2006). Asparagine synthesis could also be eliminated in cancer cells 
via mutation in asparagine synthetase (ASNS) transferring amide groups from Gln to make 
asparagine from aspartate (Richards and Kilberg, 2006). Mutation in Gln synthetase (GS) also 
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makes the cells rely on exogenous Gln (Tardito et al., 2015). Leukaemia stem cells rely on 
access to external sources of AAs to survive and supply energy from the oxidative 
phosphorylation process (Jones et al., 2018). Depletion of Gln in human glioblastoma results 
in lower ATP production and cell apoptosis. However, providing asparagine to the cells under 
Gln starvation could rescue the cells from apoptosis (Zhang et al., 2014). Therefore, access of 
cancer cells to external sources of AAs to meet their metabolic demands is necessary in 
different conditions. Mechanotransduction upon ECM stiffness causes an 
aspartate/glutamate crosstalk between CAFs and cancer cells, where cancer cells receive 
aspartate from CAFs for purine and pyrimidine biosynthesis and supporting cancer cell growth 
and metastasis (Bertero et al., 2019). Lack of Glc and serum derived-nutrients in the TME of 
pancreatic ductal adenocarcinoma (PDAC) induce stroma-associated pancreatic stellate cells 
(PSCs) autophagy. Knockdown of proteins contributing to autophagy decreases the levels of 
both intracellular and secreted alanine in PDAC. Thus, it is believed that autophagy is the 
source of alanine in the TME for cancer cells. Deficiency in Glc and other nutrients make 
alanine a major carbon source for TCA cycle, NEAAs and lipid synthesis in PDACs (Sousa et al., 
2016). Therefore, Glc and Gln starvation could be compensated by other alternative sources 




Figure 1.11. Metabolic pathways of non-essential amino acids. Major metabolic pathways 
contributing to amino acid metabolism are glycolysis, glutaminolysis and TCA cycle.  Cells receive their 
essential amino acids from external sources. There are some glutamine transporters that efflux 
glutamine in exchange of essential amino acids (Bhutia and Ganapathy, 2016).  Glutamine is utilized 
as a precursor for proline, arginine, aspartate, and serine production. Aspartate and serine can be 
converted to asparagine and glycine, respectively (Figure is adapted from (Baenke, 2012)). Image is 
“Created with BioRender.com.” 
 
1.4.6 CAFs and metabolism 
‘Deregulating cellular energetics’ is one of the cancer cells hallmarks (Hanahan and Weinberg, 
2011). Even though many studies focused on the autonomous role of cells in charge of 
metabolic reprogramming, recently the role of the TME has been considered. Among cells in 
the TME, CAFs show a major reciprocal metabolic interaction with cancer cells to support 
their growth.   
A study on ovarian cancer cells revealed that co-culture of CAFs with cancer cells induce 
metastasis via increasing energy content and glycolysis in cancer cells. Secretion of TGF-β in 
the TME induces the P38-MAPK signalling pathway in CAFs resulting in secretion of cytokines 
such as IL-6, CCL5 and CXCL10. Cytokines increase glycogen mobilisation and higher 
phosphoglucomutase 1 (PGM1) expression. Higher activity of PGM1 in ovarian cancer cells in 
the presence of CAFs induces conversion of glycogen to glycolysis intermediates. Therefore, 
higher glycolysis activity in cells results in higher proliferation and invasion (Curtis et al., 2019). 
CAFs also release exosomes carrying AAs, TCA intermediates and lipids. Nutrient deprived 
conditions increase the uptake of these exosomes in pancreatic and prostate cancer cells. 
Heavy carbon labelling of exosomes content revealed that by taking the exosomes inside the 
cancer cells, their content contributed to production of AAs and TCA cycle intermediates 
(Zhao et al., 2016). CAFs associated with ovarian cancer cells show increased Gln anabolic 
pathways as a response to cancer cells residing in Gln starvation environments. Ovarian 
cancer cells increase Gln synthesis in CAFs under Gln starvation. Secretion of Gln from CAFs 
helps cancer cells to maintain their growth under Gln deficiency condition (Yang et al., 2016).  
CAFs can also induce the ‘reverse Warburg effect’. Higher levels of glycolysis in CAFs increases 
the secretion of lactate. The presence of lactate in the TME increases the TCA cycle and 
NAD+/NADH level in prostate cancer cells in the vicinity of CAFs. Higher mitochondria mass 
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and activity increase oxidative phosphorylation (OXPHOS) pathway in cancer cells, resulting 
in higher metastasis rate and chemotherapy resistance (Ippolito et al., 2019).  Similarly, 
secretion of pyruvate from CAFs in the lymphoma microenvironment increases TCA cycle 
intermediates, decreases reactive oxygen production, and eventually increases cell survival 
(Sakamoto et al., 2019).   
There is some evidence showing that ECM stiffness could also manipulate breast cancer cells 
and CAF metabolism. Stiff ECM induces a metabolic crosstalk between carcinoma and CAFs 
through NEAA flux. Carcinoma cells increase Gln uptake and glutamate release in the TME on 
stiffer substrates; whereas, in CAFs, glutamate is internalized, and aspartate is secreted. 
Following, CAFs-derived aspartate is consumed by cancer cells and participates in nucleotide 
formation and finally cell proliferation (Bertero et al., 2018).   
Therefore, Interaction of cancer cells with CAFs provides different sources of nutrients for 
cancer cells such as AAs and lipids facilitating growth, invasion, and survival of cancer cells 
under different nutrient conditions.   
1.4.7 Nutrient scavenging from microenvironment 
High rate of tumour growth and inadequate vasculature forming or blood supply inside the 
tumours substantially increase the chance of nutrient deficiency in TME (Weis and Cheresh, 
2011). Therefore, cancer cells adapt to use alternative sources of nutrients, such as albumin 
or collagen from the TME to meet their metabolic needs.  
Leaky blood vessels and shortage of lymphatic vessels around the tumours permit cancer cells 
to have access to blood serum and its protein content such as albumin. (Stehle et al., 1997, 
Son et al., 2013). Higher tendency toward proteins in blood serum is the result of different 
types of nutrient deficiency in cancer cells. In addition, constitutive activation of Ras induces 
macropinocytosis facilitating ECPs internalization. Under AA starvation, albumin 
macropinocytosis followed by lysosomal degradation in Ras-driven PDACs and Ras-
transformed mouse embryonic fibroblasts (MEFs), increases AA content of the cells. Presence 
of AAs inside the cells induces mTORC1 activity and eventually protein synthesis and growth. 
It has been also shown that simulating nutrient deficiency via inhibiting mTORC1 signalling 
pathway encourages cells to rely on ECPs. In contrast, activation of mTORC1 inhibits lysosomal 
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degradation of ECPs to avoid excessive uptake of proteins from extracellular sources 
(Commisso et al., 2013, Kamphorst et al., 2015, Palm et al., 2015). Cells have also access to 
the cell debris from cells that died due to lack of nutrient or oxygen. AA and Glc starvation in 
K-Ras-driven pancreatic cancer cells and PTEN-deficient prostate cancer cell lines induces 
scavenging cell debris. Nutrient deficiency in these cells promotes AMPK activation (by 
increasing Rac1 activation) leading to macropinosome formation, mTORC1 inactivation and 
cell debris scavenging. Extracting nutrients from cell debris finally assists cells to have higher 
proliferation and cell biomass production rate (Kim et al., 2018). Cancer cells are also 
surrounded by a network of ECM components inside the tumours. Low Glc and Gln conditions 
induce PDAC cells to uptake collagen I and IV through macropinocytosis or receptor-
dependent endocytosis, respectively. PDAC cells extract proline via digestion of collagen I and 
IV inside the lysosomes. Proline could be fed into the TCA cycle and result in higher ATP 
production and cell survival through ERK1/2 activation (Olivares et al., 2017). It has been 
revealed that in MEFs, ECPs uptake happens as the result of GF dependent macropinocytosis 
through PI3 kinase activation. Based on the nutrient condition, PI3K triggers different 
downstream signalling pathways. Under AA deficiency conditions, activation of Rac1 and PLCγ 
as a PI3K downstream target induces macropinocytosis and provides nutrients via ECP uptake. 
However, in the presence of AAs and Glc, another PI3k effector, Akt, is activated resulting in 
activation of mTORC1 signalling. Activation of mTORC1 signalling pathway forces cells to rely 
on free AA instead of macropinocytosis of macromolecules from the environment (Palm et 
al., 2017). PDAC cells are heterogeneous in terms of macropinocytosis. Some have 
constitutive macropinocytosis not influenced by the amount of nutrients, while others display 
inducible macropinocytosis. In the cells with inducible macropinocytosis, Gln starvation 
induces transcriptional upregulation of EGFR ligands.  EGFR ligand binding causes Ras and 
EGFR-Pak signalling activation, which leads to ECPs macropinocytosis and lysosomal 
degradation (Lee et al., 2019). In addition, in vivo studies also demonstrate that 
hypoalbuminemia is observed in some cancer patients, suggesting that the tumours could 
rely on albumin as an alternative source of nutrients (Fearon et al., 1998).  Another in vivo 
study revealed that PDAC cells inside the tumour do albumin macropinocytosis followed by 
AA extraction. In contrast, normal cells in the vicinity of tumours do not have the ability to 
benefit from the albumin uptake (Figure 1.12) (Davidson et al., 2017). Therefore, cancer cells 
can rely on alternative nutrient sources such as albumin, laminin, collagen, or cell debris via 
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different mechanisms to adapt to the nutrient deficient environment and maximize their 
nutrient uptake (Figure 1.12) (Nazemi and Rainero, 2020).  
 
Figure 1.12.  Schematic representation of signalling pathways induces macropinocytosis and ECP 
internalization. Amino acid and glucose starvation induce macropinocytosis of ECPs via Ras or GF 
dependent macropinocytosis. ECP internalization is usually followed by lysosome degradation and 
amino acid extraction. Amino acids can later be fed into the TCA cycle intermediates and facilitate ATP 















1.5 Aim of the thesis  
As the ECM is produced by stromal cells constantly around the tumours, we hypothesise that 
invasive breast cancer cells might have adopted the characteristic to use ECM components as 
either a substitute source of nutrients during starvation, through internalization and 
lysosomal degradation, or as signalling molecules to trigger signalling pathways to induce 
survival/growth. Therefore, the aim of this study is to monitor mammary cancer cell 
behaviour in terms of ECM uptake during starvation and dissecting the signalling pathways 
following that. 
To do so, we will examine whether the presence of different types of ECM (collagen, laminin, 
Matrigel and cell-derived matrices) could support cell growth under specific nutrient 
starvation conditions (AA, Gln, Glc and serum starvation) by: 
● Specifying which types of ECM induce cell growth/survival under starvation 
conditions. 
● Determining whether ECM internalization and lysosomal degradation is required to 
support growth during the different starvation conditions. 
● Dissecting whether ECM-dependent cell growth is linked to mTOR activation. 
● Determining whether signalling downstream of cell-ECM interaction is involved in cell 
growth under starvation. 
● Analysing metabolic changes inside the cells due to the presence of ECM. 
● Investigating the role of different genes participating in ECM trafficking on ECM-















Table 2.1. Reagents and suppliers. 
Reagent Supplier 
0.45μm filter  Gilson 
10cm2 petri dishes  Greiner bio-one 
11130-MEM amino acid solution (50x) liquid Gibco 




2-NBDG Glucose Uptake Assay Kit Abcam 
3.5cm2 glass-bottom dishes  SPL Life Science 
384-well glass-bottom plates  Perkin Elmer 
6-well tissue culture plates  Greiner bio-one 
96-well glass bottom plates  Greiner bio-one 
96-well plastic bottom plates  FALCON 
Alexa fluorTM 555/488/647 Phalloidin Invitrogen 
Bafilomycin A1 Alfa Aesar 
BioTracker ATP-Red Live Cell Dye Merck 
Bovine Serum albumin Sigma-Aldrich 
CellEvent™ Caspase-3/7 Green Detection Invitrogen 
Collagen type I (Rat tail high concentration)  Corning 
D-glucose anhydrase Fisher chemical 
D-Glucose-13C6 Sigma-Aldrich 
DharmaFect 1 (DF1) Reagent Dharmacone 
Dialyzed FBS Gibco 
Dimethyl sulfoxide (DMSO)  Fisher Scientific 
DNase I Sigma 
DRAQ5TM Rocher 
E64d (Aloxistatin) AdooQ Bioscience 
Epidermal growth factor Sigma 
Fetal Bovine Serum Gibco 
Filipin Sigma 
Gelatin Sigma 
Glutamine stable 100x biowest 
Glutaraldehyde solution  Sigma Aldrich 
Glycine Sigma 
GM6001 APEXBIO 




PVDF membrane IMMOBILON-FL 
Insulin solution human Sigma 
IRDye 800CW N-Hydroxysuccinimide (NHS Ester LI-COR 
L-Ascorbic acid  Sigma 
Laminin/entactin complex Corning 
Laemmli Sample Buffer Bio-Rad 
Matrigel Corning 
NH4OH  Fluka Analytical 
NHS-Fluorescein Thermo Scientists 
Oligomycin A AdooQ Bioscience 
PBS containing calcium and magnesium  Sigma 
Penicillin/Streptomycin (PS) Life Technologies 
PF573228 AdooQ Bioscience 
Paraformaldehyde  Fluka Chemika 
Protein ladder Colour protein standard broad 
range. Bio-Labs 
QiaShredder QIAGEN 
siGLO Red/Green Transfection Indicator (20 nmol) Thermo Fisher 
Triton-X100  Sigma 
Trypan blue stain 0.4% Gibco by life technologies 
Trypsin EDTA solution 1x Sigma 
Tween-20  Sigma 
Vectashield mounting reagent +DAPI VECTOR 
 
2.1.2 Cell culture media 
Table 2.2. Media, suppliers, and reference numbers. 
Media Supplier Ref No 
DMEM, high glucose, no 
glutamine 
Gibco 11960-044 
DMEM, no glucose Gibco  11966-025 
DMEM, no amino acids US Biological life science  
DMEM, high glucose, 
pyruvate 
Gibco 41966-029 
DMEM, no glucose, no 
glutamine 
Gibco A14430-01 
EBSS, calcium, magnesium, 
phenol red 
Gibco 24010-043 
DMEM/F-12, HEPES Gibco 31330-038 








Table 2.3. Recipes of solutions. 
Solutions Recipe 
TBS  10mM Tris-HCl pH7.4, 150mM NaCl 
TBS-T TBS, 0.1% Tween-20 (v/v) 
Towbin buffer 10x 1.92M Glycin, 0.25M Tris 
Transfer buffer 10% 10x Towbin buffer, 20% methanol 
Sample Buffer 31.5 mM Tris-HCl, pH 6.8 buffer 10% 
glycerol 1% SDS 0.005% Bromophenol Blue 
1% SDS lysis buffer 1% SDS (v/v), 50mM Tris-HCl pH7.0 
 
Cell extraction buffer 20mM NH4OH, 0.5% Triton X-100 (v/v) in 
PBS with calcium and magnesium 
Metabolite extraction solution 5 MeOH: 3 AcN: 2 H2O 
 
2.1.4 siRNA 
Table 2.4. siRNA used for siRNA knockdown.  
Target siRNA Supplier 
Non-targeting (NT) SiGenome control Non-
Targeting siRNA pool #1 
Thermo Fisher 
Non-targeting (NT) ON TARGET plus non-
targeting siRNA pool #4 
Dharmacon 
siRNA library for Traffic-om ON-TARGETplus 
siGENOME® Human siRNA 
Library for Traffic-om 
Dharmacon  





SiGenome Smart Pool 
Human PLK1 
Dharmacon 
HPD ON TARGET plus human 





HPDL ON TARGET plus human 




2.1.5 Primary antibodies 
Table 2.5. Primary antibodies. 











(Tyr397)   
Rabbit Western blot 
(1:1000) 
Thermo Fisher 
GAPDH Mouse Western blot 
(1:500) 
Cell signalling 




2.1.6 Secondary antibodies 
Table 2.6. Secondary antibodies 
Antibody Host Technique Supplier 










IRDye® 800CW Anti 
Mouse IgG 
Goat Western blot 
(1:30K) 
LI-COR 
IRDye® 680CW Anti 
Rabbit IgG 











2.2.1 Cell culture 
MDA-MB-231 cells, telomerase immortalised fibroblast (TIF) cells and CAFs were cultured in 
high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin streptomycin (PS). Cells were grown at 5% CO2 and 37oC 
and passaged every 3 to 4 days. CAFs were from breast cancer and were generated in 
Professor Akira Orimo’s lab, Paterson Institute, Manchester. MCF10A-DCIS cells were cultured 
in DMEM/F12 supplemented with 5% Horse serum (HS), 20 ng/ml EGF and 1% PS. MCF10A 
cells were cultured in DMEM/F12 supplemented with 5% HS, 20 ng/ml EGF, 0.5mg/ml 
hydrocortisone, 10μg/ml insulin and 1% PS.  
To passage the cells, media was removed, cells were washed once in PBS, and incubated in 
0.25% trypsin for 2 minutes at 5% CO2, 37oC. After cells were detached, they were 
resuspended in complete growth media and plated at the needed density in tissue culture 
dishes. 
Cryofreezing was performed for long term storage. Cells from a 10cm2 dish at around 90% 
confluency were trypsinized and resuspended in complete media, and then centrifuged at 
1000rpm for 3 minutes at room temperature (RT). Pelleted cells were resuspended in 1ml 
freezing solution containing 10% DMSO, 25% complete media and 65% FBS. Vials were 
transferred to -80oC for a few days. Then, they were transferred to liquid nitrogen for long-
term storage. 
2.2.2 ECM preparation 
2.2.2.1 Collagen I, Matrigel and Laminin coating. 
To coat plates/dishes, collagen I, Matrigel and laminin were diluted with cold PBS on ice to 
have 2mg/ml, 3mg/ml, and 3.5 mg/ml concentration, respectively. Diluted ECM were added 
to each well/dish and properly spread on the bottom with pipette tips. Plates/dishes coated 
with ECM were transferred to the incubator at 5% CO2, and 37oC for 3hrs for polymerization. 
To avoid dryness, after three hours, PBS were added to each well/dish and the matrices were 
kept into the incubator overnight. 
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2.2.2.2 Preparation of cell-derived matrices. 
Cell-derived matrix (CDM) was generated from TIFs and CAFs. CDMs were generated either in 
a 6-well plate or 96-well glass-bottom plate. Plates were first coated with 0.2% gelatine in PBS 
and incubated at 37oC for 1hr. Gelatine was washed twice with PBS followed by being cross-
linked with 1% glutaraldehyde in PBS at RT for 30 minutes. Glutaraldehyde was removed and 
the wells were washed twice with PBS. Cross-linker was quenched in 1M glycine at RT for 20 
minutes, followed by two PBS washes, and an incubation in complete media at 5% CO2 and 
37oC for 30 minutes. In 96-well plates, 6x103 cells and in 6-well plates 2x105 cells were seeded 
per well. Cells were incubated at 5% CO2, 37oC until being fully confluent (1 or 2 days). Once 
the cells were 100% confluent, the media was changed to complete growth media containing 
50μg/mL ascorbic acid, and it was refreshed every two days. To prepare CDMs, TIFs were kept 
under media supplemented with ascorbic acid for 6 days while CAFs were kept under the 
same condition for 7 days. The media was aspirated, and the cells were washed once with 
PBS containing calcium and magnesium (PBS++). The cells were incubated with the extraction 
buffer containing 20mM NH4OH and 0.5% triton in PBS++ for 2 minutes at RT until no intact 
cells were visible by phase contrast microscopy. The extraction buffer was removed and the 
CDM was washed twice with PBS++. Residual DNA was digested with 10μg/mL DNase I in PBS++ 
at 5% CO2, 37oC for 1hr. Following two PBS++ washes, the CDMs were stored at 4°C in PBS++ 
containing 1% PS.  
2.2.3 Cell proliferation assay 
To monitor cell proliferation on ECM compared to plastic under different starvation 
conditions, 96-well plates containing TIF-CDM or collagen I, Matrigel and laminin as described 
in section 2.2.2.1 and 2.2.2.2 were prepared and left in PBS. Three wells were allocated to 
each condition as technical replicates.  The following day, the PBS was removed from each 
well and 103 cells/well were seeded under full growth media. After 5hrs incubation in 5% CO2 
and 37oC, the full growth media was replaced with 200μL of the starvation media shown in 
table 2.7 or Plasmax. Plasmax was kindly provided by Dr Tardito, The Beatson Institute, 
Glasgow. The details of Plasmax composition were previously described by Vande Voorde et 
al 2019 (Vande Voorde et al., 2019). In all the media where FBS was needed, we used dialyzed 
FBS (DFBS). The manufacturing process of DFBS is designed to significantly reduce the number 
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of low weight molecules in the serum including AAs, cytokines, salts, and hormones. After 
incubating cells under starvation conditions, cells were fixed every two days up to day six or 
eight by adding 4% paraformaldehyde (PFA) for 15mins RT followed by two PBS washes.  
 
2.2.3.1 Starvation media compositions 
Table 2.7. Composition of different media used for different cell lines. 
Cell line Starvation conditions Media composition 
1. MDA-MB-231 
 
Glucose and glutamine 
starvation 
1. DMEM [-] D-glucose, [-] L-
glutamine [+] 10% DFBS 
1.   MDA-MB-231 
2. MCF10A 
3. MCF10A-DCIS 
Serum starvation 1. DMEM [+] 4.5 g/L D-glucose [+] 
L-glutamine  
2, 3. DMEF/F12 4.5 g/L D-glucose 
[+] L-glutamine 
1.   MDA-MB-231 
2.   MCF10A 
3.   MCF10A-DCIS 
Amino acid starvation 1. DMEM [+]4.5 g/L D-glucose [+] 
10% DFBS 
2, 3. DMEM [+]4.5 g/L D-glucose 
[+] 10% HS 
1. MDA-MB-231 Non-essential amino acid 
starvation 
1. DMEM [+]4.5 g/L D-glucose [+] 
10%DFBS [+]1/50 MEM amino 
acid solution (50x) liquid 
 
2. MDA-MB-231 Essential-amino acid 
starvation 
1. DMEM [+]4.5 g/L D-glucose [+] 
10%DFBS [+]1/100 MEM non-





Glutamine starvation 1. DMEM [+] 4.5 g/L D-glucose [+] 
10%DFBS 
2. DMEM [+] 4.5 g/L D-glucose [+] 
10% HS 
3. DMEM/F12 [+] 4.5 g/L D-glucose 
[+] 5% HS 
1. MDA-MB-231 
2. MCF10  
3. MCF10A-DCIS 
Glucose starvation 1. DMEM [+] L-glutamine [+] 
10%DFBS. 
2. DMEM [+] L-glutamine [+] 10% 
HS. 
3. DMEM/F12 [+] L-glutamine [+] 




2.2.3.2 Media formulation (DMEM).  
Table 2.8. Concentration of different DMEM media. 

















Amino Acids       
Glycine 30 Absent 30 30 
L-Arginine hydrochloride 84 Absent 84 84 
L-Cystine 2HCl 63 Absent 63 63 
L-Glutamine 580 Absent Absent 580 
L-Histidine hydrochloride-H2O 42 Absent 42 42 
L-Isoleucine 105 Absent 105 105 
L-Leucine 105 Absent 105 105 
L-Lysine hydrochloride 146 Absent 146 146 
L-Methionine 30 Absent 30 30 
L-Phenylalanine 66 Absent 66 66 
L-Serine 42 Absent 42 42 
L-Threonine 95 Absent 95 95 
L-Tryptophan 16 Absent 16 16 
L-Tyrosine disodium salt dihydrate 72 Absent 104 104 
L-Valine 94 Absent 94 94 
Vitamins        
Choline chloride 4 4 4 4 
D-Calcium pantothenate 4 4 4 4 
Folic Acid 4 4 4 4 
Niacinamide 4 4 4 4 
Pyridoxine hydrochloride 4 4 4 4 
Riboflavin 0.4 0.4 0.4 0.4 
Thiamine hydrochloride 4 4 4 4 
i-Inositol 7.2 7.2 7.2 7.2 
Inorganic Salts        
Calcium Chloride (CaCl2-2H2O) 264 265 
 
200 200 








Potassium Chloride (KCl) 400 400 
 
400 400 
Sodium Bicarbonate (NaHCO3) 3700 Absent 3700 3700 
Sodium Chloride (NaCl) 6400 6400 
 
6400 6400 







Other Components        
D-Glucose (Dextrose) 4500 1000 4500 Absent 
Phenol Red 15 15.9 15 15 
Sodium Pyruvate 110 Absent Absent Absent 
 
2.2.3.3 MEM Non-Essential Amino Acids Solution (100x) 
Table 2.9. Concentration of amino acids in MEM NEAAs solution. 





L-Aspartic acid 1330 




2.2.3.4 MEM Essential amino acid solution (50x) 
Table 2.10. Concentration of amino acids in MEM solution 
Amino Acids  Concentration 
(mg/L) 
L-Arginine hydrochloride 6320 
L-Cystine 1200 
L-Histidine hydrochloride-H2O 2100 
L-Isoleucine 2620 
L-Leucine 2620 













2.2.3.5 Media formulation (DMEM/F12). 
















Amino Acids       
Glycine 18.75 18.75 18.75 
L-Alanine 4.45 4.45 4.45 
L-Arginine hydrochloride 147.5 147.5 Absent 
L-Asparagine-H2O 7.5 7.5 7.5 
L-Aspartic acid 6.65 6.65 6.65 
L-Cysteine hydrochloride-H2O 17.56 17.56 17.56 
L-Cystine 2HCl 31.29 31.29 31.29 
L-Glutamic Acid 7.35 7.35 7.35 
L-Glutamine 365 Absent Absent 
L-Histidine hydrochloride-H2O 31.48 31.48 31.48 
L-Isoleucine 54.47 54.47 54.47 
L-Leucine 59.05 59.05 59.05 
L-Lysine hydrochloride 91.25 91.25 Absent 
L-Methionine 17.24 17.24 17.24 
L-Phenylalanine 35.48 35.48 35.48 
L-Proline 17.25 17.25 17.25 
L-Serine 26.25 26.25 26.25 
L-Threonine 53.45 53.45 53.45 
L-Tryptophan 9.02 9.02 9.02 
L-Tyrosine disodium salt 
dihydrate 
55.79 55.79 55.79 
L-Valine 52.85 25.85 25.85 
Vitamins       
Biotin 0.0035 0.0035 0.0035 
Choline chloride 8.98 8.98 8.98 
D-Calcium pantothenate 2.24 2.24 2.24 
Folic Acid 2.65 2.65 2.65 
Niacinamide 2.02 2.02 2.02 
Pyridoxine hydrochloride 2 2 2 
Riboflavin 0.219 0.219 0.219 
Thiamine hydrochloride 2.17 2.17 2.17 
Vitamin B12 0.68 0.68 0.68 
i-Inositol 12.6 12.6 12.6 
Inorganic Salts       
Calcium Chloride (CaCl2) 
(anhyd.) 
116.6 116.6 116.6 
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Cupric sulfate (CuSO4-5H2O) 0.0013 0.0013 0.0013 
Ferric Nitrate (Fe(NO3)3"9H2O) 0.05 0.05 0.05 













Potassium Chloride (KCl) 311.8 311.8 311.8 
Sodium Bicarbonate (NaHCO3) 1200 2438 2438 
Sodium Chloride (NaCl) 6995.5 6995.5 6995.5 
Sodium Phosphate dibasic 
(Na2HPO4-7H2O) 
134 71 71 
Sodium Phosphate monobasic 
(NaH2PO4-H2O) 
62.5 62.5 62.5 
Zinc sulfate (ZnSO4-7H2O) 0.432 0.432 0.432 
Other Components      
D-Glucose (Dextrose) 3151 3151 Absent 
HEPES 3574.5 Absent Absent 
Hypoxanthine Na 2.39 2.39 2.39 
Linoleic Acid 0.042 0.042 0.042 
Lipoic Acid 0.105 0.105 0.105 
Phenol Red 8.1 8.1 Absent 
Putrescine 2HCl 0.081 0.081 0.081 
Sodium Pyruvate 55 55 55 
Thymidine 0.365 0.365 0.365 
 
 
Cell proliferation was quantified using two different techniques 1) Nuclei staining with DRAQ5 
and staining intensity per well detection with the Licor Odyssey imaging system. DRAQ5 is a 
far-red fluorescing DNA probe used for normalization of cell number in In-Cell Western (ICW) 
Assays (https://www.licor.com/documents/zfiq072j08h7bf4wcg4m). 5µM DRAQ5 in PBS was 
added to the cells for 1hr at RT with a gentle rocking. Cells were washed two times with PBS, 
20 to 30 minutes to avoid the background fluorescence, and kept in PBS for imaging with the 
Licor Odyssey imaging system. DRAQ5 was detected with a 700nm channel with 200µm 
resolution by an Odyssey Sa instrument. The signal intensity, which was the total intensity 
minus total background, of each well was quantified with Image Studio Lit software.  2) Using 
Hoechst nuclei staining and imaging by ImageXpress micro. In this technique, cells were fixed 
with 4% PFA containing 10µg/ml Hoechst 33342 for 15 mins, followed by two PBS washes.  
Image analyses of cells stained with Hoechst 33342 was done by MetaXpress and Costum 
Module Editor software (CME) in the Sheffield RNAi Screening Facility (SRSF). To obtain cell 
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number, plates were imaged by ImageXpress micro with 2x objective and DAPI filter. Images 
were acquired at multiple sites to cover the entire well. With 2x magnification, 4 sites/well in 
96-well plate and one site/well for 384-plates covers the whole well. The CME application was 
used to design an algorithm to detect every nucleus in each image based on the range of 
nuclei intensity and size (Figure 2.1).  
2.2.3.6 Cell proliferation assay on CAF-CDM 
Even though fibroblast extraction was performed when preparing CAF-CDMs, it was realized 
that some CAF nuclei remained in the CDM, which could affect the accuracy of cell counting 
for proliferation assays. To overcome this, cell seeding, fixation and Hoechst 3342 nuclei 
staining was performed following the same protocol described in section 2.2.3. In addition, 
cells were permeabilized for 5 min with 0.25% Triton X-100 and stained with Phalloidin Alexa 
Fluor 488 diluted 1:400 in PBS for 30mins to stain the actin cytoskeleton. Cells were washed 
twice with PBS and were left in PBS for imaging. Images were collected by ImageXpress micro 
and analysed by MetaXpress and CME software. To obtain cell number, plates were imaged 
by ImageXpress micro with 10x objective and with both DAPI and GFP filter. To measure cell 











Figure 2.1. Designing algorithm by CME to detect cells positive for actin staining. To extract data 
from images, an algorithm was designed by CME software. For this purpose, (A) Find object tools was 
selected to mask objects in grayscale images based on the fluorescent intensity and area. (B) To do 
segmentation ‘Find Blobs’ were selected to detect nuclei staining, and ‘Adaptive Threshold’ was 
selected to detect actin staining. To mask nuclei and actin staining, ‘Approximate Minimum and 
Maximum Width’ of selected objects and the ‘Level of Intensity above the Local Background’ were 
defined. (C) Once all the objects of interests were marked, we decided what was going to be the ‘Main 
objective’ to measure the ‘Features’ within each object. Here our main object was nuclei mask and 
the features object we were looking for within them was GFP wavelength or actin. (D) Applying this 
measurement to each mask identified (E) cells positive for actin (yellow nuclei) or negative for actin 
(blue nuclei).  
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2.2.3.7 Cell proliferation assay in the presence of pharmacological inhibitors 
 
96-well plates were coated with ECM as described in section 2.2.2.1 and 2.2.2.2.  103 MDA-
MB-231 cells/well were seeded in full growth media. After 5hrs incubation in 5% CO2 and 37oC, 
full growth media was replaced with 200μL of the starvation media as shown in table 2.7. 
Either 10µM of GM6001 (MMP inhibitor), 0.5 µM PF573228 (FAK inhibitor), 200nM 
Bafilomycin A (V-ATPase inhibitor), 5μg/ml Filipin (lipid raft-mediated endocytosis inhibitor), 
or DMSO as control were added to each well every two days up to day six or day three for 
Bafilomycin A and Filipin. Sample fixation and staining was performed as described above in 
section 2.2.3. 
2.2.4 Measurement of ECM consumption 
96-well plates were coated with 15μl/well of 2mg/ml collagen I and 3mg/ml Matrigel as 
described in section 2.2.2.1. Polymerized ECM were incubated with 50µl of 0.2μg/ml IRDye 
800CW N-hydroxysuccinimidyl (NHS) ester reactive dye for 1hr at RT with gentle rocking. NHS 
reactive dyes bind to free amine groups on lysine residues and form a stable conjugate. 
Labelled matrices were left overnight in PBS at 5% CO2 and 37oC. Cells were seeded the 
following day, and media was replaced with starvation conditions after 5hr. Cells were fixed 
on day 2 and day 8. Intensity of NHS-Ester bound to collagen I or Matrigel was quantified by 
imaging with the Licor Odyssey imaging system. The NHS was detected with 800nm channel 
with 200µm resolution. Image analysis was done by Image Studio Lite.  
2.2.5 ECM cross-linking 
After ECM polymerisation/preparation as described in section 2.2.2, ECMs were treated with 
10% glutaraldehyde for 30mins at RT, followed by two PBS washes. The cross-linker was 
quenched in 1M glycine at RT for 20 minutes, followed by two PBS washes. Cross-linked ECMs 




2.2.6 ECM uptake assay 
To monitor the internalization of ECM, 3.5cm2 glass-bottomed dishes were coated with either 
100µl of 1mg/ml collagen I, 70µl of 3mg/ml Matrigel or 80µl of 3.5mg/ml laminin. Dishes 
coated with ECM were incubated at 5% CO2, and 37oC for 3hrs for polymerization. Following 
that, ECMs were labelled with 10μg/ml N-Hydroxysuccinimide-Fluorescein (diluted in PBS) for 
1hr at RT on a gentle rocker, followed by two PBS washes. 105 MDA-MB-231 cells per dish 
were seeded in full growth media. After a 5hr incubation in 5% CO2 and 37oC, full growth 
media were replaced with 1ml of the indicated starvation media in the presence of 20μM 
lysosome inhibitor (E64d) or DMSO (control). E64d and DMSO were added after two days, and 
cells were fixed at day three by adding 4% PFA for 15mins at RT followed by a PBS wash. To 
permeabilize, cells were treated with 0.25% triton X-100 for 5mins followed by two PBS 
washes. For actin cytoskeleton staining, cells were incubated with Phalloidin Alexa Fluor 555 
diluted 1:400 in PBS for 10mins followed by two PBS washes and one wash with distilled water 
(dH2O). To avoid dryness and preserve the samples, 2-3 drops of Vectashield mounting 
medium containing DAPI were added to the dishes, which were then sealed with parafilm and 
kept at 4oC.  Cells were visualised by confocal microscopy using a Nikon A1 microscope and 
60x 1.4NA oil immersion objective. To cover the full area of cells, Z stacks with 1 μm intervals 
were collected. To quantify ECM uptake, a similar protocol to the one described in Commisso 
et al., 2014 was followed. ECM uptake was measured in ImageJ by specifying both cell area 
and then the area of ECM inside each cell and using the following formula for normalization. 
𝐸𝐶𝑀 𝑎𝑟𝑒𝑎
𝐶𝑒𝑙𝑙 𝑎𝑟𝑒𝑎
 × 100 
 
To monitor internalization of cross-linked ECMs, ECM cross-linking (as described in section 
2.2.5) was done after the ECMs were labelled with N-Hydroxysuccinimide-Fluorescein.  
 
To track ECM uptake in the presence of MMP inhibition, 10µM of MMP inhibitor (GM6001) 
and 20μM E64d were added to the cells immediately after replacing the full growth media 





2.2.7 Cell division assay (EdU labelling) 
To monitor the cell's ability to proliferate, Click-iT EdU Imaging Kits (Invitrogen) were used. 
EdU (5-ethynyl-2´-deoxyuridine) is a nucleoside analogue of thymidine and is incorporated 
into the DNA during DNA synthesis. This labelling is based on a click reaction, a copper-
catalysed covalent reaction between the EdU containing the alkyne and the Alexa Fluor 555 
dye containing the azide.  
As described in section 2.2.2.1 plates were coated with desired ECM and 103 MDA-MB-231 
cells/well were seeded under full growth media. After a 5hr incubation at 5% CO2 and 37oC, 
the full growth media was replaced with 200μL of the starvation media (Table 2.7). At day six 
of starvation, cells were treated with 5µM EdU. To do this, 100µl of media from each well was 
removed and replaced by 100µl of fresh starvation media containing 10µM EdU. Cells were 
incubated with EdU for two days at 5% CO2 and 37oC. At day eight, cells were fixed with 4% 
PFA containing 10µg/ml Hoechst 33342 for 15mins at RT followed by a PBS wash. To 
permeabilize, cells were treated with 0.25% triton X-100 for 5mins followed by two PBS 
washes and two washes with 3% bovine serum albumin (BSA). Cells were incubated with EdU 
detection cocktail (Invitrogen, Click-iT EdU Alexa Fluor 555) for 30 min at RT with gentle 
rocking. To prepare 1.5ml of total volume of the cocktail, following amounts of the kit 
components were mixed in order, 1290 μl 1x Click-iT reaction buffer (component D), 60 μl 
Copper (II) sulfate solution (Component E, 100 mM CuSO4) and 3.75 μl Alexa Fluor 555 azide 
(Component B, in 70 μl DMSO) and 150µl reaction buffer additive (Component F). Cells were 
washed twice with PBS and were kept in PBS for imaging. Images were collected by 
ImageXpress micro detecting DAPI and Cy3 wavelength through 2x objective and four fields 
per well were taken. Data analysis was done by MetaXpress and CME software. To measure 
the percentage of cells positive for EdU labelling, an algorithm was designed in CME which 
could detect all the nuclei (Figure 2.1) and the nuclei are positive for EdU.  
 
2.2.8 Measurement of mTORC1 activity (p-S6 labelling) 
We examined the rate of phosphorylation of an mTORC1 downstream target, ribosomal 
subunit S6 (p-S6), as an indicator for mTORC1 activity. Plates were coated with desired ECM 
as described in section 2.2.2.1, and 103 MDA-MB-231 cells/well were seeded in full growth 
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media. After a 5hr incubation at 5% CO2 and 37oC, the full growth media was replaced with 
200μL of the Gln, Glc, or AA starvation media. Where indicated, cells were incubated with 
either 200nM Bafilomycin A or DMSO as a control. Bafilomycin A or DMSO were added to the 
cells every day up to day three. Bafilomycin A is a V-ATPase inhibitor which causes 
deacidification of lysosome and consequently inhibits lysosomal degradation (Yoshimori et 
al., 1991). After three days of starvation, cells were fixed with 4% PFA containing 10µg/ml 
Hoechst 33342 for 15mins at RT followed by a PBS wash. To permeabilize, cells were treated 
with 0.25% triton X-100 for 5mins followed by two PBS washes. Unspecific binding sites were 
blocked by incubating with 3%BSA at RT with gentle rocking. Cells were incubated with the 
primary antibody, anti-Phospho-S6 Ribosomal protein, diluted 1:100 in PBS overnight at 4oC. 
The primary antibody was removed, and cells were washed twice with PBS for 5mins to 
10mins each time. Cells were incubated with secondary antibody (anti-Rabbit IgG Alexa Fluor 
594) diluted 1:1000 in PBS for 1hr at RT with gentle rocking. Cells were washed twice with PBS 
for 10 to 30mins and were kept in PBS for imaging. Images were collected by ImageXpress 
micro detecting DAPI and Cy3 wavelengths through 10x objective and around 48 fields per 
well were taken. Image analysis was done by MetaXpress and CME software. To measure the 
intensity of p-S6 labelling, an algorithm was designed to detect and mask the DAPI wavelength 
(Nuclei) as the main objects. Because S6 is a cytoplasmic protein, the masks detecting the 
nuclei were grown to cover the cytoplasmic area as well. Then the grown nuclei masks were 
used as the main objects and Cy3 (p-S6 labelling) wavelength integrated intensity was 







Figure 2.2. Designing algorithm by CME to detect the intensity of p-S6 staining per cell. (A and B) 
Find object tools was selected to mask objects in grayscale images based on the fluorescent intensity 
and area. To do the segmentation ‘Find Blobs’ were selected to detect nuclei staining, ‘Grow Objects 
Without Touching’ was used to grow the nuclei mask to cover the cytoplasm (cytoplasm mask), and 
‘Adaptive Threshold’ was used to mask p-S6 staining. To mask objects, ‘Approximate Minimum and 
Maximum Width’ of selected objects and the ‘Level of Intensity above the Local Background’ were 
defined. (C) ‘Cytoplasm mask’ was considered as ‘Main object’ to measure integrated intensity of p-
S6 (Features within each object) within. (D and E) Applying this measurement to each mask identifies 





2.2.9 Measurement of cell apoptosis 
Plates were coated with desired ECM as described in section 2.2.2.1, 103 MDA-MB-231 
cells/well were seeded in full growth media. After 5hrs incubation at 5% CO2 and 37oC, the full 
growth media was replaced with 200μL of the starvation media (Table 2.7). Cells were kept 
under starvation conditions either for 3 or 8 days. At day 3 or 8, the starvation media were 
replaced by 5µM CellEvent™ Caspase-3/7 Green Detection Reagent diluted into PBS, 
containing calcium and magnesium, and 5% DFBS for 1.5hrs at 5% CO2 and 37oC.  Cells were 
fixed with 4% PFA containing 10µg/ml Hoechst 33342 for 15mins at RT followed by a PBS 
wash. Images were collected by ImageXpress micro detecting DAPI and GFP wavelengths 
through 10x objective and around 20 fields per well were imaged. Image analysis was done 
by MetaXpress and CME software. To measure the percentage of cells positive for Caspase-
3/7, an algorithm was designed to detect and mask the DAPI wavelength (Nuclei) as the main 
objects. Because Caspase-3/7 is a cytoplasmic protein, the masks detecting the nuclei were 
grown to cover some cytoplasm. Then the grown nuclei masks were used as the main objects 
to detect GFP (Cas-3/7 labelling) wavelength as a feature within each object.  
2.2.10 Glucose uptake assay 
96-well plates were coated with collagen I and Matrigel, cells were seeded and starved as 
described in section 2.2.9. Cells were kept under starvation conditions either on ECM or 
plastic for six days. At day six, 100µM of 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) Amino)-2-
Deoxyglucose (2-NBDG) was added to the cells for 1hr at 5% CO2 and 37oC.  The media was 
removed, and cells were washed twice with ice-cold PBS. Cells were fixed with 4% PFA 
containing 10µg/ml Hoechst 33342 for 15mins at RT followed by a PBS wash. Cells were then 
incubated for 1hr with Phalloidin Alexa Fluor 647 diluted 1:400 in PBS, followed by two PBS 
washes. Images were collected by ImageXpress micro and analysed by MetaXpress and CME 
software. To measure the intensity of 2-NBDG staining, an algorithm was designed to detect 
and mask DAPI wavelength (Nuclei staining) as the main objects. Because 2-NBDG is found in 
the cytoplasm, the masks detecting the nuclei were grown to cover the cytoplasm. Then 
grown nuclei masks were used as the main objects to detect Cy3 (2-NBDG) wavelength 
integrated intensity as a feature within each object. 
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2.2.11 Live imaging of ATP content 
96-well plates were coated with collagen I or Matrigel as described in section 2.2.2.1. 103 
MDA-MB-231 cells/well were seeded in full growth media. After 5hrs incubation in 5% CO2 
and 37oC, the full growth media was replaced with 200μL of the starvation media (Table 2.7). 
Cells were kept under the indicated starvation conditions either for 3 or 8 days. At day 3 or 8, 
126.4µM Oligomycin A were added to the cells for 1hr at 5% CO2 and 37oC.  The control group 
received DMSO as a vehicle. 10µM BioTracker ATP-Red Live Cell Dye was added to the cells 
for 15min at 5% CO2 and 37oC.  The media was removed, and cells were washed with PBS. 
Cells were incubated with complete media without phenol red containing 10µg/ml Hoechst 
33342 for 15min at 5% CO2 and 37oC, then washed and replaced by complete media with no 
phenol red and no Hoechst for imaging. Live-cell imaging was performed with ImageXpress 
micro detecting DAPI and Cy3 wavelengths through a 10x objective and around 48 fields per 
well were imaged. Image analysis was done by MetaXpress and CME. To measure the intensity 
of cells positive for BioTracker ATP-Red Live Cell Dye, a similar algorithm to the one described 
in section 2.2.8 was used in which the integrated intensity of the Cy3 wavelength was 
detected as a feature within each object. 
2.2.12 Western blot 
MDA-MB-231 cells were trypsinized and 106 cells were collected in each Falcon tube. Cells 
received 0.2, 0.5, 0.7 and 1µM P573228 (FAK inhibitor) for 30mins at 5% CO2 and 37oC, while 
they were kept in suspension. Cells were transferred to a 6-well plate which had been coated 
with 900µL of 0.5mg/ml collagen I. Cells were allowed to adhere to collagen I for 30 mins at 
5% CO2 and 37oC. The media was aspirated, and cells were put on ice. After two washes with 
ice-cold PBS (~2ml), 100μl per well of lysis buffer (50mM Tris pH7 and 1% SDS) were added 
and lysates were collected and transferred to QiaShredder columns, which were spun for 
5mins at 6000rpm. The filter was discarded, and the extracted proteins were kept at -20oC.  
To run the samples, 12% gels were prepared. 10ml of resolving gel containing 3.3ml H2O, 5ml 
of 30% acrylamide mix, 2.5ml of 1.5 M Tris (pH 8), 0.1ml of 10% ammonium persulfate and 
0.004ml of tetramethylethylenediamine (TEMED) were prepared. 5ml of resolving gel were 
added to each cast for 30mins at RT. After polymerization, 2ml of stocking gel was added on 
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top. 4ml of stocking gel contained 2.7ml H2O, 0.67ml of 30% acrylamide mix, 0.5ml of 1 M Tris 
(pH 6.8), 0.04ml of 10% ammonium persulfate and 0.004ml of TEMED.  
Samples were fully thawed at RT. 15µl of 2x sample buffers were added to 15µl of each sample 
and were heated at ~70˚C for 5 min. 30µl of sample and 8µl of protein ladder were loaded 
into the 12% gel and ran at 100V for ~2hr 30min. Proteins were transferred from the gel to 
FL-PVDF membranes in a transfer buffer for 75mins at 100V.  Membranes were washed three 
times with TBS-T (Tris-Buffered Saline, 0.1% Tween) and blocked in 5% w/v skimmed milk 
powder in TBS-T for 1hr at RT. Membranes were then incubated with primary antibodies, 
1:500 GAPDH and 1:1000 pFAK in TBS-T + 5%w/v skimmed milk overnight at 4oC. Membranes 
were washed three times in TBS-T for 10min on the rocker at RT. Membranes were incubated 
with secondary antibodies, IRDye® 800CW anti-mouse IgG for GAPDH (1/30,000) and IRDye® 
680CW anti-rabbit IgG for pFAK (1/20,000) in TBS-T + 0.01% SDS, for 1hr at RT on the rocker. 
Membranes were washed three times in TBS-T for 10min on the rocker at RT followed by 
being rinsed with water. Images were taken at the Licor Odyssey system. Each band intensity 
was quantified with the Image Studio Lite software. 
2.2.13 Quantification of cellular focal adhesion content 
35mm2 glass-bottomed dishes were coated with ECM. 4x104 MDA-MB-231 cells were seeded 
and incubated at 5% CO2 and 37oC for 5hrs. The full growth media was then replaced with AA 
starvation condition. After three days of starvation, cells were fixed with 4%PFA for 15 mins 
and permeabilized with 0.25% triton X-100 for 5mins, followed by 1hr incubation in 3% BSA 
as a blocking buffer. Cells were incubated with anti-mouse Paxillin primary antibody (1:200 
dilution in PBS) at RT for 1hr. Cells were washed three times with PBS for 20mins and 
incubated with Alexa-Fluor 488 α-Mouse IgG secondary antibody (1:1000 dilution in PBS) for 
1hr at RT with gentle shaking and protected from light. Cells were washed twice with PBS and 
once with H2O. Vectashield mounting reagent containing DAPI was added on top. Cells were 
visualised by confocal microscopy using a Nikon A1 microscope and 60x 1.4NA oil immersion 
objective. To quantify the number of focal adhesions, both cell and paxillin area for each cell 




2.2.14 Mass spectrometry  
2.2.14.1 Non-targeted metabolite profiling 
MDA-MB-231 cells were seeded on 96-well plates coated with ECM under the full growth 
media. After a 5hr incubation at 5% CO2 and 37oC, the full growth media was replaced with 
the starvation media. Cells were kept under starvation for six days; the media was removed, 
and cells were washed with ice-cold PBS three times. The PBS were aspirated very carefully 
after the last wash to remove every remaining drop of PBS. The extraction solution (cold; 5 
MeOH: 3 AcN: 2 H2O) was added for 5min at 4oC with low agitation. Metabolites were 
transferred to eppendorf tubes and centrifuged at 4°C and 14000 rpm for 10 mins. Each 
sample was transferred into HPLC vials. The samples were directly injected into a Waters G2 
Synapt mass spectrometer in electrospray mode within the Sheffield Faculty of Science Mass 
Spectrometry Centre. Three technical replicates of each sample were run, technical replicates 
were a combination of nine individual wells, and the replicates were combined to obtain an 
average intensity. The dataset only includes peaks present in all three replicates. The intensity 
is a measure of abundance of any particular mass. The data is binned into 0.2amu m/z bins 
and the m/z in each bin is used to identify putative IDs using the HumanCyc database.  
2.2.14.2 Data analysis 
The mass spectrometry data were analysed using Perseus software version 1.5.6.0. There 
were three samples for each group. First, each group was defined for the late t-test. Here, we 
had two groups that each contained three technical repeats. Then, the minimal number of 
valid values that each row needs to have in the expression columns to survive the filtering 
process was defined, which was 3 in this study. The intensity of each metabolite was 
normalized by the median intensity of all the metabolites in each sample/column. T-test was 
done between two groups of samples to show the differences between their metabolic 
contents. To do the t-test, S0, which defines the artificial within groups variance, was set to 
0.1 and false discovery rate (FDR) to 0.05. Hence, test results below p<0.05 were reported as 
significant. To find the metabolic pathways being upregulated in cells on ECM compared to 
the plastic, the metabolites significantly upregulated in MDA-MB-231 cells on ECM were 
compared to homo sapiens KEGG pathway library via https://www.metaboanalyst.ca/ to find 
pathways with significantly higher enrichment, p<0.05.  
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2.2.14.3 Targeted metabolite profiling 
MDA-MB-231 cells were seeded on 6-well plates coated with ECM under full growth media. 
After a 5hr incubation at 5% CO2 and 37oC, the full growth media were replaced with the AA 
starvation media. Cells were kept under starvation for six days; the media was removed, and 
metabolites were extracted as described above (section 2.2.14.1). Then, mass spectrometer 
Waters Synapt G2-Si coupled to Waters Acquity UPLC was used to separate phenylalanine, 
tyrosine and fumaric acid with Column Waters BEH Amide 150x2.1mm. The injection was 
10μl. The flow rate was 0.4ml/min. To identify the targeted metabolites, the retention time 
of the compound coming off the column and the mass of the compound were matched with 
the standards.  
2.2.15 RNAi screen 
2.2.15.1 Optimisation of RNAi-mediated gene knockdown 
Glass-bottomed 384-well plates were coated with 5µl 2mg/ml collagen I and 5µl 3mg/ml 
Matrigel. 5µl of 150nM siGlo, SiGenome control Non-Targeting siRNA, SiGenome Smart Pool 
Human UBB or SiGenome Smart Pool Human PLK1 were added on top of the ECMs. 0.06µl of 
DharmaFect 1 (DF1) (Transfection reagent) was diluted in 4.94µl of DMEM. 5µl of diluted DF1 
were transferred to each well. Plates were left 30mins inside the hood at RT to let the siRNA 
and DF1 make complexes. 6×102 cells in 15μl DMEM media containing 10%FBS, but no 
antibiotics, were transferred to each well. The final concentration of siRNA reached 30nM. 
Cells were transferred to the incubator with 5% CO2 and 37oC over-night. The full growth 
media was replaced by 50µl of fresh complete or NEAA starvation media. After 3 or 6 days, 
cells were fixed and incubated with 10µg/ml Hoechst 33342 and Phalloidin Alexa Fluor 555 
1:400 in PBS for 30mins followed by two PBS washes. Images were collected by ImageXpress 
micro and analysed by MetaXpress and CME software. To measure the number of cells 
showing siGlo uptake, an algorithm was designed to detect Cy3 wavelength (actin) as the main 
object. Then, GPF wavelength (siGlo) was detected as a feature within each main object. 
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2.2.15.2 High throughput RNAi screening 
The non-target (Nt) siRNA showing highest compatibility to MDA-MB-231 cells were chosen 
from ON-TARGET plus Non-targeting Control siRNAs (Dharmacon) from pools #1 to #5. For 
the screening, two 384-well plates containing 150nM siRNA library for Traffic-ome 
(Dharmacon ON-TARGETplus siGENOME® Human siRNA Library) (Table 2.12) were used. This 
library was already prepared and frozen at -80ᵒC by Sheffield RNAi Screening Facility (SRSF). 
The library was designed by Professor Elizabeth Smyth and Dr Andrew Peden (University of 
Sheffield, Department of Biomedical Science). The screening was done on MDA-MB-231 cells, 
which were split the day before to have 70%-80% confluence at the screening start day. siRNA 
libraries were thawed and centrifuged for 1minute to avoid loss of any siRNA. 5µl of diluted 
DF1 were added to each well as described in section 2.2.15.1. 15µl of complete media with 
no antibiotic were added to each well. The final siRNA concentration reached to 30nM in each 
well with the addition of DF1 and media. 15µl of media containing 7x102 MDA-MB-231 cells 
were added per well in two separate glass-bottomed 384-well plates pre-coated with 5µl 
3mg/ml Matrigel. Cells were incubated for 5hrs at 5% CO2 and 37oC. After the cells were 
attached to the Matrigel, the media was fully removed. 30nM siRNA library was transferred 
to the cells on ECM by the Hamilton robot. Cells were incubated at 5% CO2 and 37oC over-
night. Full growth media was replaced by 50µl of NEAA free media or fresh complete media 
the day after. Cells were incubated for 6 days at 37ᵒC and 5% CO2. On day 6, cells were fixed 
with 4% PFA, stained with Hoechst 33342 and imaged by ImageXpressmicro with a 2× 
objective and DAPI filters. 
 2.2.15.2.1 Traffic-ome screen. 
Table 2.12. Name, ID, and sequence of genes participating in Traffic-ome siRNA library. 
Gene symbol Gene ID Gene accession GI number Sequence 
STX1A 6804 NM_004603 4759181 GGAACACGCGGUAGACUAU 
STX2 2054 NM_001980 37577286 UAGACAAGCUCUCAAUGAA 
STX3 6809 NM_004177 34147491 GAUCAUUGACUCACAGAUU 
STX4 6810 NM_004604 34147603 GGACAAUUCGGCAGACUAU 
STX5 6811 NM_003164 94400931 CAGAACAUUGAGUCGACAA 
STX6 10228 NM_005819 58294156 GCAGUUAUGUUGGAAGAUU 
STX7 8417 NM_003569 4507294 GAGUUUGUUGCUCGAGUAA 
STX8 9482 NM_004853 4759187 AAUGAAACCAGGCGGGUAA 
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STX10 8677 NM_003765 4507284 GGAAGAGACCAUCGGUAUA 
STX11 8676 NM_003764 33667037 AGCACUGAAUAUCGAACAA 
STX12 23673 NM_177424 28933464 CCACAAAUCAGCUCGCCAA 
STX16 8675 NM_001001434 47778944 GUAUGAUGUUGGCCGGAUU 
STX17 55014 NM_017919 8923603 CGAUCCAAUAUCCGAGAAA 
STX18 53407 NM_016930 39725935 CUGUCUGAGUCAACGAAUA 
STX19 415117 NM_001001850 49258195 GAGAAGGUUUAGUCUACUU 
SNAP23 8773 NM_130798 18765730 UAACAGAACUCAACAAAUG 
SNAP25 6616 NM_130811 18765734 CUGGAAAGCACCCGUCGUA 
SNAP29 9342 NM_004782 18765736 GAAGCUAUAAGUACAAGUA 
SNAP47 116841 NM_053052 26024192 CCACUCACCUUACGAAAUU 
VAMP1 6843 NM_016830 40549443 UAACAUGACCAGUAACAGA 
VAMP2 6844 NM_014232 7657674 GCGCAAAUACUGGUGGAAA 
VAMP3 9341 NM_004781 42544205 GGAUUACUGUUCUGGUUAU 
VAMP4 8674 NM_003762 42544206 CAACUUCGAAGGCAAAUGU 
VAMP5 10791 NM_006634 31543930 UGACGGAAAUUAUGCGUAA 
VAMP7 6845 NM_005638 27545446 GUACUCACAUGGCAAUUAU 
VAMP8 8673 NM_003761 14043025 CCACUGGUGCCUUCUCUUA 
YKT6 10652 NM_006555 34304384 GCUCAAAGCCGCAUACGAU 
SEC22A 26984 NM_012430 14591918 GGGCAAGGCUCCCGAUUAU 
SEC22B 9554 NM_004892 34335289 AAUAGUGUAUGUCCGAUUC 
SEC22C 9117 NM_032970 21536309 CCUCCAGGCCAUACGCUUU 
BET1 10282 NM_005868 83779007 GGAACUAUGGCUAUGCUAA 
BET1L 51272 NM_016526 34365798 UCCCUUAGGACUCGGAUUU 
GOSR2 9570 NM_054022 60499002 ACGAAUCACUGCAGUUUAA 
GOSR1 9527 NM_001007025 55770857 CAGAAGAACUGAGCUAUUU 
VTI1A 143187 NM_145206 21624647 CGUGAAAGACUUCGGGAAA 
VTI1B 10490 NM_006370 5454165 CCAAAGUAUUGAACGUUCU 
USE1 55850 NM_018467 49574516 UGAAGGUCCACGCGAGCAA 
BNIP1 662 NM_013978 153946402 GGUCCUCUAUAUUGUGAAA 
STXBP1 6812 NM_001032221 73760414 GGACCUUGUUUGUCGAAGA 
STXBP2 6813 NM_006949 5902127 GAGCGGAGUUAUUCGGAGU 
STXBP3 6814 NM_007269 6005885 AGAGUGACAUGAUUCGUAA 
VPS33A 65082 NM_022916 91206458 GGGCGUAACCUUCGCUGAA 
VPS33B 26276 NM_018668 18105057 CCAGUAUGAUCGCCGGAGA 
VPS45 11311 NM_007259 91822913 GCAUAAACAACAAUCGGAU 
SCFD1 23256 NM_182835 33469977 AAGCAUUGGUGCACGAUGU 
EXOC6 54536 NM_001013848 62243651 GAUAAUUGCUGUCCUUAGA 
EXOC7 23265 NM_015219 62241043 CUAAGCACCUAUAUCUGUA 
STXBP6 29091 NM_014178 46048194 GGUUAAUGGUAUCGAUCCU 
STXBP5L 9515 XM_938898 88970941 AGACACGGCCAGUGCGAAU 
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GOPC 57120 NM_001017408 62868212 GGCCUUGGCAUUUCAAUUA 
RABEP1 9135 NM_004703 49574500 UGAGAGACAUGCAGCGAAU 
GAPVD1 26130 NM_015635 51093831 AAGAAGUGGCCAAUCGAUA 
RABGEF1 27342 NM_014504 7657495 AAAUUAAGCCUCCGAAUCA 
RIN1 9610 NM_004292 68989255 AGAAGCUGCUGUCGCCUAA 
RIN2 54453 NM_018993 35493905 GGUCUGGACAAGCGAGGAA 
RIN3 79890 NM_024832 40353728 UCAGAUUGAUUGCGUUCUA 
ALS2 57679 NM_020919 40316934 GAAUGUGUCCUUCGACUAA 
SH3GL2 6456 NM_003026 4506930 CAACCUAAACCACGAAUGA 
RAB22A 57403 NM_020673 34577103 GGACUACGCCGACUCUAUU 
RAB21 23011 NM_014999 7661921 GAUAACUGUUCACGCCUAA 
RAB31 11031 NM_006868 33589860 UGAAGGAUGCUAAGGAAUA 
ARHGAP26 23092 NM_015071 32189359 GCACUACUGUACAUAUCAA 
SNX9 51429 NM_016224 23111056 GUAACCGGAUCUAUGAUUA 
EHD1 10938 NM_006795 30240931 CCGCAAGCUCAACGCGUUU 
MICAL1 64780 NM_022765 20127615 UGGAGAACAUUGUGUACUA 
APPL2 55198 NM_018171 82617617 CUAGUAGAGAUGCGCGAUA 
RBSN 64145 NM_022340 70980546 CGUGAAGCUCUACGAGAAA 
OCRL 4952 NM_001587 21396492 GAACGAAGGUACCGGAAAG 
PICALM 8301 NM_001008660 56788367 CAACAGGCAUGAUAGGAUA 
RAPH1 65059 NM_025252 47132517 GGAAACAGUAAGCGUCAAA 
ARHGDIA 396 NM_004309 34147601 GGUGUGGAGUACCGGAUAA 
FLOT1 10211 NM_005803 6552331 GCAGAGAAGUCCCAACUAA 
ANKFY1 51479 NM_020740 31317251 GGUGUUAUGUCUCUAGUGA 
APPL1 26060 NM_012096 6912241 GAAACUAUGCGCCAAAUCU 
 
2.2.15.3 HPD and HPDL RNAi-mediated gene knockdown 
Glass-bottomed 96-well plates were coated with 15µl 2mg/ml collagen I. 20μl of 150nM ON 
TARGET plus Human HPDL and HPD smart pool were added on top of the ECM. 0.24µl of DF1 
was diluted in 19.86µl of DMEM. 20µl of diluted DF1 were transferred to each well. Plates 
were left 30mins inside the hood at RT to let DF1 and siRNAs make complex. 3×103 cells in 
60μl DMEM media containing 10%FBS, but no antibiotics, were transferred to each well. The 
final concentration of siRNA reached 30nM. Cells were transferred to the incubator with 5% 
CO2 and 37oC over-night. The full growth media was replaced by 200µl of fresh complete or 
depleted media for up to 6 days. At day 2 and 6, cells were fixed and incubated with 10µg/ml 
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Hoechst 33342. Images were collected by ImageXpress micro and analysed by MetaXpress 
and CME software. 
2.2.16 Statistical analysis 
Graphs were created by GraphPad Prism software and t-test and ANOVA tests were 
performed.  To compare two datasets, an unpaired t-test was performed. To compare more 
than two data set, one-way ANOVA was used when there was one independent variable. Two-
way ANOVA was performed when there were two independent variables. Statistical analysis 
for non-targeted metabolic profiling was performed by Perseus software and used Student t-



























Chapter 3: The extracellular matrix supports breast cancer growth 
under amino acid starvation by regulating tyrosine metabolism. 
 
This result chapter is prepared in a format of paper which is soon going to be published in 
bioRxiv. 
Mona Nazemi conceived, planned, and carried out most of the experiments. Montserrat 
Llanses Martinez performed an experiment for Matrigel uptake in the presence of Filipin 
(Figure 5H). Heather Walker ran Mass-spectrometry for the samples (Figure 7 and 
Supplementary Figure 5). 
Abstract 
Breast cancer tumours are embedded in a collagen I reach the extracellular matrix (ECM) 
network where nutrients are scarce due to angiogenesis deficiency and elevated tumour 
growth. Metabolic adaptation is required for the breast cancer cells to endure this condition. 
Here, we demonstrated the presence of ECM rescued cell growth under amino acid (AA) 
starvation, through a mechanism that required ECM uptake. ECM internalisation, followed by 
lysosomal degradation, contributed to upregulation of amino acid content in the cells, 
including tyrosine and phenylalanine. Finally, we revealed that cells on ECM increased the 
phenylalanine and tyrosine metabolism pathway, potentially feeding into the TCA cycle via 
fumarate production. Interestingly, this pathway was required for ECM-dependent cell 
growth under amino acid starvation. Collectively, our results highlight that the ECM 
surrounding breast cancer tumours represents an alternative source of nutrients to support 
cancer cell growth by regulating phenylalanine and tyrosine metabolism.   
Introduction 
Breast cancer is the most common type of cancer among women. In 2012 around 1.7 million 
women were diagnosed with breast cancer with 521,900 deaths worldwide (Coughlin, 2019). 
There are different factors that increase the risk of breast cancer, including the density of 
stroma around the tumour (Provenzano et al., 2008, Kim et al., 2014). There is growing 
evidence that the tumour microenvironment (TME) facilitates tumour growth and survival 
(Hanahan and Coussens, 2012). The TME consists of stromal cells and extracellular matrix 
(ECM). The ECM is a highly dynamic three-dimensional network of macromolecules providing 
structural and mechanical support to the tissues while interacting with cells through different 
receptors (Bergamaschi et al., 2008, Insua-Rodriguez and Oskarsson, 2016). In breast cancer, 
high breast tissue density is associated with a shift to malignancy and invasion. In malignant 
tumours, mRNA expression of procollagen I and III is higher compared to benign tumours 
(Kauppila et al., 1998). Increase in secretion of collagen is linked to higher adhesion, sprouting 
and invasiveness of breast cancer cells (Kim et al., 2014, Liverani et al., 2017, Provenzano et 
al., 2008). The stroma of mammary glands during post-lactational involution, with high level 
of fibrillar collagen and proteolytic fragment of fibronectin and laminin, also supports breast 
cancer metastasis (McDaniel et al., 2006).   
Due to angiogenesis deficiency, the TME is usually nutrient deprived (Baluk et al., 2005, Nagy 
et al., 2010). Different studies showed that cancer cells benefit from extracellular proteins 
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during food scarcity (Muranen et al., 2017, Palm et al., 2015, Rainero et al., 2015b). The main 
biosynthetic needs of cells are accomplished by glucose (Glc) and glutamine (Gln) uptake 
working as carbon building blocks for macromolecules production (Pavlova and Thompson, 
2016). Gln is the most abundant amino acid (AA) in the plasma providing reduced nitrogen as 
a building block of nitrogen-containing compounds including non-essential AAs (NEAAs), 
pyrimidine and purine nucleotides (Nicklin et al., 2009, Bergstrom et al., 1974). Even though 
Gln is known as a NEAA, proliferative cells such as cancer cells need the external sources to 
meet their high demand (Lacey and Wilmore, 1990). Although cancer cells are mainly 
dependent on their microenvironment to provide the nutrients, tumour blood vessels are 
highly branched, leaky, enlarged with inconsistent blood flow, resulting in inefficient nutrient 
transportation and starvation (Nagy et al., 2010, Baluk et al., 2005). One of the cancer 
hallmarks is the reprogramming of energy metabolism, which provides metabolic flexibility 
allowing the cells to adapt to different nutrient conditions (Hanahan and Weinberg, 2011). 
There are alternative sources that cancer cells can benefit from during starvation. In Ras-
driven pancreatic ductal adenocarcinoma cells (PDACs) AA and Gln starvation induced 
albumin and collagen internalization respectively, followed by lysosomal degradation and AA 
extraction (Commisso et al., 2013, Kamphorst et al., 2015, Palm et al., 2015, Olivares et al., 
2017). Serum and growth factor (GF) starvation also induced normal mammary epithelial cells 
to uptake laminin to raise their AA content (Muranen et al., 2017). Despite this growing data, 
the role of internalization of different components of the ECM in breast cancer cells’ 
metabolism and regulatory mechanisms of this process have not been addressed in detail yet.  
To determine whether the ECM surrounding breast cancer cells could provide a metabolically 
favourable microenvironment, here we investigated the effect of the presence of ECM on 
breast cancer growth and metabolism under Gln and full AA starvation. We found that the 
growth of starved invasive breast cancer cells, but not non-transformed mammary epithelial 
cells or non-invasive breast cancer cells, could partially be rescued by the presence of 
different types of ECM. Indeed, Matrigel and collagen I induced MDA-MB-231 cell division and 
enhanced mTORC1 activity under AA starvation. Interestingly, ECM endocytosis was required 
for cancer cell growth under starvation, as matrix cross-linking or reduction of ECM 
internalisation by the endocytosis inhibitor, Filipin, significantly reduced ECM-dependent cell 
growth. Moreover, examining metabolic content of cells on collagen I and Matrigel, compared 
to plastic, showed higher AA content and upregulation of phenylalanine and tyrosine 
metabolism during AA scarcity. Phenylalanine and tyrosine metabolism can lead to the 
production of the TCA cycle intermediate fumarate, resulting in higher cell growth. Indeed, 
inhibition of tyrosine and phenylalanine metabolism opposed ECM-dependent breast cancer 
cell growth under AA starvation. 
Results 
The presence of ECM partially rescued breast cancer cell growth under starvation 
conditions. 
To assess whether the presence of ECMs could help survival or growth of invasive breast 
cancer cells under nutrient deprivation, MDA-MB-231 cells were seeded either on plastic or 
different components of the ECM under Gln or AA deficiency condition. Observing cell growth 
on collagen I, Matrigel and laminin in comparison to the plastic displayed consistent results. 
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MDA-MB-231 cells showed significantly higher cell number and growth rate in plates coated 
with collagen I, Matrigel and laminin compared to the cells on plastic after eight days of Gln 
or AA starvation (Figure 1A-F). Our data also indicated that receiving all the essential nutrients 
make cell growth independent of ECM, as there were no remarkable differences in cell 
number on ECM compared to the plastic under the complete media (Supplementary figure 
1A-C). To test the effect of Gln and AA deficiency on the cell growth in a more physiologic 
condition, MDA-MB-231 were seeded on matrices derived from normal telomerase-
immortalized fibroblasts (TIFs) or cancer associated fibroblasts (CAFs) extracted from the 
breast tumours. There are different studies showing that the ECM surrounding tumours 
released by CAFs has different structure and composition compared to the ECM derived from 
normal fibroblasts (Pankova et al., 2016, Hanley et al., 2016). Desmoplastic stroma around 
the tissue usually correlates to poor prognosis and severe cancer (Saadi et al., 2010, Surowiak 
et al., 2007). Here, cell derived matrices (CDM) from TIFs rescued the growth of cells under 
Gln deficiency but not AA starvation, whereas, on CAF-CDM cell number was significantly 
higher after eight days of Gln or AA starvation (Figure 1G-H). This data implies that CAF-CDM 
might provide a more favourable environment for cancer cells’ growth compared to the TIF-
CDM under AA deprivation. In parallel, to reproduce the in vivo metabolic environment, 
Plasmax, a physiological medium, was used. Plasmax is designed to contain metabolites and 
nutrients at the same concentration of human blood to avoid adverse effects of commercial 
media on cancer cells (Vande Voorde et al., 2019). To simulate starvation conditions, Plasmax 
was diluted with PBS. Our data from cell growth on diluted Plasmax showed that cells on 
collagen I, Matrigel and CAF-CDM had significantly better growth compared to the cells on 
plastic (Figure 1I-J). Taken together, these data demonstrate that the presence of ECM 








Figure 1. The ECM rescued cell growth under starvation conditions. MDA-MB-231 cells were seeded 
either on plastic or on plates coated with (A-B) collagen I (2mg/ml), (C-D) Matrigel (3mg/ml) and (E-F) 
laminin/entactin (3.5mg/ml) for eight days under glutamine (Gln) and amino acid (AA) starvation. Cell 
proliferation was measured by DRAQ5 nuclear staining quantification with the Licor Odyssey system 
every two days up to day eight. Signal intensity from cells under each condition were collected by 
Image Studio Lit software. (G) MDA-MB-231 cells were seeded either on plastic or plates containing 
TIFs-CDM or (H) CAF-CDM under Gln or AA starvation condition for eight days. Cell proliferation was 
measured via Hoechst nuclear staining. Images were collected by ImageXpress micro and analysed by 
MetaXpress software. (I) cells were seeded either on plastic or on plates coated with collagen I 
(2mg/ml) or Matrigel (3mg/ml) in the presence of Plasmax media diluted 1:4 in PBS for eight days. Cell 
proliferation was measured by DRAQ5 nuclear staining. (J) cells were seeded either on plastic or on 
plates containing CAF-CDM in the presence of Plasmax media diluted 1:4 in PBS for six days. Cell 
proliferation was measured via Hoechst nuclear staining. Images were collected by ImageXpress micro 
and analysed by MetaXpress software. Values are mean ± SEM and are representative of at least three 
independent experiments (the black dots in the bar graphs represent the mean of individual 
experiments). *p<0.05, **p<0.01, ***P< 0.001, **** p<0.0001 ANOVA test. 
 
Matrigel partially rescued the growth of non-invasive breast cancer cells under glutamine 
starvation. 
To assess whether the ECM only affects the growth of highly invasive breast cancer cells, the 
growth rate of normal mammary epithelial cells (MCF10A) and non-invasive breast cancer 
cells (MCF10A-DCIS) was tested.  Breast cancer progression starts from benign hyperplasia of 
epithelial cells of the mammary duct, then it evolves to atypical ductal hyperplasia, with a 
little abnormality in cell shape, and ductal carcinoma in situ (DCIS), with cells showing features 
of cancer cells.  At the end, the cells acquire the invasive ductal cancer phenotype (Dawson 
et al., 1996, Rhee et al., 2008, So et al., 2012). To assess cell lines with different tumorigenicity, 
MCF10A and MCF10A-DCIS were seeded either on plastic, collagen I and Matrigel under Gln 
or AA depleted media for eight days. In contrast to MDA-MB-231 cells (Figure 1), MCF10A cell 
growth pattern under starvation on collagen I and Matrigel was similar to plastic. Although 
cell number was higher on collagen I and Matrigel under AA starvation compared to the 
plastic (Figure 2A and C), cells did not show higher growth rate (Figure 2B and D). Experiments 
on MCF10A-DCIS cells, representative of non-invasive breast cancer cells, showed no 
significant changes in cell number on collagen I or Matrigel under AA depleted media 
compared to the plastic (Figure 2E-H). In terms of Gln deficiency, cells on plastic and collagen 
I followed a similar pattern of growth with no remarkable differences in their cell number 
during the starvation time (Figure 2E-H). However, MCF10A-DCIS cells on Matrigel had 
significantly higher cell number and growth rate at day eight of post Gln starvation compared 
to the plastic (Figure 2G-H). These data suggest that the ability of using ECM to compensate 
for nutrient starvation could have been gradually developed in cancer progression while the 








Figure 2. The ECM did not affect normal epithelial cells and non-invasive breast cancer cell growth. 
MCF10A and MCF10A-DCIS cells were seeded either on plastic or on plates coated with (A-B and E-F) 
2mg/ml collagen I, (C-D and G-H) 3mg/ml Matrigel for eight days under Gln and AA starvation. Cell 
proliferation was measured by DRAQ5 nuclear staining quantification with the Licor Odyssey system 
on day two and day eight post starvation. Signal intensity from cells under each condition were 
collected by Image Studio Lit software. Values are mean ± SEM and are representative of at least three 
independent experiments (the black dots in the bar graphs represent the mean of individual 
experiments).  **p<0.01, **** p<0.0001 ANOVA test. 
 
Collagen I and Matrigel increased cell division under starvation conditions. 
Above data demonstrate that MDA-MB-231 cell number was higher on ECM compared to 
plastic during eight days of AA and Gln starvation (Figure 1). However, the ECM mechanism 
of action was still unknown. We therefore asked whether being surrounded by collagen I and 
Matrigel either induced cell survival, proliferation, or both. To answer this question, we used 
5-Ethynyl-2´-deoxyuridine (EdU) as a thymidine analogue to identify cells which passed 
through DNA synthesis and mitosis. Cells were starved for six days when they received EdU. 
EdU incorporation was measured after two days, on day eight of post starvation. According 
to the data comparing cell division on ECM with plastic, MDA-MB-231 cells had significantly 
higher EdU incorporation on collagen I and Matrigel under Gln and AA starvation conditions 
compared to the cells seeded on plastic (Figure 3A-B). Whereas cells growing in complete 
media were around 100% EdU positive on both ECM and plastic (Figure 3A-B). To clarify 
whether the ECM also played an anti-apoptosis role, cell death was assessed by measuring 
the number of cells positive for an apoptosis marker, activated caspase-3/7, at day three and 
eight post AA starvation. The data revealed that, although the apoptosis rate increased 
between day three and day eight under all nutrient condition, there were no significant 
differences between the apoptosis rate on collagen I and Matrigel compared to the plastic 
either at day 3 or day 8 under AA depleted media (Supplementary figure 3A-B). Thus, our data 
indicate that collagen I and Matrigel induce invasive breast cancer cell proliferation under AA 





Figure 3. Collagen I and Matrigel induced cell proliferation under glutamine and amino acid 
starvations. MDA-MB-231 cells were seeded either on plastic or plastic coated with (A) 2mg/ml 
collagen I or (B) 3mg/ml Matrigel under Gln and AA starvation conditions. Cells were incubated with 
EdU on day six post starvation, fixed and stained with Hoechst and Click iT EdU imaging kit on day 8.  
Images were collected by ImageXpress micro and analysed by MetaXpress software. Values are mean 
± SEM and are representative of three independent experiments (the black dots represent the mean 
of individual experiments).  *p<0.05, **p<0.01, **** p<0.0001 ANOVA test.   
 
Collagen I and Matrigel rescued mTORC1 activity in starved cells. 
We next tested whether higher proliferation rate of cells on ECM linked to mTORC1 activity. 
The mTOR signalling pathway is the pivotal regulator of anabolic and catabolic processes in 
the cells. Receiving AA, GFs and energy activates mTORC1 triggering downstream anabolic 
signalling pathways. However, the lack of AA and GFs deactivates mTORC1 and induces 
catabolism resulting in lysosome biogenesis and autophagy (Mossmann et al., 2018). 
Therefore, we investigated whether higher proliferation rate of cells on collagen I and 
Matrigel was linked to higher mTORC1 activity in starved MDA-MB-231 cells. To do this, we 
examined the phosphorylation of an mTORC1 downstream target, ribosomal subunit S6 (S6), 
as an indicator for mTORC1 activity. MDA-MB-231 cells, which were starved for three days 
either on collagen I, Matrigel or plastic, were fixed and stained for phospho-S6 (p-S6).  
Quantifying the intensity of p-S6, as expected, demonstrated that AA starvation resulted in a 
significant reduction in mTORC1 activity on plastic. Interestingly, the presence of the ECM 
could fully rescue mTORC1 activation under starvation (Figure 4A-B). Together, these results 
suggest that collagen I and Matrigel might work as alternative sources of AA for starved MDA-
MB-231 cells to remarkably increase mTORC1 activity. 
 
 
Figure 4. Collagen I and Matrigel rescued mTORC1 activity in starved cells. MDA-MB-231 cells were 
plated either on plastic or plastic coated with (A) 2mg/ml collagen I or (B) 3mg/ml Matrigel under 
complete media or AA starvation. Cells were fixed and stained for p-S6 and nuclei at day three. Images 
were collected by ImageXpress micro and analysed by MetaXpress and Costum Module Editor (CME) 
software. Values are mean ± SEM and are representative of three independent experiments. (The 
bigger dots represent the mean of individual experiments). *p<0.05, **p<0.01 ANOVA test.   
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ECM internalisation inhibition opposed cell growth under amino acid starvation. 
It was previously shown that cancer cells rely on scavenging extracellular proteins and 
extracting AAs from them under starvation to maintain their survival and growth (Olivares et 
al., 2017, Kamphorst et al., 2015). To examine whether invasive breast cancer cells have the 
ability to internalize the ECM under different starvation conditions, we tracked the journey of 
the ECM inside the cells in the presence of a lysosomal protease inhibitor (E64d), to prevent 
lysosomal degradation. Uptake of fluorescently labelled collagen I (Figure 5A) and Matrigel 
(Figure 5B) was monitored under AA depleted media three days post starvation. The 
quantification of collagen I and Matrigel uptake demonstrated that under all nutrient 
condition, MDA-MB-231 cells significantly accumulated higher amount of collagen I and 
Matrigel inside the cell if lysosomal degradation is inhibited (Figure 5A-B), showing that ECM 
components go through lysosomal degradation following internalization. We then wanted to 
investigate whether the growth of cancer cells relies on ECM internalization under nutrient 
deficiency conditions. To assess this hypothesis, collagen I and Matrigel coated plates were 
treated with 10% glutaraldehyde to chemically cross-link amine groups of proteins. Our data 
confirmed that cross-linking completely opposed collagen I and Matrigel internalisation 
(Figure 5C-D). Moreover, the data collected from cell growth on cross-linked collagen I and 
Matrigel demonstrated that MDA-MB-231 growth under complete media did not depend on 
ECM uptake (Figure 5E). In contrast, lack of collagen I and Matrigel uptake due to cross-linking 
completely opposed cell growth under AA starvation (Figure 5F). ECM cross-linking has been 
shown to increase matrix stiffness, thereby affecting cell adhesion and integrin signalling 
(Levental et al., 2009). To examine the signalling effect of ECM crosslinking, the number of 
focal adhesions (FAs) per cell were measured on normal and cross-linked ECM in complete 
media, by staining the cell for the FA protein, paxillin. Our results showed that the number of 
FAs on collagen I was slightly reduced by the cross-linking. However, Matrigel cross-linking 
did not change the number of FAs (Figure 5G), suggesting that the effect of ECM cross-linking 
on cell growth was not due to adhesion defects. To further assess whether lack of ECM 
internalization reduced cell growth under starvation, cells were treated with Filipin. Filipin is 
a cholesterol binding agent that prevents lipid raft-mediated endocytosis (Dutta and 
Donaldson, 2012). Our data revealed that Filipin treatment significantly reduces Matrigel 
uptake and cell growth on Matrigel under AA starvation (Figure 5H and J); whereas it does 
not affect cell growth under complete media (Figure 5I).   
ECM cross-linking has been reported to also prevent MMP-mediated degradation 
(Pourfarhangi et al., 2018). To investigate whether matrix metalloproteinase (MMP)-
dependent ECM degradation is required for internalization, we treated the cells with a broad 
spectrum MMP inhibitor (GM6001) under complete and AA depleted media. MMPs are a 
proteolytic enzyme family that have a major role in ECM degradation associated with 
metastasis and invasion. Expression of different types of MMPs such as MMP-2, MMP-14 and 
MMP-9 in breast cancer is associated with poor prognosis and could be used as an indicator 
for survival rate (Talvensaari-Mattila et al., 1998, Tetu et al., 2006, Yousef et al., 2014). Our 
data showed that MMP inhibition did not affect collagen I and Matrigel uptake and cell growth 
under AA starvation (Supplementary figure 4). Parallel to our results, it has previously been 
shown that inhibition of extracellular proteolytic enzymes including MMP did not change the 
amount of internalized ECM (Everts et al., 1989, Han et al., 2015). Altogether, these results 
indicate that ECM internalization is necessary for breast cancer cell growth under AA 
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Figure 5. MDA-MB-231 cells internalized and degraded collagen I and Matrigel. MDA-MB-231 cells 
were plated under complete (Com) or AA depleted media on dishes coated with N-
Hydroxysuccinimide-fluorescein labelled (A) 1mg/ml collagen I (green) or (B) 3mg/ml Matrigel for 
three days, in the presence of the lysosomal inhibitor E64d (20µM) or DMSO (control). (C-D) Dishes 
were coated with 2mg/ml collagen I or 3mg/ml Matrigel, treated with 10% glutaraldehyde for 30 mins 
or left untreated and labelled with N-Hydroxysuccinimide-fluorescein. Cells were plated on the cross-
liked matrices for three days under AA starvation in the presence of the lysosomal inhibitor E64d 
(20µM). Cells were fixed and stained for actin (red) and nuclei (blue). Images were collected by a Nikon 
A1 confocal microscope. (E-F) MDA-MB-231 cells were seeded on untreated (control) or cross-linked 
(X-linked) collagen I (2mg/ml) or Matrigel (3mg/ml) under complete media or AA starvation and 
stained with Hoechst. Images were collected by ImageXpress micro and analysed by MetaXpress 
software. Values are mean ± SEM and are representative of three independent experiments. (G) MDA-
MB-231 cells were plated under complete media on dishes coated with normal (control) or cross-
linked collagen I (2mg/ml) or Matrigel (3mg/ml) for three days. Cells were fixed and stained for Paxillin, 
actin and nuclei. Images were collected by a Nikon A1 confocal microscope. (H) MDA-MB-231 cells 
were plated under complete media on dishes coated with N-Hydroxysuccinimide-fluorescein labelled 
Matrigel (3mg/ml) in the presence of 5μg/ml Filipin or DMSO control. MDA-MB-231 cells were plated 
under (I) complete media or (J) AA starvation condition on plastic or plates coated with 3mg/ml 
Matrigel. Cells received 5μg/ml Filipin or DMSO as control everyday up to day three. Cell proliferation 
was measured through Hoechst nuclei staining. Images were collected by ImageXpress micro and 
analysed by MetaXpress software. Graphs are shown in A, B and D are representative of around 150 
cells and in G around 60 cells per condition (the bigger dots represent the mean of individual 
experiments). *p<0.05,   **p<0.01 and **** p<0.0001 ANOVA test.   
 
Inhibition of focal adhesion kinase did not affect cell growth on ECM under starvation. 
ECM cross-linking has been shown to affect cell-ECM adhesion (Pourfarhangi et al., 2018). 
Binding of ECM components to the integrin family of ECM receptors induces recruitment of 
focal adhesion proteins on the intracellular domain of integrin triggering different signalling 
pathways inside the cells (Burridge et al., 1992, Maziveyi and Alahari, 2017). Focal adhesion 
kinase (FAK) is a non-receptor kinase located in the FAs. FAK mediates signalling pathways 
initiated by integrins to regulate different cell behaviours, including proliferation, migration, 
and survival. FAK is also over-expressed in some cancers, and it is linked to their 
aggressiveness (Aboubakar Nana et al., 2019).  To test whether the inhibition of focal 
adhesion signalling could affect cell growth under different nutrient conditions, MDA-MB-231 
cells were treated with focal adhesion kinase (FAK) inhibitor, PF573228. Firstly, the auto-
phosphorylation of FAK Tyr397 was measured under different concentrations of PF573228. Our 
results revealed around 80% inhibition of FAK activity with 0.5μM PF573228 concentration 
(Figure 6A-B). Therefore, to assess the effect of FAK inhibition on cell growth, MDA-MB-231 
were seeded either on collagen I, Matrigel or CAF-CDM under complete media or AA 
starvation condition, in the presence of 0.5µM PF573228 or DMSO as control (Figure 6C-F). 
Monitoring cell growth up to day six post starvation revealed no significant difference 
between the control group and the cells receiving the FAK inhibitor on collagen I and Matrigel 
(Figure 6C-D), either in complete or AA-depleted media. Cells growing on CAF-CDM also 
showed no significant differences in cell number at day six under AA starvation. However, in 
the complete media the cell number was significantly lower in the presence of the FAK 
inhibitors compared to the control group (Figure 6E-F). In addition, no changes in quantity of 
FAs were observed in cells under AA starvation compared to the complete media.  (Figure 
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6G). Taken together, these data indicate that signalling events following cell-ECM interaction 
did not affect cell growth under starvation conditions and ECM-dependent cell growth is 





Figure 6. FAK inhibition did not affect cell growth on collagen I, Matrigel and CAF-CDM under AA 
starvation. (A-B) MDA-MB-231 cells were suspended in complete media containing either 0.2μM, 
0.5μM, 0.7m or 1μM of PF573228 or vehicle for 30 mins. Cells were seeded on collagen I for 30 mins 
under the same media. Cells were lysed and proteins were analysed via western blotting with 
antibodies recognising pFAK Tyr397 and GAPDH.  The intensity of the bands was quantified with Licor 
Odyssey technology. Values are mean ± SEM and are representative of three independent 
experiments. *p<0.05, and **p<0.01 ANOVA test. (C-F) MDA-MB-231 cells were seeded on either 
2mg/ml collagen I, 3mg/ml Matrigel or CAF-CDM under complete media or AA starvation for six days. 
Cells received 0.5μM PF573228 (FAKi) or DMSO (control) every two days. Cells were fixed at day two 
and day six and stained with Hoechst. Images were collected by ImageXpress micro and analysed by 
MetaXpress software.  **p<0.01 ANOVA test.   (G) Cells were plated under complete media or AA 
starvation on dishes coated with collagen I (2mg/ml) or Matrigel (3mg/ml) for three days. Cells were 
fixed and stained for Paxillin, actin and nuclei. Images were collected by a Nikon A1 confocal 




ECM promoted cell growth under amino acid starvation by modulating tyrosine and 
phenylalanine metabolism. 
Because cancer cells were able to internalize ECM components and degrade them in the 
lysosomes (Figure 5A-B), and mTORC1 activity was enhanced under AA starvation on ECM 
(Figure 4), we reasoned that the presence of collagen I and Matrigel might lead to increase 
the intracellular AA level. To investigate the differences in the cell metabolite content, we 
performed direct infusion mass spectrometry (DI-MS) of MDA-MB-231 cells either on plastic, 
collagen I or Matrigel under AA starvation. The data showed that the intracellular level of 
many AAs was upregulated on collagen I compared to the plastic. There were significantly 
increase in level of mostly essential AAs (EAAs) including phenylalanine, threonine, 
tryptophan, leucine, isoleucine, and methionine in addition to cysteine, tyrosine, and hydroxy 
proline as NEAAs, on collagen I and Matrigel (Figure 7A and supplementary figure 5A). 
Metabolomic pathway analysis also revealed that phenylalanine and tyrosine metabolism was 
significantly enriched in cells on both collagen I and Matrigel compared to the plastic under 
AA starvation (Figure 7C-D and supplementary figure 5C-D). Comparing metabolites being 
significantly upregulated on collagen I and Matrigel revealed that around 36% of them are 
common in both groups (Data not shown). To confirm the upregulation of phenylalanine and 
tyrosine metabolic pathway on ECM, we performed ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) to measure the concentration of 
phenylalanine, tyrosine, and fumarate in cells growing on collagen I compared to the plastic 
under AA starvation. Phenylalanine and tyrosine metabolic pathway give rise to formation of 
fumarate, which can be fed into the TCA cycle (Figure 8A). The data collected from UPLC-
MS/MS revealed the upregulation of phenylalanine, tyrosine and fumarate in cells seeded on 




Figure 7. Cells had different metabolite content on collagen I compared to plastic under amino acid 
starvation. Cells were starved for 6 days either on collagen I or plastic. (A) Fold changes of amino acid 
levels and (D) fold changes of phenylalanine and tyrosine metabolism pathway intermediates in MDA-
MB-231, which are normalized to the median of total metabolites in each condition. P values were 
measured by Student’s t-test. (B) Volcano plot of cells on collagen I and plastic comparing the fold 
changes and P value of individual metabolites, p-value < 0.05.  Each number is representative of the 
bins allocated to different metabolites which are statistically significant. (C) Highlights the most 
enriched pathways, p-value < 0.05. (E) MDA-MB-231 cells were grown on collagen I or plastic under 
amino acid starvation for 6 days, phenylalanine, tyrosine and fumarate concentrations were measured 
via UPLC-MS/MS. Values are mean ± SEM and are representative of three biological replicates. ***P< 
0.0001 ANOVA test.  
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Phenylalanine metabolism is composed of a series of metabolic reactions, resulting to the 
production of fumarate, which can enter the tricarboxylic acid cycle (TCA), leading to energy 
production. We reasoned that, if the ECM supported cell growth by promoting phenylalanine 
metabolism, the knockdown (KD) of enzymes involved in this pathway would inhibit ECM-
dependent cell growth under AA deprivation. To test this, MDA-MB-231 cells were 
transfected with siRNA against 4-hydroxyphenylpyruvate dioxygenase (HPD), and 4-
hydroxyphenylpyruvate dioxygenase-like (HPDL) (Figure 8A). Indeed, the inhibition of HPDL, 
but not HPD completely opposed cell growth on collagen I under AA starvation (Figure8C). In 
complete media on collagen I, both HPDL and HPD resulted in a small but statistically 
significant reduction in cell growth, while on plastic HPDL KD did not have any impact on cell 
numbers. (Figure 8B and D). Taken together, these data demonstrated that ECM-dependent 
cell growth under AA starvation is mediated by the activation of phenylalanine and tyrosine 





Figure 8. HPDL KD significantly opposed cell growth under AA starvation on collagen I. (A) Schematic 
representation of phenylalanine and tyrosine metabolism pathways. siRNA gene silencing was done 
for HPD and HPDL for MDA-MB-231 cells transfected with siRNA targeting HPD, HPDL or non-targeting 
control (Nt siRNA) on collagen I (A) under complete media, and (B) under AA starvation or (C) on plastic 
under complete media. Cells were fixed at day two and day six post KD. Cell proliferation was 
measured through Hoechst nuclei staining. Images were collected by ImageXpress micro and analysed 




Cancer cells to maintain their high proliferation rate need to optimize their metabolism to 
acquire the maximum amount of nutrients from the environment (Pavlova and Thompson, 
2016). However, nutrient delivery to tumours is inefficient due to lowering vascularization 
and deformed vessels (Forster et al., 2017).  Breast cancer cells are embedded into a highly 
fibrotic microenvironment with unlimited access to various ECM components (Kim et al., 
2014). Different studies suggested that cancer cells rely on extracellular protein 
internalization during starvation (Commisso et al., 2013, Kamphorst et al., 2015, Muranen et 
al., 2017, Palm et al., 2015, Rainero et al., 2015a). Here, we highlight that the ECM 
surrounding breast cancer tumours represents an alternative source of nutrients to support 
cancer cell growth through ECM internalization and lysosomal degradation followed by 
regulating phenylalanine and tyrosine metabolism.   
In this study, we showed that the presence of collagen I, Matrigel, laminin and CAF-CDM 
induced the growth of MDA-MB-231 cells under Gln and AA starvation, while CDM derived 
from normal fibroblasts (TIF) was unable to support cell growth in AA depleted media. It was 
previously shown that the unique composition of CAF-CDM induces invasiveness of breast 
cancer cells while CDM from TIF does not have this property (Hernandez-Fernaud et al., 2017). 
Our data indicate that CDM derived from CAFs could also provide a more favourable 
environment for cells to grow under AA starvation compared to CDM from noncancerous 
fibroblasts. However, cells had similar growth rate when they were growing under complete 
media regardless of them being seeded on plastic, CAF-CDM or TIF-CDM. Contrary to our data, 
it was previously shown that lower stiffness of CDM from TIF compared to CAF-CDM restricts 
cancer cell growth via downregulation of the YAP/TAZ mechanotransduction pathway in 
MDA-MB-231 cells (Kaukonen et al., 2016). In that study TIF cells were producing CDM for 10 
days and cell proliferation was examined at day six. In our study the time allocated for TIF-
CDM production was six days and cell growth was assessed at day eight. Therefore, shorter 
time for CDM production might result in different composition and structural characteristics 
of CDMs. In addition, longer time for cell growth assessment might have given the cells more 
opportunity to adapt and compensate for their lower growth rate.   
In addition, our data comparing the growth rate of invasive breast cancer cells to normal 
mammary epithelial cells and non-invasive breast cancer cells highlighted that the ability of 
using ECM to compensate cell growth under starvation could have been gradually developed 
in cancer cells while they were becoming more invasive. There are studies showing that highly 
invasive breast cancer cells are more prepared to switch between different metabolic 
pathways as a mechanism to adapt to different nutrient availability and environmental stress 
compared to their non-metastasis counterparts (Simoes et al., 2015). In addition, Gln 
deficiency has more deleterious effects on invasive ovarian cancer cells (SKOV3) compared to 
low invasive tumours (OVCAR3) as invasive cells mainly rely on Gln to produce energy (Yang 
et al., 2014). However, in these studies the effect of ECM on cell behaviour was not taken into 
the account. Here, we showed that the lack of Gln also affected the growth of non-invasive 
breast cancer cells, suggesting that this effect could be cell line dependent. Moreover, the 
presence of Matrigel, but not collagen I, could rescue MCF10A-DCIS cell growth under Gln 
depletion. Matrigel is a basement membrane (BM) extract. Non-invasive breast cancer cells 
reside inside the mammary duct and are in contact with the BM (Muschler and Streuli, 2010) 
suggesting the reason why Matrigel has more compensatory effect compared to the collagen 
I. Collagen I is the main component of interstitial matrix with no contact with mammary 
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epithelial cells (Muschler and Streuli, 2010). In addition, our data showed that the presence 
of collagen I and Matrigel did not rescue the growth of normal mammary epithelial cells under 
AA starvation. In contrast, normal mammary epithelial cells were shown to be able 
compensated serum deficiency in their environment by scavenging laminin (Muranen et al., 
2017). However, soluble laminin was used by Muranen at al., while in our study all the ECMs 
were in the form of matrices. In addition, we observed partial rescue of cell growth of serum 
starved MCF10A cells on collagen I (data not shown) suggesting that normal mammary 
epithelial cells’ response to presence of ECM might vary based on different starvation 
conditions.   
Our study demonstrated that higher MDA-MB-231 cell number on collagen I and Matrigel 
under starvation was linked to their higher division rate while their apoptosis was similar to 
the cells growing on plastic. Although it has been previously shown that coating culture area 
with 2D collagen I protects MCF-7 cells from apoptosis under serum starvation (Badaoui et 
al., 2018), our study demonstrated that under AA starvation there is no differences in 
apoptosis between cells on collagen I, Matrigel or plastic. However, other types of cell death 
could be affected by the presence of ECM and further work is required to investigate this. 
Starvation is the condition that the activity of mTORC1 is prevented to allow cells use 
alternative sources of nutrient obtainment like autophagy (Korolchuk et al., 2011, Yang et al., 
2011). There are studies showing that mTORC1 could be reactivated by providing extracellular 
protein to cells under AA deficiency (Muranen et al., 2017, Palm et al., 2015) through a 
positive feedback loop as inhibition of mTORC1 induce ECP scavenging (Muranen et al., 2017, 
Palm et al., 2015, Rainero et al., 2015a). Therefore, here we could suggest that higher 
proliferation rate in starved MDA-MB-231 in the presence of collagen I and Matrigel is 
associated with the higher mTORC1 activity inducing anabolic processes. Furthermore, we 
revealed that the presence of ECM fully restored mTORC1 activity in cells under starvation, 
whereas the ECM could only partially rescue the growth under starvation. Our data are 
consistent with the observation that mTORC1 activity restrains growth if cells rely on 
scavenging ECP as a source of AAs. Indeed, it was shown that AA scarcity induced protein 
scavenging independent of mTORC1 activity. High activity of mTORC1 resulted in a higher 
translation rate. Cells that rely on ECP cannot support the high rate of translation and growth 
at the same time, due to their lower access to free AAs. Therefore, persistence of mTORC1 
activity while cells rely on ECP resulted in lower growth due to insufficient AA sources (Nofal 
et al., 2017), which brings up the question whether mTORC1 inhibition is an efficient target 
for cancer therapy. 
We showed that cell growth relies on ECM uptake and lysosomal degradation in AA depleted 
media. In support of this, we demonstrated that breast cancer cells are able to internalize 
ECM followed by lysosomal degradation under starvation. In addition, lack of ECM 
internalization through either ECM cross-linking or inhibition of lipid raft-mediated 
endocytosis opposed cell growth under AA depleted media. There are some concerns about 
the cytotoxicity of chemical cross-linkers such as glutaraldehyde (Oryan et al., 2018). In our 
study, cells had the same growth rate on both normal and cross-linked ECM under complete 
media. It was also previously revealed that exposing collagen I to glutaraldehyde for 
crosslinking for less than one hour (we treated ECMs with glutaraldehyde for 30mins) did not 
significantly affect growth and metabolic activity of the cells (Lai and Ma, 2013). Moreover, 
we showed that inhibiting MMP activity did not affect cell growth and ECM internalization 
under starvation. This is consistent with previous observations indicating that, even though 
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MMPs can facilitate ECM internalization, cells were shown to internalize intact ECM in vivo 
and in vitro in the presence of MMP inhibitors (Madsen et al., 2013, Han et al., 2015). It is still 
possible that other proteases might be involved in promoting ECM internalisation and further 
work is required to elucidate this. 
In addition, inhibiting signalling pathways downstream of ECM receptors, which induce cell 
proliferation and invasion by activating FAK (Begum et al., 2017), did not affect cell 
proliferation under nutrient starvation. FAK phosphorylation triggers downstream signalling 
pathways ultimately resulting in upregulation of cyclin D1 expression and G1 to S transition 
(Lee et al., 2015, Serrels et al., 2012). Highly metastatic cells have been shown to have higher 
FAK phosphorylation in comparison to their low metastasis counterparts. In addition, 
inhibition of either FAK or β1 integrin reduced cell proliferation in 3D environments but not 
in 2D (Shibue and Weinberg, 2009). In our study, to assure that lack of cell growth is not solely 
due to the FAK inhibition, we optimised a dose of FAK inhibitor reducing FAK phosphorylation 
around 80% with non-significant effect on cell proliferation. Application of that specific dose 
of FAK inhibitor did not affect cell proliferation under starvation. These data imply that the 
role of the ECM here is through endocytosis and lysosomal degradation and not signalling. 
However, further work is needed to fully characterise the contribution of integrin signalling 
in this condition. 
Several studies revealed that cancer cells could rely on scavenging extracellular proteins to 
provide AA and energy in nutrient deprived conditions (Commisso et al., 2013, Davidson et 
al., 2017, Kamphorst et al., 2015, Muranen et al., 2017, Olivares et al., 2017, Palm et al., 2015). 
Here, accumulation of AAs in cells under AA depleted media indicate that invasive breast 
cancer cells catabolize collagen I and Matrigel and derive AAs from their breakdown. It was 
previously shown that PDAC cells extracted proline from collagen I and IV under nutrient 
deprived conditions and this rescued cell growth (Olivares et al., 2017). Interestingly, we did 
not observe proline upregulation in cells on ECM compared to plastic under AA starvation. In 
our study, cells were AA starved, while in study by Olivares et al (2017) cells were under low 
Glc or low Gln conditions (Olivares et al., 2017). Therefore, differences in starvation conditions 
could be the reason why we did not see proline upregulation. However, all AA accumulated 
in the cells on ECM in our study, except cysteine, were also shown to be upregulated in serum 
starved mammary epithelial cells treated with laminin (Muranen et al., 2017). Further studies 
are needed to realize why cells upregulate different types of AA on ECM. Whether is it related 
to the starvation condition, type of ECM or type of cells? 
By performing metabolomic pathway analyses, we identified the upregulation of different 
metabolic pathways, including phenylalanine and tyrosine metabolism, leading to the 
generation of TCA cycle intermediates.  These data raise the possibility that insoluble ECM 
proteins-derived provide AA could promote invasive breast cancer cell proliferation and 
energy production by upregulating metabolic pathways that could feed the TCA cycle. 
Interestingly, a comparison between control, benign and invasive ductal carcinoma tissue 
samples has revealed a significant increase in tyrosine level and phenylalanine/tyrosine 
biosynthesis in invasive cells (More et al., 2018). Alongside, we showed that if we prevent the 
conversion of 4-Hydroxyphenylpyruvic acid (HPD substrate) to homogentisic acid (HPD 
product), we prevent cell growth, with stronger effect being apparent on collagen I under AA 
starvation. HPD is an iron-dependant dioxygenase that has important role in tyrosine 
catabolism and its deficiency has been shown to cause disease like tyrosinemia and 
hawkinsinuria. Tyrosine breakdown eventually can feed in TCA cycle via fumarate formation.  
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It was previously shown that breast cancer cells (MDA-MB-231 and MCF7) have a substantially 
higher HPD expression compared to the adjacent normal tissue. HPD expression was 
correlated to the histological grade and clinical stage of breast cancer (Wang et al., 2019). 
Taken together tyrosine metabolism and HPD activation are essential for breast cancer cell 
growth and could potentially be used as a target for cancer therapy. HPDL shares 44% 
sequence similarity with HPD, and it is the only mammalian paralogue of HPD. Similarity 
between AA sequences of HPD and HPDL suggest that they might have similar substrates. HPD 
is mainly located in cytoplasm while HPDL has been suggested to also localise in mitochondria 
(Ghosh et al., 2020). We showed that under AA starvation, HPDL KD, but not HPD KD, 
completely opposed ECM-dependent cell growth. HPDL KD also results in lower growth rate 
in invasive breast cancer cells only on collagen I, but not plastic, under the complete media. 
In colon adenocarcinoma cells, it has been shown that HPDL KD reduced oxygen consumption, 
implying that it could play a role in controlling mitochondria functions. In addition, cells with 
HPDL gene silencing did not show tyrosine accumulation or tyrosine catabolism dysfunction, 
suggesting that HPDL could have tyrosine metabolism independent functions (Ghosh et al., 
2020). Therefore, further studies are required to characterise the mechanism through which 
HPDL controls ECM-dependent cell proliferation. Future work will measure changes in 
tyrosine and fumarate concentrations upon HPDL KD in cells plated on ECMs, to find whether 
HPDL is required for tyrosine metabolism and fumarate production.  
Taken together, our results highlight a novel role for ECM providing nutrients to AA starved 
invasive breast cancer cells via ECM internalization followed by phenylalanine and tyrosine 
metabolism upregulation. This raises the possibility that targeting phenylalanine and tyrosine 
metabolism could be a viable strategy to slow down breast cancer tumour growth, eventually 
leading to the generation of improved therapies for breast cancer patients. 
Materials and Methods 
Reagents. Primary antibodies for Phospho-S6 Ribosomal Protein ser235/236 and GAPDH were from Cell 
Signalling, Phospho-FAK (Tyr397) from Thermo Fisher and Paxilin from Bdbioscience. Secondary antibodies for 
Alexa-fluor 594 α-Rabbit IgG and Alexa-fluor 488 α- Mouse IgG were from Cell Signalling, IRDye® 800CW and 
IRDye® 680CW were from LI-COR. Alexa fluor TM 555 Phalloidin, Click-iT EdU Imaging Kits and Hoechst 33342 
was from Invitrogen. Nuclear stain DRAQ5 was from LICOR. Collagen I, Matrigel and Laminin/entactin complex 
were from Corning. All media and dialyzed FBS were from Gibco except DMEM with no amino acid which was 
from US Biological life science and Plasmax which was kindly provided by Dr Tardito, The Beatson Institute, 
Glasgow. The details of Plasmax composition are previously described by Vande Voorde et al 2019 (Vande 
Voorde et al., 2019). E64d (Aloxistatin) and PF573228 was from AdooQ Bioscience.  
Cell culture. MDA-MB-231 cells, telomerase immortalised fibroblast (TIF) cells and CAFs, which were from breast 
cancer and were generated in Professor Akira Orimo’s lab, Paterson Institute, Manchester, were cultured in High 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin streptomycin (PS). Cells were grown at 5% CO2 and 37oC and passaged every 3 to 4 days. MCF10A-
DCIS cells were cultured in DMEM/F12 supplemented with 5% Horse serum (HS), 20 ng/ml EGF and 1% PS. 
MCF10A cells were cultured in DMEM/F12 supplemented with 5% HS, 20 ng/ml EGF, 0.5mg/ml hydrocortisone, 
10μg/ml insulin and 1% PS. Cells were grown at 5% CO2 and 37oC and passaged every 3 to 4 days.  
ECM preparation. To coat plates/dishes, collagen I, Matrigel and laminin/entactin were diluted with cold PBS on 
ice to have 2mg/ml, 3mg/ml, and 3.5 mg/ml concentration respectively in 15μl/well, followed by 3hrs incubation 
at 5% CO2, and 37oC for polymerization. Cell derived matrix (CDM) was generated from TIF and CAF cells as 
described in Kaukonen et al., 2017 (Kaukonen et al., 2017). Briefly, plates were coated with 0.2% gelatine in PBS 
and incubated at 37° for 1hr, followed by being cross-linked with 1% glutaraldehyde in PBS at room temperature 
(RT) for 30 minutes. Glutaraldehyde was removed and quenched in 1M glycine at RT for 20 minutes, followed 
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by two PBS washes, and an incubation in full media at 5% CO2 and 37oC for 30 minutes. CAF or TIF cells were 
seeded and incubated at 5% CO2, 37oC until being fully confluent (1 or 2 days). Once the cells were 100% 
confluent, the media was replaced to complete growth media containing 50μg/mL ascorbic acid, and it was 
refreshed every two days. TIFs were kept under media supplemented with ascorbic acid for six days while CAFs 
for seven days. The media was aspirated, and the cells washed once with PBS containing calcium and magnesium 
(PBS++). The cells were incubated with the extraction solution containing 20mM NH4OH and 0.5% triton in 
PBS++ for 2 minutes at RT until no intact cells were visible by phase contrast microscopy. Residual DNA was 
digested with 10μg/mL DNase I at 5% CO2, 37oC for 1hr. The CDMs were stored in PBS++ at 4°C. 
Starvation conditions. Media used for starvation were supplemented with either 10% dialyzed FBS for MDA-
MB-231 cell line or 10% HS, 10μg/ml insulin and 20 ng/ml EGF for MCF10A and or 5% HS and 20 ng/ml EGF for 
MCF10A-DCIS. Cells were plated in complete media for 5hrs, then the media was replaced with starvation media 
as indicated in the table 1.  
Table 1. Starvation media 
Media Supplier Ref No 
DMEM, high glucose, no 
glutamine 
Gibco 11960-044 
DMEM, no amino acids US Biological life science D9800-13 
DMEM/F-12, no glutamine Gibco 21331-020 
 
Proliferation assays. 96-well plates containing CAF-CDM, TIF-CDM, collagen I, Matrigel or laminin/entactin, as 
described above, were prepared. Three wells were allocated to each condition as technical replicates.  103 
cells/well were seeded under full growth media. After 5hr incubation in 5% CO2 and 37oC, the full growth media 
was replaced with 200μL of the starvation media shown in table1 or Plasmax. Plasmax was kindly provided by 
Dr Tardito, The Beatson Institute, Glasgow.  Cells were fixed every two days up to day six or eight by adding 4% 
paraformaldehyde (PFA) for 15mins at RT followed by two PBS washes. Cell number was quantified using nuclear 
stains: DRAQ5 or Hoechst. 5µM DRAQ5 in PBS was added to the cells for 1hr at RT with a gentle rocking. Cells 
were washed two times with PBS for 30 minutes to avoid the background fluorescence and kept in PBS for 
imaging with the Licor Odyssey imaging system. DRAQ5 was detected with a 700nm channel with 200µm 
resolution by an Odyssey Sa instrument. The signal intensity, which was the total intensity minus total 
background, of each well was quantified with Image Studio Lit software.  For the Hoechst nuclei staining, cells 
were fixed with 4% PFA containing 10µg/ml Hoechst 33342 for 15mins, followed by two PBS washes.  Image 
analyses of cells were done by MetaXpress micro and Costum Module Editor software (CME) in the Sheffield 
RNAi Screening Facility (SRSF). 
 
ECM uptake assays. To monitor the internalization of ECM, dishes coated with collagen I and Matrigel were 
labelled with 10μg/ml N-Hydroxysuccinimide-fluorescein (diluted in PBS) for 1hr at RT on a gentle rocker, 
followed by two PBS washes. Cells were seeded in full growth media. After a 5hr incubation at 5% CO2 and 37oC, 
full growth media were replaced with AA starvation with the presence of 20μM lysosome inhibitor (E64d) or 
DMSO (control). E64d and DMSO were added again after 48hrs, and cells were fixed at day three by adding 4% 
PFA for 15mins at RT. To permeabilize, cells were treated with 0.25% triton X-100 for 5mins. For actin 
cytoskeleton staining, cells were incubated with Phalloidin Alexa Fluor 555 diluted 1:400 in PBS for 10 mins. To 
preserve the samples, 2-3 drops of Vectashield mounting medium containing DAPI were added to the dishes. 
Cells were visualised by confocal microscopy using a Nikon A1 microscope. Collagen I and Matrigel uptake 
indexes were quantified as described previously by Commisso et at 2014 (Commisso et al., 2014).  
 
Cell division assays. To monitor the cell's ability to proliferate Click-iT EdU Imaging Kits were used. MDA-MB-
231 cells were plated on either ECM or plastic. At day six of starvation, cells were treated with 5µM EdU. Cells 
were incubated with EdU for two days at 5% CO2 and 37oC. At day eight, cells were fixed with 4% PFA containing 
10µg/ml Hoechst 33342 for 15mins at RT. To permeabilize, cells were treated with 0.25% triton X-100 for 5mins 
followed by two PBS washes and two washes with 3% bovine serum albumin (BSA). Cells were incubated with 
EdU detection cocktail (Invitrogen, Click-iT EdU Alexa Fluor 555) for 30 min at RT with gentle rocking. Cells were 
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washed twice with PBS and were kept in PBS for imaging. Images were collected by ImageXpress micro and 
analysed by MetaXpress and costum module editor software.  
 
Immunofluorescence. Cells were fixed with 4% PFA containing 10µg/ml Hoechst 33342 for 15 mins at RT 
followed by a PBS wash. To permeabilize, cells were treated with 0.25% triton X-100 for 5mins followed by two 
PBS washes.  Unspecific binding sites were blocked by incubating with 3% BSA at RT with gentle rocking. Cells 
were incubated with the Phospho-S6 Ribosomal (p-S6) Protein primary antibody overnight at 4oC. The primary 
antibody was removed, and cells were washed twice with PBS for 5mins to 10mins each time. Cells were 
incubated with secondary antibody 1hr at RT with gentle rocking. Cells were washed twice with PBS for 10 to 
30mins and were kept in PBS for imaging. Images were collected by ImageXpress micro and analysed by 
MetaXpress and CME software. 
 
Western Blotting. The culture media was aspirated, and cells were placed on ice. After two washes with ice-cold 
PBS, lysis buffer (50mM Tris pH7 and 1% SDS) were added and lysates were collected and transferred to a 
QiaShredder column (QIAGEN), which were spun for 5min at 14000 rpm. The filter was discarded, and the 
extracted proteins were kept at -20oC. To run the samples, 12% gels were prepared. Samples were fully thawed 
at RT and loaded into the 12% gel and ran at 100V for ~2hr 30min. Proteins were transferred from the gel to FL-
PVDF membranes for 75mins at 100V.  Membranes were washed three times with TBS-T (Tris-Buffered Saline, 
0.1% Tween) and blocked in 5% w/v skimmed milk powder in TBS-T for 1hr at RT. Membranes were then 
incubated with primary antibodies overnight at 4oC. After washing the primary antibody, membranes were 
incubated with the secondary antibodies in TBS-T + 0.01% SDS, for 1hr at RT on the rocker. Membranes were 
washed three times in TBS-T for 10min on the rocker at RT followed by being rinsed with water. Images were 
taken at the Licor Odyssey system. Each band intensity was quantified with Image Studio Lite software. 
  
Non-targeted metabolite profiling. MDA-MB-231 cells were seeded on 96-well plates coated with ECM under 
full growth media. After a 5hr incubation at 5% CO2 and 37oC, the full growth media were replaced with the AA 
starvation media. Cells were kept under starvation for six days; the media was removed, and cells were washed 
with ice-cold PBS three times. The PBS were aspirated and the extraction solution (cold; 5 MeOH: 3 AcN: 2 H2O) 
was added for 5min at 4oC with low agitation. Metabolites were transferred to eppendorf tubes and centrifuged 
at 4°C and 14000 rpm for 10 mins. Samples were transferred into HPLC vials. The samples were directly injected 
into a Waters G2 Synapt mass spectrometer in electrospray mode within the Sheffield Faculty of Science Mass 
Spectrometry Centre. Three technical replicates of each sample were run, and the replicates were combined to 
obtain an average intensity. The dataset only includes peaks present in all three replicates. The intensity is a 
measure of abundance of any particular mass. The data is binned into 0.2amu m/z bins and the m/z in each bin 
is used to identify putative IDs using HumanCyc database. 
 
Targeted metabolite profiling. MDA-MB-231 cells were seeded on 6-well plates coated with ECM under full 
growth media. After a 5hr incubation at 5% CO2 and 37oC, the full growth media were replaced with the AA 
starvation media. Cells were kept under starvation for six days; the media was removed, and metabolites were 
extracted as described above. Then, mass spectrometer Waters Synapt G2-Si coupled to Waters Acquity UPLC 
was used to separate phenylalanine, tyrosine and fumaric acid with Column Waters BEH Amide 150x2.1mm. The 
injection was 10μl. The flow rate was 0.4ml/min. 
RNAi-mediated gene knockdown. Glass-bottomed 96-well plates were coated with 15µl 2mg/ml collagen I. 20μl 
of 150nM ON TARGET plus Human HPDL and HPD smart pool were added on top of the ECM. 0.24µl of DF1 was 
diluted in 19.86µl of DMEM. 20µl of diluted DF 1 (Transfection reagent) were transferred to each well. Plates 
were left 30mins inside the hood at RT to let DF1 and siRNAs make complexes. 3×103 cells in 60μl DMEM media 
containing 10%FBS, but no antibiotics, were transferred to each well. The final concentration of siRNA reached 
30nM. Cells were transferred to the incubator with 5% CO2 and 37oC over-night. The full growth media was 
replaced by 200µl of fresh complete or AA starvation media for up to 6 days. At day 2 and 6, cells were fixed and 
incubated with 10µg/ml Hoechst 33342. Images were collected by ImageXpress micro and analysed by 
MetaXpress and CME software. 
Statistical analysis. Graphs were created by GraphPad Prism software and t-test and ANOVA tests were 
performed.  To compare two datasets, an unpaired t-test was performed. To compare more than two data set, 
one-way ANOWA was used when there was one independent variable. Two-way ANOVA was performed when 
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there were two independent variables. Statistical analysis for non-targeted metabolic profiling was performed 
by Perseus software and used Student t-test. 
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Supplementary figure 1. MDA-MB-231 cell growth on ECMs under complete media. MDA-MB-231 
cells were seeded either on plastic or on plates coated with (A) collagen I (2mg/ml), (B) Matrigel 
(3mg/ml) and (C) laminin/entactin (3.5mg/ml) for eight days in complete media containing glutamine, 
glucose and 10% DFBS. (D) MDA-MB-231 cells were seeded either on plastic or on plates coated with 
collagen I (2mg/ml) and Matrigel (3mg/ml) in Plasmax with 2.5% DFBS. Cell proliferation was measured 
by DRAQ5 nuclear staining quantification with the Licor Odyssey system. Signal intensity from cells 
under each condition were collected by Image Studio Lit software. (E) MDA-MB-231 cells were seeded 
either on plastic or on plates coated with CAF-CDM in Plasmax with 10% DFBS. Cell proliferation was 
measured via Hoechst nuclear staining. Images were collected by ImageXpress micro and analysed by 
MetaXpress software. Values are mean ± SEM and are representative of at least three independent 









Supplementary figure 2. MCF10A and MCF10A-DCIS growth on ECMs under complete media. 
MCF10A cells were seeded either on plastic or on plates coated with (A) collagen I (2mg/ml), (B) 
Matrigel (3mg/ml) for eight days in complete media containing glutamine, glucose and 10% HS. 
MCF10A-DCIS cells were seeded either on plastic or on plates coated with (C) collagen I (2mg/ml) and 
(D) Matrigel (3mg/ml) for eight days under complete media containing glutamine, glucose and 5% HS. 
Cell proliferation was measured by DRAQ5 nuclear staining quantification with the Licor Odyssey 
system. Signal intensity from cells under each condition were collected by Image Studio Lit software. 
Values are mean ± SEM and are representative of at least three independent experiments. **p<0.01 










Supplementary figure 3. The ECM did not affect apoptosis under starvation. MDA-MB-231 cells were 
seeded on either plastic or plates coated with collagen I (2mg/ml) and Matrigel (3mg/ml) under AA 
starvation or complete media. Cells were stained for activated cas-3/7 at day (A) three or (B) eight 
post starvation. Images were collected by ImageXpress micro and analysed by CME software. Values 
are mean ± SEM and are representative of two independent experiments. (the black dots represent 











Supplementary figure 4. MMP inhibition did not affect ECM uptake and cell growth under 
starvation. (A and B) MDA-MB-231 were seeded either on N-Hydroxysuccinimide-fluorescein labelled 
collagen I (2mg/ml) or Matrigel (3mg/ml) under complete media and in the presence of lysosomal 
protease inhibitor, E64d (20μM). MMP inhibitors GM6001 (10µM) or DMSO (control) were added to 
cells every two days up to day three. Cells were fixed and stained for actin (red) and nuclei (blue). 
Images were collected by a Nikon A1 confocal microscope. **** p<0.0001 ANOVA test. To assess cell 
proliferation, MDA-MB-231 were seeded on (C) collagen I (2mg/ml), (D) Matrigel (3mg/ml), or (E) 
plastic under complete or AA depleted media. GM6001 (10µM) or DMSO (control) were added to cells 
every two days. Cell proliferation was measured by DRAQ5 nuclear staining quantification with the 
Licor Odyssey system on day six post starvation. Values are mean ± SEM and are representative of 











Supplementary figure 5. Cells had different metabolite content on Matrigel compared to plastic 
under amino acid starvation. Cells starved for 6 days either on Matrigel or plastic. (A and D) Fold 
changes of amino acids (A) and tyrosine and phenylalanine metabolism pathway intermediates (D) 
levels in MDA-MB-231 normalized to the median of total metabolites in each condition. P values were 
measured by Student’s t-test. (B) Volcano plot of cells on Matrigel and plastic comparing the fold 
changes and P value of individual metabolites.  p-value < 0.05.  Each number is representative of the 
bins allocated to different metabolites which are statistically significant. (C) Highlights the most 
enriched pathways, p-value < 0.05. 
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Chapter 4: The ECM supports breast cancer cell metabolism under 
amino acid starvation. 
 
4.1 Introduction 
This chapter contains data which provide some background to the work presented in the 
format of a paper in chapter 3. In addition, in this chapter we searched deeper into the 
metabolic changes due to the presence of ECM under AA starvation. 
Previously we found that the presence of ECM rescued the growth of invasive breast cancer 
cells under AA deficiency. In particular, cells were shown to internalize and degrade ECM 
components inside the lysosomes and inhibition of internalization opposed cell growth under 
AA starvation. Metabolomic analysis revealed that the presence of collagen I and Matrigel 
remarkably changed the metabolite content of cells under AA depleted media. On ECM, cells 
mostly presented higher EAAs content, leading to mTORC1 signalling activation under AA 
starvation.  
Cells can sense nutrient fluctuations in the environment and respond to them by balancing 
between anabolic and catabolic processes inside the cells. Mechanistic target of Rapamycin 
(mTOR) signalling pathway is the pivotal regulator of anabolic and catabolic processes. When 
nutrients are available, mTOR enhances anabolic processes such as nucleotide, proteins and 
lipid biosynthesis and prevents lysosomal biogenesis and cellular autophagy. On the other 
hand, during nutrient deficiency, mTOR signalling pathway is inhibited to allow cells to 
promote catabolic activity to provide adequate amounts of nutrients to the cells. Any 
mutation in this pathway could cause metabolic disorder and cancer stimulation (Kim et al., 
2013a, Kim et al., 2013b, Zoncu et al., 2011b). mTOR is a serine-threonine protein kinase 
forming two independent complexes, mTORC1 and mTORC2.  mTORC1 regulates cell growth 
in response to the presence of AAs and GFs, while mTORC2 in involved in actin organization. 
mTORC1 is composed of three main components; 1) regulatory-associated protein of mTOR 
(RAPTOR) recruiting substrates for phosphorylation in mTORC1 complex and is responsible 
for the subcellular localisation of mTORC1; 2) DEP-domain-containing mTOR-interacting 
protein (DEPTOR), working both as mTORC1 endogenous inhibitor and substrate; 3) 
mammalian lethal with SEC13 protein 8 (mLST8), stabilizing the kinase domain of mTORC1 
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(Kim et al., 2013a, Liu and Sabatini, 2020).  Working platform for mTORC1 is the lysosome. 
Activation of mTORC1 is dependent on GFs and nutrients. Availability of nutrients induce 
recruitment of mTORC1 on lysosomes where they become activated through GFs’ 
downstream signalling (Mossmann et al., 2018). Binding of GFs to tyrosine kinase receptors 
trigger PI3K/Akt and Ras/MAPK signalling pathways eventually activates mTORC1 (Mendoza 
et al., 2011). Presence of AAs induce association of Rag GTPase to RAPTOR in mTORC1 
resulting in its activation and lysosomal recruitment. Gln triggers RAG GTPase activation via 
glutaminolysis. During glutaminolysis, Gln converts to α-ketoglutarate which activates 
mTORC1 via enhancing the GTP loading of RAG-GTPase. However, leucine and arginine have 
independent mechanisms to activate RAG-GTPase. Leucine and arginine negatively regulate 
the activity of Rag-GTPase inhibitors, sestrin2 and CASTOR1 (Jewell et al., 2015, Wolfson and 
Sabatini, 2017). Glc also activates mTORC1 via inducing ATP production through glycolysis and 
the TCA cycle. Lack of Glc or inhibition of energy production result in the accumulation of 
AMP, which activates the mTORC1 inhibitor, AMPK (Inoki et al., 2012, Hardie et al., 2012). 
Removal of GFs, sources of energy, and AAs from the intercellular environment leads to 
mTORC1 inactivation and displacement from lysosome to the cytoplasm (Sato et al., 2008, 
Martinez-Carreres et al., 2017).  Starvation is the condition when the activity of mTORC1 is 
prevented to allow cells to rely on other sources of nutrient consumption like autophagy 
(Korolchuk et al., 2011). Several studies showed that mTORC1 inhibition induced by starvation 
increase the scavenging of ECPs, such as albumin (Palm et al., 2015), laminin (Muranen et al., 
2017) and fibronectin (Rainero et al., 2015a) as a compensatory mechanism. Inhibition of 
mTORC1 activity has been suggested as a strategy to limit cancer progression (Tian et al., 
2019). However, mTORC1 might not be a favourable target for cancer therapy since its 
inactivation could help cancer cells to survive by adapting their metabolic pathways to rely on 
alternative sources of nutrients such as ECPs.  
In this chapter we showed that cells can internalize and degrade laminin under starvation. 
Presence of Laminin can partially rescue cell growth and cell division under starvation while 
it does not enhance mTORC1 activity. In addition, we demonstrated that cells under AA 
starvation uptake more Glc compared to the cells under complete media on both ECM and 
plastic. However, presence of ECM increased glycolysis and TCA cycle intermediates and cells 




4.2.1 Cell proliferation assay optimisation.  
In the previous chapter, we quantified cell growth via detecting the signal intensity of the 
nuclei stained by DRAQ5. To assess whether this quantification technique was accurate, 
between 103 to 2x104 MDA-MB-231 cells were plated on clear, flat-bottomed 96-well plates 
for 5hrs. Cells were fixed and stained with DRAQ5. Signal intensity per well was detected with 
the Licor Odyssey imaging system. Our data showed that intensity detected from DRAQ5 
staining is directly proportional to the cell number (Figure 4.1A).  
We have shown in chapter 3 that breast cancer cells were able to internalize and degrade the 
ECM under different starvation conditions. To assure that the ECM was not completely 
degraded by the cells during the proliferation assay, plates were coated with either collagen 
I or Matrigel. Polymerized ECM were incubated with a fluorescently labelled N-
Hydroxysuccinimide Ester reactive dye binding to free amine groups on lysine residues to 
form a stable conjugate. MDA-MB-231 cells were seeded on the labelled matrices the 
following day, and media was replaced with starvation conditions after 5hrs. Cells were fixed 
at day two and day eight post starvation. Intensity of N-Hydroxysuccinimide Ester bound to 
collagen I or Matrigel under each condition was quantified by imaging with the Licor Odyssey 
imaging system. Collected data from plates covered by collagen I and Matrigel revealed that 
there was still matrix remaining at the end of the experiments, suggesting that the cells did 
not completely digest the matrix. However, there was a clear reduction in the amount of 
collagen I between day 2 and day 8 for all the media conditions, while this is a lot less 
pronounced for Matrigel. In addition, the starvations did not affect the total amount of ECM 
present compared to the complete media. (Figure 4.1B-C).  Altogether, these data indicate 
that the quantification of DRAQ5 staining intensity by the Licor odyssey system can be used 
to measure cell proliferation. Moreover, the amount of ECM used to assess cell proliferation 
up to day eight was sufficient, as there was still detectable ECM inside the plates by the end 




Figure 4.1. Optimising techniques for cell proliferation assay. (A) MDA-MB-231 cells were seeded on 
flat bottom 96-well plate. After 5hrs incubation in 5% CO2 and 37oC, cells were fixed and stained with 
DRAQ5 nuclear staining. Signal intensity from well under each condition was collected and quantified 
with the Licor Odyssey system. R Square = 0.9814 linear regression test. Plates were coated with 15μl 
(B) 2mg/ml collagen I or (C) 3mg/ml Matrigel. Matrices were stained with 0.2μg/ml N-
Hydroxysuccinimide ester. 103 MDA-MB-231 cells were seeded on ECMs under complete media (Com), 
glutamine (Gln) and amino acid (AA) starvation, fixed, imaged, and quantified with the Licor Odyssey 
system.  Values are mean ± SEM and are representative of three independent experiments. * p<0.05 
ANOVA test. 
 
4.2.2 TIF-CDM, but not CAF-CDM, supported the growth of non-invasive 
breast cancer cells under glutamine starvation. 
We have previously shown in chapter 3 that the presence of Matrigel, but not collagen I, can 
partially rescue the growth of MCF10A-DCIS cells under the Gln starvation (Chp3 figure 2E-H).  
To test the effect of Gln deficiency on the cell growth in a more physiologic condition, 
MCF10a-DCIS were seeded on matrices derived from TIFs or CAFs extracted from the breast 
tumours. As shown in figure 4.2, cells on TIF-CDM had significantly higher cell number and 
growth rate after eight days of Gln starvation compared to the plastic (Figure 4.2A-B). 
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However, cells plated on CAF-CDM did not show any difference in growth rate compared to 
the cells on plastic in Gln depleted media (Figure 4.2C-D). Altogether, these data indicate that 
TIF-CDM, but not CAF-CDM, was able to support MCF10A-DCIS cell growth under Gln 
starvation. 
 
Figure 4.2. TIF-CDM rescued MCF10A-DCIS growth under glutamine starvation. MCF10A-DCIS cells 
were seeded either on plastic or on (A-B) TIF-CDM or (C-D) CAF-CDM under Gln starvation condition 
for eight days. On day zero 103 cells were seeded under each condition in each well of 96-well plate. 
In each experiment, three wells were allocated to each condition. On day eight, cell proliferation was 
measured via Hoechst nuclear staining. Images were collected by ImageXpress micro and analysed by 
MetaXpress software. Values are mean ± SEM and are representative of at least three independent 





4.2.3 Laminin increased invasive breast cancer cell division under glutamine 
and amino acid starvation conditions. 
We showed in chapter 3 that laminin could partially rescue the growth of the cells under Gln 
and AA starvation (Chp3 figure 1E-F). To confirm whether laminin could induce cell division, 
MDA-MB-231 cells were seeded either on plastic or plates coated with laminin under Gln and 
AA depleted media. Cells received EdU on day six post starvation, were fixed and stained at 
day eight (Described in detail in section 2.2.7). Our result demonstrated that cells on laminin 
have a significantly higher EdU incorporation compared to the cells growing on plastic under 
Gln and AA deficiency (Figure 4.3), while no difference was observed in complete media. 
Altogether, higher percentage of replicative cells on laminin, collagen I and Matrigel indicates 
that presence of ECM facilitates cell proliferation under starvation.   
 
Figure 4.3. Laminin induced cell proliferation under glutamine and amino acid starvations. MDA-
MB-231 cells were seeded either on plastic or plastic coated with laminin/entactin (3.5mg/ml) under 
Gln and AA starvation conditions. Cells were incubated with EdU on day six post starvation, fixed and 
stained with Hoechst and Click iT EdU imaging kit on day 8.  Images were collected by ImageXpress 
micro and analysed by MetaXpress software. Values are mean ± SEM and are representative of three 
independent experiments (the black dots represent the mean of individual experiments).  *p<0.05 





4.2.4 Invasive breast cancer cells internalized and degraded laminin. 
Our results showed that MDA-MB-231 cells had higher growth rate on laminin compared to 
the plastic under starvation (Chp3 figure 1E-F). In addition, the data from EdU labelling 
experiments confirmed that under Gln and AA starvation laminin induced cell replication 
(Figure 4.3). Monitoring collagen I, and Matrigel uptake previously demonstrated that 
invasive breast cancer cells could internalize the ECM and degrade it inside the lysosomes 
under different nutrient conditions (Chp3 figure 5A-B). Therefore, to examine whether cells 
also internalized the laminin, we tracked the journey of laminin inside the cells in the presence 
of a lysosomal protease inhibitor (E64d). Uptake of fluorescent-labelled laminin was 
monitored under complete, Gln and AA depleted media. Our results showed that MDA-MB-
231 cells internalized laminin followed by lysosomal degradation under both Gln and AA 
deficiency (Figure 4.4), since the presence of the lysosomal protease inhibitor resulted in a 
profound increase in the amount of laminin which could be detected inside the cells.  
 
Figure 4.4. MDA-MB-231 cells internalized and degraded laminin under normal and starvation 
conditions. MDA-MB-231 cells were plated under complete (Com) or Gln and AA depleted media on 
dishes coated with N-Hydroxysuccinimide-fluorescein labelled laminin/entactin (3.5mg/ml) for three 
days, in the presence of the lysosomal inhibitor E64d (20µM) or DMSO (control). Cells were visualised 
by confocal microscopy using a Nikon A1 microscope (described in more details in section 2.2.6). 
Laminin uptake index was quantified with Image J. Values are mean ± SEM and are representative of 
three independent experiments including around 150 cells per condition (the bigger dots represent 
























































4.2.5 Laminin did not support mTORC1 activity under starvation. 
In chapter 3 we showed that Matrigel and collagen I fully rescued mTORC1 activity in starved 
cells (Chp3 figure 4). We also showed that cells can internalize laminin followed by lysosomal 
degradation under starvation condition (Figure 4.4). In another study, it was shown that 
laminin increased cell growth and promoted mTORC1 activation in normal mammary 
epithelial cells (Muranen et al., 2017). Therefore, we tested whether the presence of laminin 
was able to increase mTORC1 activity in starved MDA-MB-231 cells, by examining the 
phosphorylation of an mTORC1 downstream target, S6, as an indicator for mTORC1 activity.  
Cells were seeded on laminin or plastic in AA depleted condition for three days. mTORC1 
activity was measured by quantifying p-S6 intensity.  Our data demonstrated that laminin did 
not affect p-S6 intensity under AA starvation (Figure 4.5). Taken together, these data indicate 
that the ability of laminin to rescue invasive breast cancer cell growth is independent of 
mTORC1 signalling.  
 
Figure 4.5. Presence of laminin did not affect mTORC1 activity in starved cells. MDA-MB-231 cells 
were plated either on plastic or plastic coated with laminin/entactin (3.5mg/ml) under complete 
media or AA starvation condition. Cells were fixed and stained for p-S6 and nuclei at day three. Images 
were collected by ImageXpress micro and analysed by CME software. Values are mean ± SEM and are 
representative of three independent experiments. (The dots represent the mean of individual 




4.2.6 V-ATPase inhibitor decreased cell growth. 
Vacuolar (V)-ATPase is a multi-subunit proton pump complex. It maintains the activity of 
lysosomes via lowering the pH. V-ATPase has two main domains: a peripheral domain, or V1, 
located in cytoplasm to supervise ATP hydrolysis and an integral domain, or V0, embedded in 
membrane, responsible for transferring protons from the cytoplasm to the lumen of the 
lysosome (Forgac, 2007). Inhibiting V-ATPase activity causes deacidification of lysosome and 
consequently constrain lysosomal protease degradation (Abu-Remaileh et al., 2017). V-
ATPase activity has also been shown to be required for AA sensing and mTORC1 activation. 
Accumulation of AAs inside the lysosomes induces a signal transferred to Rag GTPases via the 
V-ATPase–Ragulator interaction leading to mTORC1 lysosomal recruitment and activation 
(Zoncu et al., 2011a). The data presented in chapter 3 demonstrated that the presence of 
ECM rescued mTORC1 activity which could be a result of the ECM being degraded in the 
lysosomes to extract AAs. To test this, MDA-MB-231 cells were treated with Bafilomycin A1 
(BA1), a V-ATPase inhibitor. Our data showed that, in full media, V-ATPase inhibition 
decreased cell number and mTORC1 activity on both Matrigel and plastic (Figure 4.6A-B). 
Under AA starvation, the treatment of cells with BA1 completely blocked the ability of 
Matrigel to promote cell growth without further impeding the growth of starved cells on 
plastic (Figure 4.6C). We also expected to observe reduction in mTORC1 activity in cells on 
Matrigel in the presence of BA1, however, mTORC1 activity did not show any change upon 
BA1 treatment compared to the control group under AA starvation (Figure 4.6D). Taken 
together, these data suggest that inhibiting the V-ATPase activity in the presence of soluble 
nutrients decreased mTORC1 activity and cell growth regardless of cells being on ECM or not. 
In contrast, the inhibitory effect of BA1 on cell growth under AA starvation on Matrigel 
suggests that cells might need ECM degradation in the lysosomes to rescue their growth. 
However, the Matrigel-induced rescue of mTORC1 function was independent of V-ATPase 




Figure 4.6. Effect of V-ATPase inhibitor on cell growth and mTORC1 activity on Matrigel. MDA-MB-
231 cells were plated either on plastic or plastic coated Matrigel (3mg/ml) under (A-B) complete 
media, or (C-E) AA starvation. 200nM Bafilomycin A1 or DMSO (control) were added to each condition 
every day.  Cells were fixed and stained for p-S6 and nuclei at day three.  Images were collected by 
ImageXpress micro and analysed by CME software. Values are mean ± SEM and are representative of 
three independent experiments. (The black dots represent the mean of individual experiments).  











4.2.7 Glucose uptake was not responsible for cell growth under amino acid 
starvation. 
Previously we showed that deacidifying lysosomes to inhibit their protease activity and ECM 
degradation did not affect mTORC1 signalling under AA starvation. Despite it was preventing 
cell growth. Therefore, cells might rely on another source of nutrients or GFs to reactivate 
mTORC1 in the presence of ECM. Studies have shown that availability of Glc induces mTORC1 
activity (Liu and Sabatini, 2020). It has been revealed that NEAA biogenesis could occur 
through Glc uptake. Breast cancer cells could use Glc to produce serine and glycine, which can 
be fed into the folate and methionine cycle to produce cysteine (Geck and Toker, 2016). In 
addition, ECM degradation promotes GLUT1 expression and Glc uptake (Sullivan et al., 2018). 
Since cells under AA starvation have access to Glc, we hypothesised that the ECM could 
promote cell growth and mTORC1 activity by upregulating Glc uptake. To address this, MDA-
MB-231 cells were seeded either on collagen I, Matrigel or plastic under AA starvation 
conditions. Cells received 2-NBDG, a fluorescent tracer for Glc, for 1hr at day six post 
starvation. Quantifying the percentage of cells positive for the Glc tracer showed that there 
was no significant difference between cells on plastic or collagen I under AA starvation. 
However, the percentage of 2-NBDG positive cells was significantly higher under AA 
starvation compared to the cells growing under complete media regardless of cells being on 
collagen I or not (Figure 4.7A). Measuring the intensity of 2-NDBG per cell showed that there 
was more Glc uptake under AA starvation on plastic compared to the collagen I. In addition, 
on plastic, cells under AA depleted media showed higher 2-NBG uptake compared to the cells 
under the complete media (Figure 4.7B). Similarly, data from cells seeded on Matrigel 
revealed that there was no difference in the percentage of cells positive for 2-NBDG on 
Matrigel compared to the plastic under AA starvation. However, a significantly higher 
percentage of AA starved cells were positive for 2-NBDG compared to the cells under 
complete media (Figure 4.7C). Cells on Matrigel did not show significant changes in the 
intensity of 2-NBDG per cell compared to the plastic (Figure 4.7D). Overall, our data showed 
that cells on Matrigel or collagen I under AA starvation did not enhance Glc uptake compared 





Figure 4.7. The presence of ECM did not affect glucose uptake under amino acid starvation. MDA-
MB-231 cells were plated either on plastic or plastic coated with 2mg/ml collagen I (A and B) or 
3mg/ml Matrigel (C and D) under complete media or AA starvation. Cells were incubated with 100μM 
2-NBDG for 1 hr at day six.  Cells were fixed and stained for nuclei.  Images were collected by 
ImageXpress micro and analysed by CME software. Values are mean ± SEM and are representative of 
three independent experiments. (The black dots represent the mean of individual experiments).   
*p<0.05, **p<0.01, *** p<0.001, **** p<0.0001 ANOVA test. 
 
4.2.8 Cells on Matrigel had higher ATP content under amino acid starvation.  
It has been recently shown that cells on higher ECM density have higher Glc uptake, ATP 
production and hydrolysis to meet the energy demand of migration. It was also shown that 
cells have higher intracellular ATP:ADP level in 3D environment compared to 2D environment 
(Zanotelli et al., 2018). Our previous data showed that higher Glc uptake might be an ECM-
independent mechanism cells rely on to compensate for the lack of AAs (Figure 4.7). However, 
energy production in cells under different nutrient conditions was not determined. It is also 
important to define whether the glycolysis/OXPHOS ratio is changed on ECM under starvation 
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and whether these changes contribute to the ECM-dependent cell growth (Chp3 figure1). To 
assess whether the presence of ECM affected ATP content of cells, MDA-MB-231 were seeded 
either on collagen I, Matrigel or plastic under complete or AA depleted media. Cells received 
oligomycin A for 1hr. Oligomycin A inhibits OXPHOS and induces cells to produce ATP via 
glycolysis (Davis et al., 2020). To quantify cellular ATP content, MDA-MB-231 cells were 
incubated with bio-tracker ATP-red live cell dye for 15mins. ATP content of cells in the 
presence of oligomycin A was considered as the product of glycolysis. ATP generated by 
OXPHOS was measured by subtracting the ATP content in the presence of oligomycin A from 
the ATP content of the control group, as previously described (Mookerjee et al., 2017). The 
results showed that cells on Matrigel had a significantly higher amount of ATP compared to 
the cells on collagen I at day three regardless of their nutrient condition. In addition, the 
presence of Matrigel induced cells to rely more on glycolysis to produce ATP than OXPHOS at 
day three (Figure 4.8A). However, at day six post starvation, OXPHOS and glycolysis 
participated equally in ATP production in all groups. Cells under AA starvation on Matrigel 
produced a significantly higher amount of ATP compared to the cells on collagen I and plastic 
at day six. However, there was no difference between ATP content of cells under complete 
media regardless of their growth substrate (Figure 4.8B).  Taken together, our data suggest 
that cells have more tendency to rely on glycolysis as a source of ATP on Matrigel compared 
to other substrates.  
 
Figure 4.8. Cells on Matrigel had higher ATP content under starvation. MDA-MB-231 cells were 
plated either on plastic or plastic coated with collagen I (2mg/ml) or Matrigel (3mg/ml) under 
complete media and AA starvation. Cells were incubated with 126.4μM oligomycin A at 37oC and 5% 
CO2 for 1 hr at day (A) three or (B) six post starvation.  Cells’ ATP content were measured by 
stainingwith 10μM BioTracker ATP-Red Live Cell Dye at 37oC and 5% CO2 for 15 min.  Live cell images 
were collected by ImageXpress micro and analysed by CME software. Values are mean ± SEM and are 
representative of three independent experiments.   *p<0.05, **p<0.01, **** p<0.0001 ANOVA test. 
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4.2.9 The presence of ECM increased glycolysis and TCA cycle intermediates 
under starvation. 
We previously showed that the presence of ECM upregulated intracellular AA content in cells, 
that could be derived from collagen I and Matrigel through lysosomal degradation (Chp3 
figure7 and supplementary figure 5). Many of these AAs can directly or indirectly feed the TCA 
cycle (Yang et al., 2017). Our previous data showed that there was no difference in ATP 
content between cells seeded on collagen I and plastic. However, after six days of AA 
starvation, cells on Matrigel had a significantly higher amount of ATP compared to the cells 
on plastic and collagen I (Figure 4.8). To further analyse whether being surrounded by ECM 
could also affect the activity of metabolic pathways responsible for energy production inside 
the cells, we assessed the amount of TCA cycle and glycolysis intermediates in cells on ECM 
or plastic under starvation. To do this, we performed direct infusion mass spectrometry (DI-
MS) of MDA-MB-231 cells either on plastic, collagen I or Matrigel under six days of AA 
starvation. Our data showed that contrary to the data from 2-NBDG uptake (Figure 4.7), cells 
on both collagen I and Matrigel had higher Glc content compared to the cells on plastic. On 
collagen I, glycolysis intermediates downstream of Glc including fructose-1,6-bisphosphate 
and fructose-6-phosphate were upregulated compared to the plastic (Figure 4.9A). On 
Matrigel, fructose-1,6-bisphosphate was upregulated while amounts of 3-phosphoglycerate 
and 2-phosphoglycerate were downregulated (Figure 4.9C).  Moreover, both collagen I and 
Matrigel induced upregulation of some TCA cycle intermediates including malate, succinate 
and fumarate compared to the cell growing on plastic (Figure 4.9B and D).  Therefore, our 
results indicated that on collagen I, both TCA cycle and glycolysis could be more active 
compared to the cells on plastic under AA starvation, even though cellular ATP content was 
similar in both groups (Figure 4.8B). On Matrigel, cells’ higher TCA cycle intermediates could 
imply that higher ATP content could be due the higher TCA cycle activity. However, while the 
early stage of glycolysis was upregulated on Matrigel, cells on plastic had higher content of 





Figure 4.9. TCA cycle and glycolysis intermediates on collagen I and Matrigel compared to the plastic 
under starvation. Cells starved for six days either on (A-B) collagen I (2mg/ml), (B-C) Matrigel (3mg/ml) 
or plastic. Fold changes of metabolites in MDA-MB-231 normalized to the median of total metabolites 
in each condition. P values were measured by Student’s t-test. Values are mean ± SEM and are 
representative of three biological replicates.  
 
4.3 Discussion   
In this chapter we showed that laminin, like collagen I and Matrigel, induce the proliferation 
of invasive breast cancer cells. In addition, cells were able to internalize and degrade laminin 
under starvation conditions. However, the presence of laminin did not enhance mTORC1 
activity. We also showed that deacidification of the lysosome prevented ECM-dependent cell 
growth without affecting mTORC1 activity under AA depleted media. Assessing Glc uptake 
and cell energy production revealed that AA starvation induced Glc uptake regardless of cells 
being on ECM or not. Cells on ECM upregulated Glc consumption via glycolysis under 
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starvation. Cells on ECMs also upregulated TCA cycle intermediates which could be the reason 
of higher ATP content on Matrigel compared to the plastic.  
First, we tried to validate the technique we use to quantify the cell number and assess cell 
growth.  DRAQ5 datasheet provided by the Licor company 
(https://www.licor.com/documents/zfiq072j08h7bf4wcg4m), suggests that it can be used as 
a cell number normalizing agents at least up to 105 cells/well in 96 well plates. However, we 
have been unable to seed more that 2x104 cells/well without inducing the formation of 
clumps.  We know that plating a very high number of cells for a short time is different from 
having cells growing in the well. Thus, it is likely that the linear range is bigger in the actual 
proliferation experiments. In addition, cell number under starvation conditions in our 
experiments were still within this range.   
Along with the results showing that the compensatory effect of ECM under starvation is linked 
to the level of aggressiveness of the cells (Chp3 figure 2), here we tested the growth rate of 
non-invasive breast cancer cells on CDMs under starvation. Previously we showed that 
Matrigel, but not collagen I, was able to partially rescue MCF10A-DCIS growth under Gln, but 
not AA starvation (Chp3 figure 2G-H). Here, we examined the effect of TIF-CDM and CAF-CDM 
on MCF10A-DCIS cell growth. Our data demonstrated that TIF-CDM, but not CAF-CDM, 
rescued MCF10A-DCIS growth compared to plastic under Gln starvation. The composition of 
breast CAF-CDM and TIF-CDM has been characterised by mass spectrometry showing no 
significant differences in laminin and fibronectin content. However, CAF-CDM has been 
reported to contain a remarkably higher number of collagens including COL4A1, COL4A2 and 
COL8A1 (BM components) and COL1A1 and COL5A3 (IM components) (Hernandez-Fernaud 
et al., 2017). In addition, our data in chapter 3 showed that collagen I did not rescue the 
growth of MCF10A-DCIS cells under starvation (Chp3 figure 2E-F). Hence, higher density of 
collagen might have an adverse effect on non-invasive breast cancer cell growth under 
starvation. However, more studies are required to assess the effect of other types of collagens 
under the same conditions. Taken together, these data indicate that MCF10A-DCIS cells have 
the ability to use some types of ECM, but nor others, to compensate for specific nutrient 
starvation. However, invasive breast cancer cells have potentially acquired more plasticity 




Here, we revealed that laminin induced MDA-MB-231 cell replication under Gln and AA 
starvation. In addition, cells were able to internalize laminin and degrade it inside the 
lysosome under starvation. In agreement with our data, a study showed that serum starvation 
induced soluble laminin uptake in mammary epithelial cells resulting in higher growth and 
lower cell death (Muranen et al., 2017). In addition, adding laminin to MCF10A cells under 
serum and AA starvation enhanced mTORC1 activity by providing AAs for the cells (Muranen 
et al., 2017). In our study, the presence of laminin did not affect mTORC1 activity in MDA-MB-
231 cells under the Gln and AA starvation. In parallel, another study showed that adding 
collagen I or IV to PDAC cells suffering from either Gln or Glc deficiency did not impact 
downstream mTORC1 signalling pathway (Olivares et al., 2017). mTORC1 activation is a 
negative regulator of nutrient scavenging from alternative sources, such as ECPs under 
starvation (Muranen et al., 2017, Palm et al., 2015). Therefore, the absence of a rescue in 
mTORC1 activity in the presence of laminin under starvation might be a way for the cells to 
rescue the growth avoiding mTORC1 negative feedback on ECM uptake. It was previously 
shown that the presence of collagens under Glc and Gln starvation induced cell proliferation 
via ERK1/2 activation in PDAC cells (Olivares et al., 2017). Therefore, it is worth investigating 
whether laminin affects ERK1/2 activation in breast cancer cells under AA starvation, to find 
the mTORC1-independent signalling pathways induced by laminin to support cell growth. 
It has been previously shown that inhibiting V-ATPase activity suppress the mTORC1 activity 
in the presence of laminin in starved cells (Muranen et al., 2017). V-ATPase maintains the 
activity of lysosomes via lowering the pH (Forgac, 2007). In addition, V-ATPase activity is 
required for AA sensing and mTORC1 activation and lysosomal recruitment (Zoncu et al., 
2011a). It has been recently shown that the lack of V-ATPase activity, resulting in lower pH in 
lysosomes, negatively affected iron uptake. Lack of iron uptake in the cells can cause electron 
transport chain impairment and eventually inhibit proliferation (Weber et al., 2020). Hence, 
the reduction of growth under complete media in the presence of BA1 could be mediated by 
iron uptake inhibition. However, the effect of BA1 on cell growth under AA starvation might 
also be linked to inhibition of Matrigel lysosomal degradation limiting accessibility of cells to 
the source of AAs, as no effect on proliferation on plastic was observed. Assessment of 
mTORC1 activation in cells in complete media showed that V-ATPase inhibition reduced p-S6 
intensity. It has been reported that there is an inside-out signalling pathway from lysosome 
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to promote mTORC1 lysosomal recruitment and activation. Accumulation of AAs inside the 
lysosome induces interaction between V-ATPase and Ragulator, a scaffolding complex that 
anchors the Rag GTPases to the lysosome, resulting in RagGTPase lysosomal recruitment 
followed by mTORC1 activation (Zoncu et al., 2011a). Therefore, inhibiting V-ATPase activity 
could impede mTORC1 activity regardless of the availability of nutrients. AA starvation has 
been shown to induce V-ATPase assembly, increasing H+ content of lysosomes (Stransky and 
Forgac, 2015). This suggests that AA depletion might induce ECM lysosomal degradation and 
AA extraction by stimulating lysosomal acidification. In parallel, in chapter 3, we showed that 
cells had a lower amount of ECM accumulated inside the lysosome under AA starvation 
compared to the complete media.  Therefore, under AA starvation, we expected to observe 
higher mTORC1 activity due to enhancement of V-ATPase assembly. In contrast, our data 
revealed that cells on Matrigel had similar p-S6 intensity regardless of them being treated by 
BA1 or not under AA depletion. These results suggest that there might be an alternative 
pathway cells benefit from to induce mTORC1 activity on ECM under AA starvation. In 
addition, lower cell growth in the presence of BA1 under AA starvation on ECM might be due 
to the lack of lysosome activity rather than an mTORC1 dependent effect. 
Metastatic cancer cells have more plasticity in terms of using different metabolic pathways 
under different nutrient conditions. Cancer cells can compensate for lack of glutaminolysis via 
switching to glycolysis for energy production or vice versa (Méndez-Lucas et al., 2020). In this 
study, we asked whether cells on ECM under AA starvation could more efficiently rely on Glc 
uptake followed by glycolysis due to lack of AAs. To address this question, we tracked Glc 
uptake. Our data revealed that lack of AAs induced a greater number of cells to internalize 
Glc compared to the cells in complete media. Comparing the amount of Glc uptake in each 
cell did not show any significant changes between cells on ECMs regardless of their nutrient 
condition. However, cells on plastic had higher Glc uptake under AA deficiency compared to 
the cells in complete media. Thus, MDA-MB-231 cells might mainly rely on Glc during AA 
deficiency as a compensatory mechanism when plated on plastic. However, the presence of 
the ECM reduced the increase of Glc uptake induced by AA starvation, as the cells are mainly 
relying on AA, and potentially sugars, extracted from the ECM. We believe that extraction of 
AAs from the ECMs could be the reason why cells on collagen I and Matrigel had lower Glc 
uptake compared to the cells on plastic. However, there are studies showing that different 
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substrate stiffness changes cellular metabolic pathways.  It was demonstrated that stiff 
environments such as glass induce glycolysis (Mah et al., 2018).  Therefore, it is possible that 
changes in mechanosensing might be one of the reasons why cells on glass had higher Glc 
uptake under AA starvation. However, our data from cells in complete media are not 
consistent with this hypothesis, as cells on both ECM and glass showed similar Glc uptake.  
It was recently shown that changes in matrix density affect the metabolic pathways that 
invasive breast cancer cells rely on to produce energy. However, normal mammary epithelial 
cells do not have this flexibility. Invasive breast cancer cells are more glycolytic on stiff 
collagen and glass. In contrast, they mainly produce energy via OXPHOS on soft collagen (Mah 
et al., 2018). In our study, we found that cells on Matrigel are more glycolytic and have higher 
ATP content compared to cells on collagen I and plastic. Concentration of Matrigel is higher 
in our study compared to the collagen I. However, further studies are needed to measure the 
stiffness differences between collagen I and Matrigel. Another study showed that cells on 
higher ECM density have higher ATP production and hydrolysis, as they need more energy for 
their migration (Zanotelli et al., 2018). In addition, higher ECM degradation resulted in higher 
Glc uptake and energy production during metastasis (Sullivan et al., 2018). Therefore, higher 
energy production in cells on Matrigel compared to collagen I could be due to differences in 
ECM density and energy needed for their degradation as we used higher concentration of 
Matrigel than collagen I. However, more studies are needed to characterise the contribution 
of matrix stiffness and the crosstalk between metabolism and mechanosensing. Furthermore, 
ATP content of cells under AA starvation was similar, or it was even higher on Matrigel, 
compared to the cells growing under the complete media. Recently it was demonstrated that 
the addition of a higher amount of Glc and serum increases ATP:ADP ratio of the cells 
(Zanotelli et al., 2018). We previously showed that cells have higher Glc uptake under AA 
starvation compared to the complete media. Taken together, it is possible that higher glucose 
consumption might result in higher ATP accumulation. However, to consolidate this, the 
ATP:ADP ratio will need to be tested, to find whether accumulation of ATP in cells is due to 
their higher ATP production or it is due to the lower energy consumption. Hence, there is the 
possibility that the higher ATP levels on plastic under starvation were due to lack of cell 
growth and therefore low ATP consumption.  
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In contrast to our previous data showing that Glc uptake of cells on collagen I and plastic was 
similar, data from non-targeted metabolomics revealed that cells on collagen I upregulated 
glycolysis and the TCA cycle compared to the cells on plastic in AA starved cells. In the previous 
chapter we showed that cells on Matrigel and collagen I have higher AA content compared to 
the cells on plastic. Many of these AAs can directly or indirectly feed the TCA cycle (Yang et 
al., 2017). Therefore, the presence of ECM as a source of AA could be the reason why cells 
had higher TCA cycle intermediates. Comparing Glc content of the cells via MS was 
inconsistent to the results assessing 2NBDG uptake. MS data revealed that cells on collagen I 
and Matrigel had higher Glc content compared to the plastic. 2NBDG cannot be utilized in the 
glycolysis pathway. Therefore, 2NBDG content of cells is not an indicator of Glc consumption 
rate and glycolysis. In addition, comparing glycolysis components of cells on Matrigel and 
plastic showed that while the intermediates of early stage of glycolysis was upregulated on 
Matrigel, cells on plastic had higher content of glycolysis intermediates belonging to the later 
steps. Therefore, there is this possibility that the uptake is the same, but the consumption 
rate is different on plastic and ECM resulting in higher Glc, detected by MS, inside the cells on 
ECM. In order to characterise how the ECM affects energy production, further work is 
required to follow incorporation of Glc in different metabolic pathways under AA starvation. 
In conclusion, our data showed that invasive breast cancer cells can internalize laminin and 
degrade it inside the lysosome under Gln and AA starvation. Presence of laminin partially 
increase division rate of MDA-MB-231 cells under starvation conditions which is independent 
of mTORC1 activity. We also showed that AA starved cells on Matrigel have higher ATP 
content compared to the plastic. In addition, cells have higher TCA cycle and glycolysis 
intermediates on ECM compared to plastic in AA depleted media. Taken together, these data 
implying that cells on ECM produce more energy. To find whether Glc could be the source of 
energy in AA starved cells, we measured 2NBDG uptake and we did non-targeted MS to 
measure Glc content of the cells on ECM and plastic. Our data suggests that AA starvation 
increases Glc uptake compared to the complete media. We showed that in AA starved cells, 
Glc uptake is not affected by the substrate cells were growing on. However, Presence of ECM 
might reduce Glc consumption rate compared to the plastic. These data suggest that cells on 
ECM might rely more on ECM degradation to meet their need for energy while cells on plastic 
might rely on Glc consumption. 
142 
 
Chapter 5: An RNAi screen identified AP3, RIN3 and MAPK8IP3 as 
novel regulators of ECM-dependent cell growth under starvation. 
5.1 Introduction 
In chapter 3 we showed that ECM internalization is essential to rescue cell growth under AA 
starvation. We also demonstrated that ECM uptake is followed by lysosomal degradation 
(Chp3 figure5). In addition, cells on ECM showed higher AA content compared to cells on 
plastic indicating that cells can extract AA from ECM (Chp3 figure7). Therefore, it is important 
to characterise how ECM trafficking is regulated.  
ECM degradation facilitates invasion and metastasis in cancer cells. It happens either 
extracellularly via enzymes such as MMPs (more details in section 1.3.3), or intracellularly by 
ECM endocytosis followed by lysosomal degradation. Different pathways can control the 
internalisation of ECM components. Collagen had been shown to be internalized either 
through phagocytosis or clathrin-dependent endocytosis (Madsen et al., 2013). Collagen 
phagocytosis in fibroblast cells occurs via activation of stretch-activated Ca++ channel. Ca++ 
uptake induces interaction of an actin binding protein, gelsolin, to an actin motor protein, 
non-muscle myosin IIA (NMMIIA), to trigger actin assembly and collagen-α2β1 integrin 
phagocytosis (Segal et al., 2001, Arora et al., 2013). Phagosomes containing collagen go 
through maturation by showing late endosome/lysosome marker and Cathepsin B resulting 
in collagen degradation (Arora et al., 2000). Another collagen binding receptor is Endo180 
which is a member of the mannose receptor family (MRs). Endo180 can bind to both soluble 
and native collagen (Madsen et al., 2011). Collagen-bound Endo180 can be internalized and 
trafficked to early endosomes by clathrin-dependent endocytosis (Wienke et al., 2003). 
Collagen is then degraded in lysosomes in a cysteine proteases-dependent way while 
Endo180 is recycled back to the plasma membrane from the early endosomes (Melander et 
al., 2015). FN turnover also happens via its internalization and lysosomal degradation. In 
contrast to collagen, FN uptake is a caveolin-1 mediated endocytosis through its binding to 
α5β1 integrin (Sottile and Chandler, 2005, Shi and Sottile, 2008). Binding of FN to α5β1 in 
migratory fibroblasts causes α5 ubiquitination. α5 ubiquitination results in endosomal sorting 
complex required for transport (ESCRT) delivery of FN bound integrin to intraluminal vesicles 
(ILVs) and eventually lysosomes for degradation (Lobert et al., 2010). Laminin internalization 
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occurs via its binding to α3β1 integrin and phagocytosis. α3β1 in breast cancer cells is 
responsible for Matrigel, and gelatin trafficking and degradation inside the lysosomes. Binding 
of laminin to α3β1 activates the integrin and downstream signalling pathways that results in 
phagocytosis (Coopman et al., 1996). Laminin assembly and internalization has also been 
shown to be regulated by dystroglycan. Binding of laminin to dystroglycan results in its 
internalization to early endosome and finally degradation in lysosomes (Leonoudakis et al., 
2014). Therefore, different ECM components might follow different trafficking routes inside 
the cells (Figure 5.1). However, all, finally, end up in the lysosome for degradation. 
 
Figure 5.1. Schematic representation of ECM internalization pathways. (A) Collagen internalization 
happens through α2β1 integrin dependent phagocytosis activated by Ca++ or through Endo180 and 
clathrin dependent endocytosis. (B) Fibronectin uptake happens through 5β1 and ESCRT or caveolin-
1 dependent pathways. (C) Laminin internalization happens via its binding to dystroglycan or α3β1 
integrin. ECM internalization in the early endosome can be directed to lysosome for degradation 
(Figure is adapted from (Rainero, 2016)). Image is “Created with BioRender.com.” 
 
 In this chapter we characterised the genes participating in ECM trafficking under starvation 
via an siRNA gene silencing approach. The aim of this study is to find genes that are required 
for ECM-dependent cell growth under NEAA starvation. In cancer cells, high proliferation 
rates result in higher metabolic demand. Therefore, they rely on external sources to provide 
NEAAs, a process called NEAAs auxotrophy. NEAAs auxotrophy is linked to different mutations 
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in genes encoding for NEAAs synthesis enzymes (Szlosarek et al., 2006). NEAAs have roles in 
protein, lipid, and nucleotide biosynthesis in cancer cells and recently their metabolic 
pathway became a target for cancer therapy (Choi and Coloff, 2019). It has been shown in 
different studies that NEAA can induce metastasis, survival, and proliferation in cancer cells, 
while NEAA consumption can increase mortality rate and decrease relapse time in patients 
(further details in section 1.4.5) (Jain et al., 2012, Jeschke et al., 2013, Locasale et al., 2011, 
Pollari et al., 2011). Therefore, it is important to understand the compensatory mechanisms 
cancer cells can use to rescue their growth/survival under NEAA starvation. 
5.2 Results 
5.2.1 The presence of collagen I rescued breast cancer cell growth under non-
essential amino acid starvation. 
Chapter 3 showed that the presence of ECMs can partially rescue invasive breast cancer cell 
growth under AA starvation (Chp3 figure 1). To further characterise the role of the ECM in 
conditions where specific AAs were lacking, we assessed cell proliferation on collagen I in 
media containing different AA combinations. We added either essential (Table 2.10) or non-
essential (Table 2.9) AAs to the AA depleted media and monitored cell growth between day 
two up to day eight post starvation in the presence or absence of Gln. Cells seeded under 
EAAs starvation, with or without addition of Gln, did not show any growth regardless of the 
substrate they were plated on (Figure 5.2A-B). In contrast, cells on collagen I under NEAAs 
and Gln starvation had significantly higher cell numbers between day four up to day eight 
(Figure 5.2C). Addition of Gln to the cells growing under NEAAs starvation promoted cell 
growth on plastic. However, there was still a significant increase on collagen I, suggesting that 
the effect of NEAA starvation is not entirely due to Gln starvation (Figure 5.2D). To examine 
MDA-MB-231 cell behaviour in a more physiologic environment, we assessed their growth on 
TIF-CDM and CAF-CDM under NEAA and Gln starvation. Similarly, to what we observed on 
collagen I, both types of CDMs significantly induced cell growth compared to the plastic 
(Figure 5.2E-F). Taken together, these data suggest that ECM can rescue cell growth under 





Figure 5.2.  Collagen I and CDMs partially rescued cell growth under NEAAs starvation. MDA-MB-231 
cells were seeded either on plastic or on plates coated with 2mg/ml collagen I under (A) essential AA 
(EAA) and Gln starvation (Gln), (B) EAA starvation in the presence of Gln, (C) non-essential AA (NEAA) 
and Gln starvation, and (D) NEAA starvation in the presence of Gln. Cell proliferation was measured 
by quantifying DRAQ5 nuclear staining with the Licor Odyssey system every two days up to day eight. 
MDA-MB-231 cells were seeded either on plastic or plates containing (E) TIFs-CDM or (F) CAF-CDM 
under Gln and NEAA starvation for eight days. Cell proliferation was measured via Hoechst nuclear 
staining. Images were collected by ImageXpress micro and analysed by MetaXpress software. Values 
are mean ± SEM and are representative of at least three independent experiments. *p<0.05, ***P< 





5.2.2 ECM cross-linking opposed cell growth under NEAAs starvation. 
We showed in chapter 3 that lack of ECM internalization due to cross-linking opposed breast 
cancer cell growth under AA starvation (Chp3 figure 5F). To assess whether the inhibition of 
ECM uptake has a similar effect under NEAA starvation, we seeded cells on normal or cross-
linked ECMs in NEAA depleted media. Henceforward, NEAA starvation refers to AA depleted 
media with the addition of EAAs (Table 2.10) in the absence of Gln.  Our data revealed that 
cross-linking of Matrigel and CAF-CDM significantly reduced cell growth (Figure 5.3B-C); while 
on collagen I, cross-linking resulted in a small and not statistically significant reduction (Figure 
5.3A).  Altogether, our data indicate that ECM internalisation is required for ECM-dependent 
cell growth under NEAA starvation.  
 
Figure 5.3. ECM cross-linking opposed matrix-dependent cell growth under NEAA starvation. MDA-
MB-231 cells were seeded on untreated (control) or cross-linked (X-linked) (A) 2mg/ml collagen I, (B) 
3mg/ml Matrigel or (C) CAF-CDM under NEAA starvation. Cell proliferation was measured through 
Hoechst nuclei staining. Images were collected by ImageXpress micro and analysed by MetaXpress 
software. Values are mean ± SEM and are representative of three independent experiments. *p<0.05,   






5.2.3 RNAi screen setup and evaluation on Matrigel. 
So far, we demonstrated that MDA-MB-231 cells had significantly higher growth on collagen 
I, Matrigel and CDM under NEAA starvation (Figure 5.2 and 5.3). In addition, lack of Matrigel 
and CDM uptake opposed cell growth (Figure 5.3). In addition, we showed in chapter 3 that 
endocytosis inhibition via Filipin addition reduced ECM internalisation and cell growth on 
Matrigel under AA starvation (Chp3 figure 5H). Thus, our data suggest that ECM trafficking 
might be required for ECM-dependent cell growth under AA starvation. To investigate this, 
we took an RNAi approach to downregulate the expression of genes controlling vesicular 
trafficking using the traffic-ome library, in collaboration with the SRSF. Since the RNAi 
screening was previously performed on plastic, further optimisation was needed to adapt the 
workflow in the presence of ECM. To measure the siRNA transfection efficiency in MDA-MB-
231 cells plated on ECM, we used siGLO siRNA as a positive control. siGLO siRNA is a 
fluorescent control providing visual indication of siRNA transfection. We added siGLO and the 
transfection reagent into plates which were pre-coated with collagen I or Matrigel. Then, cells 
were seeded on top for the transfection to occur overnight in complete media. The media 
was exchanged the day after with the NEAA starvation condition. The data collected from 
siGLO transfection showed that on the Matrigel, the number of siGLO positive cells are 
substantially higher compared to the collagen I and plastic (Figure 5.4A). In addition, cells had 
better growth on Matrigel after transfection under NEAA starvation condition (Figure 5.4B). 
Therefore, we continued the rest of optimization on Matrigel.  
Since our proliferation assays are performed up to six or eight days, we decided to examine 
whether siRNA-mediated transient gene knockdown (KD) was stable up to six days after 
transfection. To do this, we chose two genes whose lack of function induces cell death, 
ubiquitin B (UBB), and polo Like Kinase 1 (PLK1). PLK1 is essential for initiation of mitosis and 
its inhibition induces apoptosis and cell death (Colicino and Hehnly, 2018). In addition, PLK1 
expression is usually upregulated in tumours with different origins (Holtrich et al., 1994). 
Ubiquitin's main role is targeting cellular proteins for degradation via the 26S proteasome. It 
has been reported that ubiquitin is upregulated in different tumours. In addition, 
downregulation of ubiquitin through UBB KD inhibits cancer cell proliferation and has a 
cytotoxic effect in MCF7 breast cancer cells (Oh et al., 2013). To examine whether gene KD 
could be effective up to day six on ECM, we coated the plates with Matrigel. Then, PLK1, UBB 
148 
 
and non-targeted (Nt) siRNA were added on top of Matrigel with transfection reagent. To do 
the reverse transfection, MDA-MB-231 cells were transferred to the ECM-coated plates 
containing the siRNAs and were incubated overnight. Cell media was exchanged with the 
fresh media the day after. Our data demonstrated that there is no significant cell growth 
between day three up to day six post UBB and PLK1 siRNA gene KD. In contrast, cells 
transfected with Nt siRNA displayed a significantly higher cell number at day six (Figure 5.4C). 
These data suggest that siRNA-mediated gene KD could be effective up to six days. However, 
we realized that for the siRNA library screening forward transfection was needed due to some 
technical difficulties (explained in detail in section 5.2.4). Therefore, to test effectiveness of 
forward siRNA transfection, we coated the plates with Matrigel. Cells were then seeded on 
Matrigel and incubated for 5 hrs to fully attach to the matrix. Then, media on the top of the 
cells were exchanged with PLK1 and Nt siRNA previously complexed with the transfection 
reagent. After an overnight transfection, the media was replaced by either complete or NEAA 
depleted media to assess cell growth under starvation. Our data revealed that cells 
transfected with PLK1 siRNA had substantially lower cell number six days after transfection 
under both complete and NEAA depleted media (Figure 5.4D). Taken together, our data 
suggests that cells can be transfected on Matrigel via both reverse and forward transfection 








Figure 5.4. Optimizing siRNA transfection on ECM. (A-B) 150nM siGLO was added into the plates 
coated with collagen I (2mg/ml), Matrigel (3mg/ml) or plastic. The addition of the transfection reagent 
and the media containing the cells to the plates reduced the concentration of siRNA to 30nM per well. 
Cells were incubated under NEAA starvation for six days. Cells were fixed, stained with Hoechst, and 
imaged with ImageXpress micro and analysed by MetaXpress and CME software. (C) Reverse siRNA 
transfection. 150nM UBB, PLK1 or Nt siRNA were added into the plates coated with Matrigel (3mg/ml). 
Cells were seeded on top of the siRNAs as described in (A) and incubated overnight. Media was 
changed the day after. Cells were fixed and stained with Hoechst at day six post starvation. (D) Forward 
siRNA transfection. MDA-MB-231 cells were seeded on plates coated with Matrigel (3mg/ml). After 5 
hrs of incubation, the media was removed, and cells were transfected with 30nM PLK1 and Nt siRNA 
overnight. Media was changed the day after. Cells were fixed, stained with Hoechst, and imaged with 
ImageXpress micro and analysed by MetaXpress software. *p<0.05, **p<0.01 and ***p<0.001 ANOVA 





5.2.4 The RNAi Traffic-ome screen. 
Having optimised the transfection condition, an RNAi screen was performed with siRNAs 
targeting mammalian genes involved in vesicular trafficking, called traffic-ome (Table 2.12). 
We received the traffic-ome library from Sheffield RNAi Screening Facility (SRSF), which was 
already printed into 384 well plates. The library comprised siRNA SMART pools (4 siRNA 
pooled per gene) for 75 genes. The single replicate of 75 individual siRNAs were distributed 
in one 384-well plate. After receiving the siRNA plate, positive control, PLK1 siRNA, and 
negative control, Nt siRNA, were added to the plate.  
To perform the screen, we coated two 384-well plates with Matrigel. We seeded MDA-MB-
231 cells on top and left it at 37͘oC for 5hrs for the cells to be fully attached to the Matrigel. 
Meanwhile, we added the transfection reagent to the plate containing pre-printed siRNAs. To 
do the transfection, the media on top of the cells was removed, while fresh media was added 
to the plate containing the siRNAs and transfection reagent. To transfer the siRNA-containing 
media onto the cells, we used the Hamilton robot in SRSF (programmed by the SRSF team). 
Cells were then incubated with siRNAs overnight (Figure 5.5). The day after, the media was 
replaced with either complete or NEAAs depleted media. Therefore, we had two sets of cells 
transfected with the traffic-ome library. One set of cells was growing in complete media and 
the other was growing under NEAA starvation. Six days post starvation, cells were fixed, 





Figure 5.5. High throughput RNAi screen set up. (A) We Added Dharmafect 1(DF1) (Transfection 
reagent) to the plates containing traffic-ome siRNA (4 siRNA pools per gene) library. Cells were 
incubated for 30 minutes for the siRNA and DF1 to become complex. Then, we Added fresh media on 
top. (B) Cells were seeded in a separate plate which is coated with Matrigel (3mg/ml) and they were 
Incubated at 37oC for 5hrs. To do the transfection, we remove the media from cells, and (C) transfer 
four plates (two plates containing siRNA and two plates containing cells) to the Hamilton robot. The 
robot transfers the siRNA with the media to the plates containing cells. (D) Finally, Cells were 
incubated with siRNA overnight at 37oC. 
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Since we showed that ECM-dependent MDA-MB-231 cell growth required ECM 
internalization under NEAA starvation (Figure 5.3), we hypothesized that knocking down 
genes involved in ECM trafficking could reduce cell growth under starvation. We used the z-
score (the number of standard deviations from the mean) to normalize the data to provide 
clearer information about the effect of each siRNA on cell number relative to the rest of the 
sample distribution. PLK1 KD, which has a direct effect on cell proliferation, had z scores 
between -1.5 to -2.5. Thus, we decided to nominate genes with z score < -1.5 as hits. In 
complete media, the following genes were listed as hits, SH3GLB2, COPA, PLK1, SEC22B, 
IHPK3, ACTR2, Myo5b, ARHGDIA, WASF2, ARF6, and RAB22A (Figure 5.6A-B). Under NEAA 
starvation the hits were PACSIN1, COPA, RAB3C, PLK1, GAPVD1, RIN3, SEC22B, AP3D1, 
MAPK8IP3, and Myo5b (Figure 5.6C-D). Among hits, there were some genes in common 
between complete media and NEAA starvation, indicating that their downregulation affected 
cell growth regardless of the nutrient condition. Therefore, we narrowed down the list of hits 
to the genes emerged as hits specifically under NEAA starvation for the further validation. To 
do this, we coated 96-well plates with collagen I and Matrigel. We seeded the cells on top of 
the ECMs and incubated for 5hrs. We prepared siRNAs against GAPVD1, AP3D1, MAPK8IP3, 
RIN3, PACSIN1 and RAB3C genes with transfection reagent in separate tubes. After 5hrs of 
incubation, we exchanged the media on top of the cells with siRNAs and fresh media. Due to 
some technical difficulties, we could not use the data from gene KD on Matrigel. The data 
from siRNA KD on collagen I confirmed that silencing of AP3D1, MAPK8IP3, and RIN3 
significantly reduced cell number compared to the non-targeting siRNA control group under 
NEAA deficiency (Figure 5.6E). However, no interaction between these genes has been found 
so far (Figure 5.6F). AP-3 complex subunit delta-1 (AP3D1) is a subunit of AP3 adaptor-like 
complex, which plays role in transport of proteins from trans-Golgi network (TGN) and early 
endosomes to the lysosomes or other destined organelles (Petrenko et al., 2006).  Mitogen-
Activated Protein Kinase 8 Interacting Protein 3 (MAPK8IP3) has a role in axonal transport in 
the nervous system (Iwasawa et al., 2019).  RIN3 is a Rab5-binding protein that participates 
in transport from the plasma membrane to the early endosomes (Kajiho et al., 2003). So far, 
our data suggests that AP3D, RIN3 and MAPK8IP3 are potential proteins playing a role in ECM 
trafficking under AA starvation. Further studies and validation are needed to characterise 
whether there is any link between them and to define how they control ECM trafficking and 




Figure 5.6. Traffic-ome siRNA screening. Histograms of z score value for number of cells after siRNA- 
mediated gene KD under (A) complete media or (C) NEAAs starvation. The graphs in B and D show the 
quantification of cell number for the proteins being identified as hits (z score <-1.5) under (B) complete 
media or (D) NEAAS starvation. (E) MDA-MB-231 cells were plated on collagen I, transfected with 
GAPVD1, AP3D1, MAPK8IP3, RIN3, PACSIN1 and RAB3C gene siRNA and starved for six days. Cells were 
fixed, stained with Hoechst, and imaged with ImageXpress micro and analysed by MetaXpress 




In this chapter we showed that the presence of collagen I and Matrigel could rescue invasive 
breast cancer cell growth under NEAA starvation, but not EAA starvation. We also 
demonstrated that lack of ECM uptake opposed cell growth under NEAA deficiency, 
suggesting that cells need ECM internalization for their growth under nutrient depleted 
media. In addition, an RNAi screen identified AP3D1, MAPK8IP3 and RIN3 as potential genes 
participating in ECM trafficking under NEAA starvation.  
Our data revealed that the presence of collagen I and Matrigel could induce cell growth under 
NEAA starvation. Interestingly, comparing the metabolite content of MDA-MB-231 cells on 
plastic and collagen I under AA starvation showed upregulation of some NEAAs on collagen I 
including cysteine, hydroxyproline, and tyrosine (Chp3 figure7). NEAAs play different roles in 
breast cancer cells survival, proliferation, and invasion. Higher catabolism of proline in breast 
cancer cells results in higher ATP production and metastasis (Elia et al., 2017). Serine synthesis 
is upregulated via higher expression of 3-phosphoglycerate dehydrogenase (PHGDH) in breast 
cancer cells, which is correlated to lower survival rate and shorter relapse time (Locasale et 
al., 2011, Pollari et al., 2011). Serine is also responsible for producing glycine and cysteine. 
Serine and glycine participate in one carbon metabolism, resulting in nucleotide production 
and proliferation. A previous study showed that blocking of serine, but not glycine, uptake 
inhibits proliferation in breast cancer cells (Labuschagne et al., 2014). Cancer cell glycine 
consumption and biosynthesis has also been shown to correlate with their proliferation and 
metastasis; and breast cancer patients with high reliance on glycine show higher mortality 
rate (Jain et al., 2012). In addition, in our study we showed that even in the presence of EAAs 
and Gln there is a significant difference in cell numbers between cells growing on collagen I 
and plastic. Taken together, it is suggested that NEAA could be important for breast cancer 
cell growth and cells rely on external sources of NEAAs.  
However, invasive breast cancer cells could not grow under EAA starvation regardless of the 
substrate they were seeded on, in the presence or absence of Gln. Therefore, our data suggest 
that the mixture of exclusively NEAAs inhibits MDA-MB-231 cell growth, as we previously 
showed that the ECM was able to rescue cell growth under full AA starvation. In contrast, 
there is a study showing that the presence of dominantly EAAs (100% EAAs with no NEAAs or 
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mixture of 85% EAAs with 15% NEAAs) adversely affects cancer cells growth, including Hela 
cells, while it does not have any effect on normal cells like MCF10A. It was shown that EAAs 
rich media inhibits proteasome activities results in accumulation of proteins associated with 
apoptosis and finally induces apoptosis (Bonfili et al., 2017). It should be considered that in 
the study by Bonfili et al (2017), measurement of cell growth was done on plastic, and we 
could speculate that in the presence of ECM cell behaviour might be different as we showed 
here. In parallel, another study revealed that branch chained AAs, including leucine, 
isoleucine, and valine, which all are EAAs, inhibit insulin induced hepatic tumour cell 
proliferation via inactivation of PI3K/Akt signalling pathways, causing upregulation of pro-
apoptotic and downregulation of anti-apoptotic genes, leading to cell death (Hagiwara et al., 
2012). Additionally, a study showed that addition of glycine solely into the media decreased 
the nucleotide pool of cells and inhibited cell proliferation while addition of serine as NEAA 
increases nucleotide production in cancer cells (Labuschagne et al., 2014). Taken together, 
further studies are needed to find the reason why 100% mixture of NEAAs has cytotoxic effect 
on MDA-MB-231 cells. In particular, it will be important to understand combination of NEAAs 
induces cell death. Is it either all together or is it a combination of some specific NEAAs 
without the presence of any EAAs that results in cell death? 
In this study we showed ECM internalization is required for ECM-dependent MDA-MB-231 
cell growth under starvation. Hence, we set out to investigate what genes could oversee ECM 
trafficking, by performing an siRNA screen for genes participating in vesicular trafficking. Our 
data so far revealed three genes whose silencing adversely impacted on cell proliferation 
under NEAA starvation but not under complete media, suggesting that they might be required 
for ECM internalisation and/or trafficking. One of these genes was AP3D1. AP3D1 is a subunit 
of the AP3 adaptor-like complex. The AP3 complex comprises two large subunits, δ- and β3A-
adaptins, the medium subunit μ3A-adaptin, and the small subunit σ3A-adaptin encoded by 
genes AP3D1, AP3B1, AP3M1, and AP3S1, respectively. The AP3 complex is a component of 
coating proteins recruited on the cytosolic side of membrane to sort the transport of the 
cargo to the intracellular vesicles (Lefrancois et al., 2004). It has been shown that there is a 
higher expression of AP-3 complex in cervical carcinoma which was not observed in normal 
tissue, and it has also been linked to metastasis (Petrenko et al., 2006).  There are different 
studies aiming at characterizing AP3 function. One of the early studies showed that AP3 is 
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responsible for transport of lysosomal transmembrane protein I (LAMP I) and lysosomal 
integral membrane protein II (LIMP II), from the TGN to lysosomes (Le Borgne et al., 1998). 
Additional studies showed that AP3 can recruit clathrin to make clathrin-coated vesicles 
budding from the TGN or tubular endosomes (Drake et al., 2000). It was demonstrated that 
AP3 is associated with early endosome-associated tubules. These tubules are either AP1 or 
AP3 positive. The cargo vesicles emerging from AP1 positive tubules are destined to be 
recycled. However, it was revealed that the vesicle budding from tubular endosome coated 
with AP3, containing LAMP I and LAMP II, are transported to the lysosome (Peden et al., 2004). 
Therefore, loss of function of AP3 results in loss of function of lysosomes since the lysosomal 
transmembrane proteins cannot be delivered properly (Dell'Angelica et al., 1999). Further 
studies are necessary to define the role of AP3 in terms of ECM trafficking. So far, we can 
hypothesize that either lack of lysosome functionality upon AP3D1 KD might lead to lack of 
ECM degradation and AA extraction. Or, AP3 might have a direct role in ECM trafficking from 
early endosome to lysosome (Figure 5.7A). In support of the latter, recent data from our lab 
showed that AP3D1 KD significantly reduces Matrigel trafficking to lysosomes in MDA-MB-
231 cells (Llanses Martinez, data not shown). 
Another validated traffic-ome hit was MAPK8IP3, also known as JIN3. JIN3 is a scaffold protein 
for the MAPK signalling pathway. JIN3 has different trafficking roles inside the cells. Mostly 
the focus of the studies was on neurons, as JIN3 is essential for axonal transport (Iwasawa et 
al., 2019). However, there are some studies demonstrating other functions of JIN3 inside the 
cells. It was shown that JIN3 is a FAK/Src substrate. Src phosphorylates JIN3 and induces its 
recruitment to FA complexes. It was also demonstrated that the phosphorylation of JIN3 is 
more induced by the binding of cells to fibronectin compared to cells binding to poly L lysine 
or being held in suspension. At FAs, JIN3 helps the recruitment of other phosphorylated 
proteins with SH2 domains, including paxillin and results in the formation of actin stress fibres 
and cell spreading (Takino et al., 2002). It was also demonstrated that JIN3 induces invasive 
migration of MDA-MB-231 cells into the collagen I by controlling the exocytosis of MT-MMP1. 
JIN3 work as Arf6 effectors and direct the recruitment of dynamin-dynactin and kinesin-1 
motor proteins to the late endosomes containing MT-MMP1, resulting in its exocytosis and 
ECM remodelling (Marchesin et al., 2015). In addition, in a fibrosarcoma cell line, Ras-driven 
macropinocytosis has been shown to be mediated by the recruitment of JIN3 to Arf6 on the 
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plasma membrane, followed by dynamin and kinesin motor protein engagement, resulting in 
macropinosome formation and transport inside the cell in a microtubule-dependent manner 
(Williamson and Donaldson, 2019). Taken together, here, JIN3 could affect ECM-dependent 
cell growth in multiple ways, by controlling FAK activation, ECM degradation or ECM 
macropinocytosis (Figure 5.7B). Our data presented in chapter 3 showed that ECM-dependent 
cell growth is independent of both FAK activation and MMP activity, suggesting that it is 
unlikely that JIN3 controls cell growth via the modulation of these pathways. Interestingly, it 
has previously been shown that the ECM can be internalised by macropinocytosis under 
nutrient starvation, resulting in AA extraction and cell growth (Commisso et al., 2013, Olivares 
et al., 2017). Therefore, further work is needed to investigate whether JIN3 controls breast 
cancer cell growth under starvation by controlling macropinocytosis-dependent ECM 
internalisation.  
RIN3 is another gene that was selected as a hit of the Traffic-ome screen. It was demonstrated 
that RIN3 binds to Rab5 positive vesicles but not the vesicles containing early endosomes 
markers, EEA1, in Hela cells. Rab5 is involved not only in fusion of early endosome, but it also 
participates in the budding and transport of clathrin-coated vesicles from plasma membrane 
to the early endosome. RIN3 also interacts with amphiphysin II, which has a role in receptor 
mediated endocytosis and is internalised together with RIN3 and Rab5. Therefore, RIN3 
positive vesicles are responsible for the transport between the plasma membrane and early 
endosomes (Kajiho et al., 2003). Taken together, this suggests that RIN3 downregulation 
might inhibit ECM endocytosis (Figure 5.7C). However, further studies are needed to 
characterise ECM trafficking upon RIN3 gene silencing. 
In conclusion, our data indicate that ECM internalization is required for breast cancer cell 
growth under NEAA starvation. Moreover, we identified 3 candidate genes, RIN3, MAKP8IP3 
and AP3D1 that might modulate ECM-dependent cell growth under starvation by controlling 





Figure 5.7. Schematic representation of ECM trafficking pathways that AP3, JIN3 and RIN3 might be 
involved in under starvation conditions. (A) AP3 might regulate ECM trafficking by transporting 
lysosomal membrane protein (LAMP I/II, LIMP II) or via transporting ECM from tubular endosome to 
lysosome. (B) JIN3 could promote ECM internalisation via Ras-driven macropinocytosis. JIN3 might 
also indirectly regulate ECM-dependent cell growth via recruiting FA proteins and triggering 
downstream signalling, or by exocytosis of MT-MMP1 resulting in ECM extracellular degradation. (C) 
RIN3 might play a role in ECM endocytosis controlling ECM transport between the plasma membrane 
and early endosomes.  Image is “Created with BioRender.com.” 
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Chapter 6: Signalling pathways downstream of cell-ECM interaction 
enhance the growth/survival of glucose starved breast cancer cells.  
6.1 Introduction 
In normal somatic cells, presence of nutrients in the environment does not solely trigger 
nutrient uptake. The interaction of cells with soluble GFs and extracellular matrix through 
membrane receptors is required to regulate nutrient consumption (Thompson, 2011, 
Grassian et al., 2011). The presence of GFs generally induces the expression of nutrient 
transporters. In the absence of GFs, however, nutrient transporter expression is 
downregulated, resulting in inadequate nutrient uptake and activation of pro-apoptotic 
molecules such as Bak and Bax and eventually causing cell death (Edinger, 2007). GFs trigger 
nutrient uptake via PI3K and Ras GTPase signalling. Activation of PI3K induces Akt and 
mTORC1 (for further details see section 4.1) activation (Palm and Thompson, 2017). PI3K/Akt 
signalling pathway promotes the translocation of Glc transporters to the plasma membrane 
(Cong et al., 1997, Barthel et al., 1999). Cells uptake and consume Glc to make energy via 
glycolysis. Glycolysis is composed of series of metabolic reactions that use one molecule of 
Glc to generate two molecules of pyruvate and two molecules of ATP (Pelicano et al., 2006). 
Akt activates hexokinase, which phosphorylates Glc to keep it intracellular. Akt also induces 
the activity of glycolytic enzymes (Broecker-Preuss et al., 2017). Ras GTPase signalling also 
induce the expression of a Glc transporter, GLUT1, hexokinase and glycolytic enzymes 
(Broecker-Preuss et al., 2017). Myc is a transcription factor being activated by growth-
promoting signalling has been shown to induce the expression of Gln transporters, ASC2 and 
SNAT5 (Wise et al., 2008, Gao et al., 2009). Myc also induces expression and membrane 
translocation of L-type amino acid transporters (LAT1) (Hayashi et al., 2012). In around 70% 
of cancer types, mutations in these signalling molecules result in their constitutive activation 
leading to GF-independent nutrient uptake (Thompson and Bielska, 2019). For instance, RAS 
GTPase mutation could result in GF-independent constant activation, leading to 
macropinocytosis induction. It has been shown that under nutrient deficiency, 
macropinocytosis promotes the internalization of alternative nutrients, such as albumin or 
collagen (Figure 6.1) (Kim et al., 2018, Olivares et al., 2017, Commisso et al., 2013).  
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In this chapter, we evaluated the cancer cell growth, mTORC1 activation, ECM uptake, and 
energy production on different types of ECMs under serum and Glc starvation. Here, we 
showed that the presence of Matrigel and laminin cannot rescue cell growth under serum 
starvation. In addition, none of the ECMs could enhance cell division rate in serum starved 
cells. In contrast, under Glc starvation cells have higher cell number on ECM compared to the 
plastic. Interestingly, FAK inhibition, but not ECM internalisation, was required for cell growth 
on ECM under Glc starvation. Finally, the presence of ECM did not affect the cellular 
metabolite content in Glc-deprived conditions. Altogether, our data suggest that ECM-




Figure 6.1. Role of Growth factor signalling in nutrient consumption. (A) Ras and Akt increased the 
expression of Glc transporter Glut1. PI3k/Akt signalling pathways also induce the membrane 
translocation of GLUT1 from cytoplasmic vesicles. GLUT3 concentration on the plasma membrane is 
increased by GFs. (B) Myc and Akt activation induce the expression of neutral amino acid transporter, 
LAT1. They also increase the expression of glutamine transporters, SLAT5 and ASCT2. (C) GFs induce 
macropinocytosis via Ras activation leading to ECP and ECM internalisation and lysosomal degradation 






6.2.1 Optimising cell proliferation assays under glucose and serum starvation 
To investigate the role of the ECM in supporting cell growth under serum and Glc starvation, 
we followed a similar approach to the one described in chapter three and four. To quantify 
the extent of ECM degradation during the proliferation assays, polymerized ECMs were 
incubated with a fluorescently conjugated N-Hydroxysuccinimide ester reactive dye 
(IRDye800) (as described in section 2.2.4). MDA-MB-231 cells were seeded the following day, 
and media was replaced with Glc and serum starvation conditions after 5hrs. Cells were fixed 
at day two and day eight post starvation. Intensity of N-Hydroxysuccinimide ester bound to 
collagen I or Matrigel under each condition was quantified via the Licor Odyssey imaging 
system. Our data revealed that the ECM was still detectable at the end of the experiments, 
suggesting that the cells did not completely digest the matrix (Figure 6.2). However, there 
was a substantial reduction in collagen I under all nutrient conditions at day eight compared 
to day two, without any starvation specific effect (Figure 6.2A). In contrast, the amount of 
Matrigel was not changed between day two and day eight, while serum and Glc starvation 
promoted Matrigel degradation compared to the complete media at day eight post starvation 
(Figure 6.2B).  
 
Figure 6.2. Collagen degradation occured during cell proliferation. Plates were coated with 15μl of 
(A) 2mg/ml collagen I or (B) 3mg/ml Matrigel. Matrices were stained with 0.2μg/ml N-
Hydroxysuccinimide ester. 103 MDA-MB-231 cells were seeded on ECMs. Cells were fixed at day two 
and eight. Signal intensity from N-Hydroxysuccinimide-labelled ECMs in each well was collected and 
quantified with the Licor Odyssey system. *P< 0.05, ** p<0.01 ANOVA test. 
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6.2.2 Fibrillar ECMs partially rescued breast cancer cell growth under serum 
starvation. 
To assess whether the presence of ECMs could enhance survival or growth of invasive breast 
cancer cells under GF deprivation, MDA-MB-231 cells were seeded either on plastic or on 
different ECM components under serum deficiency condition. On collagen I, cells had higher 
cell number and growth rate at day eight compared to the plastic (Figure 6.3A-B). In contrast, 
cells on Matrigel under serum starvation showed similar proliferation rate compared to the 
cells on plastic (Figure 6.3C-D). The results from cell growth on laminin was consistent with 
the results from cell growth on Matrigel. There was no difference between the patterns of 
cell growth under serum starvation on laminin or plastic (Figure 6.3E-F). To test the effect of 
serum deficiency on cell growth in a more physiologic condition, MDA-MB-231 were seeded 
on matrices derived from TIFs or CAFs extracted from breast tumours. Cells had higher 
proliferation rate on both TIF-CDM and CAF-CDM compared to the plastic on day eight post 
starvation. However, TIF-CDM resulted in a much bigger rescue on cell growth compared to 
CAF-CDM (Figure 6.3G-H). Altogether, these data demonstrated that fibrillar stromal-type 
matrices, like collagen I, TIF-CDM and CAF-CDM, rescued the growth of cells under serum 
depleted media, while basement-membrane-type matrices Matrigel and laminin, did not 





Figure 6.3.  Fibrillar matrices rescued cell growth under serum starvation. MDA-MB-231 cells were 
seeded either on plastic or on plates coated with (A-B) 2mg/ml collagen I, (C-D) 3mg/ml Matrigel and 
(E-F) 3.5mg/ml laminin/entactin for eight days under serum (FBS) starvation. Cell proliferation was 
measured by DRAQ5 nuclear staining. Signal intensity was collected and quantified with the Licor 
Odyssey system every two days up to day eight. (G) MDA-MB-231 cells were seeded either on plastic 
or plates containing (G) TIFs-CDM or (H) CAF-CDM under serum starvation for eight days. Cell 
proliferation was measured via Hoechst nuclear staining. Images were collected by ImageXpress micro 
and analysed by MetaXpress software. Values are mean ± SEM and are representative of at least three 
independent experiments (the black dots represent the mean of individual experiments). ***P< 0.001, 
**** p<0.0001 ANOVA test. 
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6.2.3 The presence of ECM did not affect normal mammary epithelial cell and 
non-invasive breast cancer cell growth under serum starvation. 
To assess whether the fibrillar ECM-dependent rescue of cell growth was correlated to breast 
cancer cell invasiveness, the growth rate of normal mammary epithelial cells (MCF10A) and 
non-invasive breast cancer cells (MCF10A-DCIS) was tested. Interestingly, the presence of 
serum starvation only resulted in a little inhibition of cell growth on plastic compared to the 
complete media for both cell lines (Figure 6.4 and Chp3 supplementary figure 2 showing the 
growth rate in complete media). In terms of compensatory effect of ECMs, our data revealed 
that the presence of collagen I did not affect the growth pattern of both MCF10A and 
MCF10A-DCIS cells under starvation conditions (Figure 6.4A-B and E-F). However, on Matrigel 
both MCF10A and MCF10A-DCIS cells showed a small increase in cell number (Figure 6.C and 
G) and significantly higher growth rate at day eight compared to cells plated on plastic (Figure 
6.4D and H). Taken together, these results demonstrate that normal mammary epithelial cells 
and non-invasive breast cancer cells are more tolerant to serum deficiency than invasive 
breast cancer cells. In addition, Matrigel, but not collagen I, slightly promotes cell growth under 




Figure 6.4. MCF10A and MCF10A-DCIS growth under serum starvation. MCF10A and MCF10A-DCIS 
cells were seeded either on plastic or on plates coated with (A-B and E-F) 2mg/ml collagen I, (C-D and 
G-H) 3mg/ml Matrigel for eight days under serum (HS) starvation. Cell proliferation was measured by 
DRAQ5 nuclear staining between day two up to day eight post starvation. Signal intensity was 
collected by Licor Odyssey and quantified by Image Studio Lit software. Values are mean ± SEM and 
are representative of at least three replicated from two independent experiments (the black dots 
represent the mean of individual experiments).  **p<0.01 and ***p<0.001 ANOVA test. 
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6.2.4 The presence of ECMs did not promote cell division under serum 
starvation in invasive breast cancer cells. 
Data presented above revealed that, under serum starvation, MDA-MB-231 was partially 
rescued in the presence of fibrillar matrices, like collagen I and CDMs, but not in the presence 
of Matrigel or laminin (Figure 6.3). Therefore, we hypothesized that cells might show an 
increased proliferation rates on collagen I compared to cells on Matrigel, laminin or plastic. 
Thus, we performed EdU incorporation experiments to identify cells which passed through 
DNA synthesis and mitosis (Figure 6.5). Cells were starved for six days when they received 
EdU. EdU incorporation was measured after two days at day eight post starvation. As shown 
in figure 6.5, serum starvation resulted in a significant inhibition of cell growth on plastic. 
MDA-MB-231 cells did not show any differences in terms of EdU incorporation on Matrigel or 
laminin under serum starvation condition compared to the cells seeded on plastic. However, 
there was a slight, but non-significant, increase in cell division rate in the presence of collagen 
I, which is consistent with the small increase in cell number we observed under serum 
depleted media. Cells growing in complete media were around 100% EdU positive on both 
ECM and plastic (Figure 6.5A-C). Taken together, our data suggest that collagen I, Matrigel 
and laminin does not substantially accelerate cell proliferation rate under serum starvation.  
 
Figure 6.5. ECMs did not affect cell division under serum starvation. (A) MDA-MB-231 cells were 
seeded either on plastic or plastic coated with (B) 2mg/ml collagen I, (C) 3mg/ml Matrigel, or (D) 
3.5mg/ml laminin/entactin in complete media (Com) or under serum starvation (FBS). Cells were 
incubated with EdU on day six post starvation, fixed and stained with Hoechst and Click iT EdU imaging 
kit on day 8. Images were collected by ImageXpress micro and analysed by MetaXpress and CME 
software. Values are mean ± SEM and are representative of three independent experiments (the black 




6.2.5 Collagen I, but not Matrigel or laminin, rescued the activity of mTORC1 
under serum starvation. 
 We previously showed that under serum starvation, only collagen I increased the growth rate 
of the MDA-MB-231 cells compared to the plastic (Figure 6.3). In chapter 3, we demonstrated 
that the presence of ECM rescued mTORC1 activity under AA starvation (Chp3 figure 4). 
Therefore, we wanted to test whether higher cell number on collagen I under serum 
starvation could correlate with higher mTORC1 anabolic activity (Mossmann et al., 2018). To 
do this, we examined the rate of phosphorylation of an mTORC1 downstream target, S6, as 
an indicator for mTORC1 activity.  Cells were seeded on collagen I, Matrigel, laminin or plastic 
under complete media or serum depletion conditions for three days and p-S6 intensity was 
quantified. In agreement with our cell proliferation results, as expected serum starvation 
significantly reduced mTORC1 activity on plastic, while the presence of collagen I rescued the 
mTORC1 activity under serum starvation (Figure 6.6A). On Matrigel, even though the p-S6 
intensity was higher compared to the plastic under nutrient deficient condition, the 
difference was not significant (Figure 6.6B). Laminin also did not induce mTORC1 activity 
under starvation as p-S6 intensity was very similar between cells growing on laminin or plastic 
(Figure 6.6C). Our data suggest that collagen I, but not Matrigel or laminin, was able to rescue 
mTORC1 activity under serum starvation in MDA-MB-231 cells.    
One mechanism through which the ECM could promote mTOR activation is by ECM 
internalisation and lysosomal degradation. This can lead to an increase in AA content, 
promoting mTOR activation. Therefore, we wanted to test whether the ECM is internalised 
and degraded in the lysosomes under serum starvation. We tracked the journey of 
fluorescent-labelled collagen I, Matrigel and laminin under complete and serum depleted 
media in the presence or absence of a lysosomal protease inhibitor (E64d). Under complete 
media, cells significantly accumulate higher amounts of ECM in the presence of the lysosomal 
protease inhibitor, suggesting that cells internalize and degrade the ECMs inside the 
lysosomes. However, under serum starvation, lack of lysosomal degradation did not affect 
the amount of collagen I and laminin accumulation within the cells, suggesting that either 
ECM endocytosis or degradation was impaired under serum starvation (Figure 6.6D and F). 
Interestingly, the amount of internalised Matrigel, under serum depleted media, was 
significantly increased in the presence of E64d (Figure 6.6E). Taken together, these data did 
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not show any direct relation between ECM lysosomal degradation and mTORC1 activity under 
serum starvation.  
 
Figure 6.6. Collagen I rescued mTORC1 activity in serum starved cells. MDA-MB-231 cells were plated 
either on plastic or plastic coated with (A) 2mg/ml collagen I, (B) 3mg/ml Matrigel or (C) 3.5mg/ml 
laminin/entactin under complete media or FBS starvation conditions. Cells were fixed and stained for 
p-S6 and nuclei at day three. Images were collected by ImageXpress micro and analysed by CME 
software. MDA-MB-231 cells were plated under complete (Com), or FBS depleted media on dishes 
coated with NHS-fluorescein labelled (D) 1mg/ml collagen I, (E) 3mg/ml Matrigel or (F) 3.5mg/ml 
laminin/entactin for three days, in the presence of the lysosomal inhibitor E64d (20µM) or DMSO 
(control). Values are mean ± SEM and are representative of three independent experiments except 
for Matrigel uptake under complete media which is the representative of two independent 
experiments. (The dots represent the mean of individual experiments). **p<0.01, *** p<0.001, and 
**** p<0.0001 ANOVA test.   
 
6.2.6 The presence of ECM partially rescued breast cancer cell growth under 
glucose starvation. 
To assess Glc dependency of invasive breast cancer cells, MDA-MB-231 cells were seeded on 
plastic under different Glc concentrations. A previous study showed that extraction of proline 
from collagen could recover the growth of pancreatic cancer cells under low Glc conditions, 
1mM and 5mM Glc concentrations. In contrast, under full Glc starvation, proline did not have 
any impact on cell growth (Olivares et al., 2017). First, we compared the growth rate of MDA-
MB-231 cells plated on plastic up to day seven post starvation to see under what Glc 
concentration the cells showed significant inhibition of growth compared to the complete 
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media.  The data showed that the concentrations of Glc between 2.5mM to 0mM significantly 
reduced cell number on plastic compared to the 25mM, which is the concentration of Glc in 
complete media (Figure 6.7A). Thus, we decided to test the growth rate of cells between day 
two up to day eight on ECMs or on plastic under media containing 2.5mM, 1mM, or 0mM Glc. 
Under 2.5mM Glc, cell growth on collagen I and CAF-CDM was similar to plastic. However, on 
Matrigel, cell number was significantly higher at day eight post starvation (Figure 6.7B-D). 
Under 1mM Glc, on collagen I and Matrigel there were higher cell number compared to plastic 
from day six to eight. Cells on CAF-CDM on day eight also showed higher growth rate 
compared to the plastic (Figure 6.7E-G). In 0mM Glc, on collagen I, MDA-MB-231 cells had 
significantly higher growth rate and cell number at day six and eight post Glc starvation 
compared to the cells growing on plastic (Figure 6.8A-B). On Matrigel, cells had substantially 
higher cell number and growth rate from day four forward (Figure 6.8C-D). However, after 
day four, cell number on Matrigel reached a plateau (Figure 6.8C). The cell growth results on 
laminin were consistent with the ones on Matrigel. In 0mM Glc media, MDA-MB-231 cells had 
a higher cell number and growth rate on laminin compared to the cells seeded on plastic 
(Figure 6.8E-F). However, after day four post Glc starvation, cell number was decreasing on 
laminin (Figure 6.8E). To test the effect of a more physiologic environment on cell growth 
under Glc deficiency, MDA-MB-231 were seeded on TIF-CDM or CAF-CDM. Cells had higher 
proliferation rate on TIF-CDM and CAF-CDM compared to the plastic on day eight post 
starvation (Figure 6.8G-H). Therefore, since the most extreme difference in cell growth on 
ECM compared to plastic was observed in media fully depleted of Glc, 0mM Glc was selected 




Figure 6.7.  Cell growth under different glucose concentration. (A) MDA-MB-231 cells were seeded 
on plastic under different Glc concentrations. Cell proliferation was measured by DRAQ5 nuclear 
staining quantification with the Licor Odyssey system on day seven post starvation. MDA-MB-231 cells 
were seeded under 2.5mM Glc on plastic or plates coated with (B) 2mg/ml collagen I, (C) 3mg/ml 
Matrigel or (D) CAF-CDM. MDA-MB-231 cells were seeded under 1mM Glc on plates coated with (E) 
2mg/ml collagen I, (F) 3mg/ml Matrigel or (G) CAF-CDM. (B, C, E, F) Cell proliferation was measured 
by DRAQ5 nuclear staining every two days up to day eight. Signal intensity was quantified by Image 
Studio Lit software. (D, G) cell proliferation was measured via Hoechst nuclear staining. Images were 
collected by ImageXpress micro and analysed by MetaXpress software. Values are mean ± SEM and 
are representative of at least three independent experiments (the dots in A represent the mean of 




Figure 6.8. The ECM rescued cell growth under glucose starvation. MDA-MB-231 cells were seeded 
under Glc free media (Glc starvation) on plates coated with (A-B) 2mg/ml collagen I, (C-D) 3mg/ml 
Matrigel, (E-F) 3.5mg/ml laminin/entactin, (G) TIF-CDM or (H) CAF-CDM and starved for eight days. (A-
F) Cell proliferation was measured by DRAQ5 nuclear staining quantification with the Licor Odyssey 
system every two days up to day eight on collagen, Matrigel and laminin. Signal intensity from cells 
under each condition were collected by Image Studio Lit software. (G, H) On TIF-CDM and CAF-CDM, 
cell proliferation was measured via Hoechst nuclear staining. Images were collected by ImageXpress 
micro and analysed by MetaXpress software. Values are mean ± SEM and are representative of at least 
three independent experiments (the black dots represent the mean of individual experiments). 
**p<0.01, ***P< 0.001, **** p<0.0001 ANOVA test. 
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6.2.7 The ECM did not affect cell growth of normal mammary epithelial cells 
and non-invasive breast cancer cells under glucose starvation. 
We showed that the presence of ECMs could partially rescue the growth of invasive breast 
cancer cells under Glc starvation (Figure 6.7 and 6.8). To assess whether the ability of the ECM 
to rescue cell growth under Glc starvation is correlated to the invasiveness of the cells, the 
growth rate of non-invasive breast cancer cells (MCF10A-DCIS) and normal mammary 
epithelial cells (MCF10A) was tested. Our data revealed that presence of collagen I or Matrigel 
did not affect the growth pattern of MCF10A-DCIS cell lines under 2.5mM, 1mM or 0mM Glc 
concentration (Figure 6.9). In Glc depleted media, MCF10A-DCIS cells were not proliferating 
regardless of the substrate they were growing on (Figure 6.9E-F). Under 1mM and 2.5mM Glc, 
cells were growing between day two up to day four. However, from day four up to day eight 
cell number started declining regardless of the presence of collagen I and Matrigel (Figure 
6.9A and C). Despite a significant difference being observed in the growth rate of MCF10A-
DCIS cells on Matrigel compared to the plastic at 2.5mM Glc, the growth pattern was very 
similar to the one observed on plastic (Figure 6.9A-B). Cells’ growth rate on Matrigel and 
collagen I was like plastic under 1mM Glc concentration or Glc depleted media (Figure 6.9D 




Figure 6.9. The ECM did not affect MCF10A-DCIS growth under glucose starvation. MCF10A-DCIS 
cells were seeded on 2mg/ml collagen I, 3mg/ml Matrigel and plastic in media containing (A-B) 2.5mM 
or (C-D) 1mM or (E-F) 0mM Glc. Cell proliferation was measured by DRAQ5 nuclear staining 
quantification with the Licor Odyssey system on day two up to day eight post starvation. Signal 
intensity from cells under each condition were collected by Image Studio Lit software. Values are mean 
± SEM and are representative of at least three independent experiments (the black dots represent the 
mean of individual experiments).  **P<0.01 and *** p<0.001 ANOVA test. 
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Testing the effect of CAF-CDM on MCF10A-DCIS growth showed that cells on day eight had a 
significantly higher cell number on plastic under all Glc starvation conditions. In addition, cells 
with access to higher concentration of Glc showed higher growth rate regardless of the 
substrate they were growing on (Figure 6.10).   
 
Figure 6.10. MCF10A-DCIS growth on CAF-CDM. MCF10A-DCIS cells were seeded either on plastic or 
on CAF-CDM in media with (A) 2.5mM, (B) 1mM Glc or (C) 0mM Glc. On day eight post starvation, cell 
proliferation was measured via Hoechst nuclear staining. Images were collected by ImageXpress micro 
and analysed by MetaXpress software. **p<0.01, ***P< 0.001 ANOVA test. 
 
Repeating the same experiments with MCF10A cells under Glc free media also revealed that 
the presence of collagen I and Matrigel could not recover cell growth. Cells’ growth pattern 
on ECMs was the same as on plastic, showing a reduction in cell number between day two up 
to day eight of Glc starvation (Figure 6.11). 
Altogether, these data suggest that the presence of ECM did not rescue the growth of non-
invasive breast cancer cells and normal mammary epithelial cells. In addition, an increase in 
Glc concentration induced the cell growth regardless of the presence of ECM in non-invasive 





Figure 6.11. ECMs did not rescue MCF10A growth under glucose starvation. MCF10A cells were 
seeded either on plastic or on plates coated with (A-B) 2mg/ml collagen I, (C-D) 3mg/ml Matrigel for 
eight days under Glc starvation. Cell proliferation was measured by DRAQ5 nuclear staining 
quantification with the Licor Odyssey system on day two, four, six and day eight post starvation. Values 
are mean ± SEM and are representative of three independent experiments (the black dots represent 
the mean of individual experiments).   
 
6.2.8 The presence of ECMs did not promote cell division under glucose 
starvation in invasive breast cancer cells. 
Data presented above revealed that MDA-MB-231 cell number was higher on collagen I, 
Matrigel and laminin compared to the plastic during eight days of complete Glc starvation 
(Figure 6.8). We therefore asked whether being surrounded by ECM either induced cell 
survival, proliferation, or both under Glc starvation. To answer this question, we performed 
EdU incorporation experiments (As described in 6.2.4). Cells were starved for six days when 
they received EdU. EdU incorporation was measured after two days on day eight of post 
starvation. Our data revealed that there was a gradual decrease in the percentage of EdU 
positive cells when the Glc concentration was reduced from 2.5mM to 0mM, regardless of 
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the substrate the cells were plated on (Figure 6.12A-B). MDA-MB-231 cells did not show any 
differences in terms of number of cells positive for EdU on ECMs under 1mM Glc or 0mM Glc 
compared to the cells seeded on plastic. Cells under 2.5mM Glc showed a significant but very 
small increase in EdU incorporation on Matrigel but not on collagen I in comparison to the 
plastic. (Figure 6.12A-B). In parallel, presence of laminin did not affect cell division rate under 
Glc depleted media (Figure 6.12C). Therefore, in general, the data demonstrate that the 
presence of ECM did not induce cell proliferation between six and eight days of Glc starvation.  
It has previously been shown that binding of ECM to integrins activate downstream signalling 
pathways which can promote cell survival (Wozniak et al., 2004). In particular, cell-ECM 
interaction activates a FAK-dependent signalling pathway which has been shown to prevent 
apoptosis by sequestering pro apoptotic factors in the cytosol (Gilmore et al., 2000).  
Therefore, we investigated whether the higher cell number we observed on ECM under Glc 
deficiency was due to an anti-apoptotic role of collagen I and Matrigel. To assess this, we 
quantified the number of cells positive for an apoptosis marker, activated caspase 3/7, at day 
three or eight post starvation. Both caspase-3 and caspase-7 have a role in the intrinsic and 
extrinsic apoptosis pathway. Caspases are a group of cysteine protease enzymes whose 
cleavage results in their activation, which mediates DNA fragmentation, cytoskeletal and 
nuclear protein degradation, formation of apoptotic bodies and eventually cell death (Elmore, 
2007). Our data revealed that the apoptosis rate increased between day three up to day eight 
under all nutrient conditions. In addition, Glc starvation significantly induced apoptosis in cells 
on plastic compared to the complete media. However, there were no significant differences 
between the apoptosis rate on collagen I or Matrigel compared to plastic either at day three 
or day eight in Glc depleted media (Figure 6.12D-E). Taken together, our data suggest that 
higher cell number on ECMs under Glc starvation compared to the plastic was linked neither 




Figure 6.12. ECMs did not affect cell division or apoptosis under glucose starvation. MDA-MB-231 
cells were seeded either on plastic or plastic coated with (A) 2mg/ml collagen I, (B) 3mg/ml Matrigel, 
under 2.5mM, 1mM and 0mM Glc (Glc free) or (C) 3.5mg/ml laminin/entactin under Glc free media. 
Cells were incubated with EdU on day six post starvation, fixed and stained with Hoechst and Click iT 
EdU imaging kit on day eight. Images were collected by ImageXpress micro and analysed by 
MetaXpress and CME software. Values are mean ± SEM and are representative of three independent 
experiments (the black dots represent the mean of individual experiments). *p<0.05, and **** 
p<0.0001 ANOVA test. MDA-MB-231 cells were seeded on either plastic or plates coated with 2mg/ml 
collagen I or 3mg/ml Matrigel under Glc starvation or complete media. Cells were stained for activated 
cas-3/7 at day (D) three or (E) eight post starvation. Images were collected by ImageXpress micro and 
analysed by MetaXpress and CME software. Values are mean ± SEM and are representative of two 
independent experiments (the black dots represent the mean of individual experiments). *** p<0.001 
ANOVA test.   
 
6.2.9 ECM affected the activity of mTORC1 under glucose starvation.  
 In the previous chapter we showed that the ECM supports the activation of mTORC1 under 
nutrient starvation conditions (Chp3 figure 4). Therefore, we wanted to investigate whether 
the ECM-dependent increase in cell number was associated with higher mTORC1 anabolic 
activity. To do this, we examined the phosphorylation of an mTORC1 downstream target, S6.  
Cells were seeded on collagen I, Matrigel, laminin or plastic under Glc depleted media for 
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three days. mTORC1 activity was measured by quantifying p-S6 signal intensity using high-
throughput microscopy. Effect of Glc on p-S6 was variable on plastic in our experiments 
(Figure 6.13A-C).  Presence of collagen I rescued the mTORC1 activity under Glc starvation 
compared to the cells on plastic (Figure 6.13A). On Matrigel, even though the p-S6 intensity 
was higher, the difference was not significant (Figure 6.13B). Finally, p-S6 intensity was slightly 
lower in cells growing on laminin compared to the plastic (Figure 6.13C). Our data suggest 
that collagen I, and to a lesser extent Matrigel, supported mTORC1 activity under Glc 
starvation in MDA-MB-231 cells. To assess whether mTORC1 activation was required for ECM-
dependent cell growth under Glc starvation, MDA-MB-231 cells were treated with 
Bafilomycin A1 (BA1) which is a V-ATPase inhibitor (For further details please refer to section 
4.2.4). V-ATPase is a proton pump that acidifies lysosomes. In addition, accumulation of AAs 
inside the lysosomes induces a signal transferred to Rag GTPases via the V-ATPase–Ragulator 
interaction leading to mTORC1 lysosomal recruitment and activation (Zoncu et al., 2011a). 
Thus, we hypothesise that if ECM-dependent cell growth was mediated by mTORC1 
activation, then, BA1 would inhibit mTORC1 reactivation and cell growth on collagen I and 
Matrigel. Previously, we showed that BA1 decreased both cell number and p-S6 intensity of 
MDA-MB-231 cells under complete media on both Matrigel and plastic (Figure 4.5A-B). Here, 
under Glc starvation BA1 decreased cell growth and p-S6 intensity on Matrigel compared to 
the DMSO control group, without affecting cell number or mTORC1 activation on plastic 
(Figure 6.13D-E). Moreover, comparing p-S6 intensity in the DMSO control groups confirms 
the observations that under Glc starvation, mTORC1 activity is enhanced on Matrigel 
compared to the plastic (Figure 6.13E). Therefore, our data suggest that ECM-driven cell 




Figure 6.13. The ECM supported mTORC1 activation in glucose starved cells, and this was required 
for ECM-dependent cell growth. MDA-MB-231 cells were plated either on plastic or plastic coated 
with (A) 2mg/ml collagen I, (B) 3mg/ml Matrigel or (C) 3.5mg/ml laminin/entactin under complete 
media (Com) and 0mM glucose (Glc). (D-E) MDA-MB-231 cells were plated either on plastic or plastic 
coated 3mg/ml Matrigel in 0mM Glc. 200nM Bafilomycin A1 or DMSO (control) were added to each 
condition every day. Cells were fixed and stained for p-S6 and nuclei at day three. Images were 
collected by ImageXpress micro and analysed by CME software. Values are mean ± SEM and are 
representative of three independent experiments (the dots represent the mean of individual 
experiments). *p<0.05, **p<0.01, *** p<0.001 and ****p<0.0001 ANOVA test.   
 
6.2.10 Blocking ECM internalization did not affect cell growth under glucose 
starvation. 
We showed above that mTORC1 activity was required for cell growth under Glc starvation. 
One way in which the ECM could drive mTORC1 activation is by endocytosis and lysosomal 
degradation, leading to an increase in nutrient concentration in lysosomes. In parallel, our 
data in chapter 3 revealed that under AA starvation, ECM internalisation is required for 
invasive breast cancer cell growth (Chp3 figure5). Therefore, we examined whether cells were 
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still able to internalize the ECMs under Glc depleted conditions. We tracked the journey of 
fluorescently labelled collagen I, Matrigel and laminin under different Glc concentrations in 
the presence of the lysosomal protease inhibitor, E64d. Our data showed that, under full Glc 
starvation, there was a strong increase in Matrigel and collagen I internalisation and 
degradation, as the uptake index was significantly increased in both DMSO and E64d. In 
contrast, in the presence of 2.5mM Glc we did not observe any difference between DMSO 
and E64d, suggesting that this Glc concentration inhibited collagen I and Matrigel endocytosis 
and/or lysosomal degradation (Figure 6.14A-B). Presence of E64d also increased 
accumulation of laminin inside the cells under both complete and Glc depleted media (Figure 
6.14C). We then wanted to investigate whether the growth of cancer cells relied on ECM 
internalization under Glc deficiency conditions. To assess this hypothesis, collagen I, Matrigel 
and CAF-CDM coated plates were treated with 10% glutaraldehyde to chemically cross-link 
amine groups of ECM proteins. We previously showed that MDA-MB-231 growth under 
complete media did not depend on ECM uptake as cell growth was similar on normal and 
cross-linked ECMs (Chp3 figure 5E). Surprisingly, under Glc starvation, matrix cross-linking did 
not oppose MDA-MB-231 growth (Figure 6.14D-E). Taken together, our data demonstrate 
that ECM internalization and lysosomal degradation were promoted under Glc deficiency, but 
they were dispensable for ECM-dependent cell growth. In addition, the presence of low Glc 
concentrations reduced ECM lysosomal degradation, suggesting that Glc deficiency might 




Figure 6.14. MDA-MB-231 cells internalized and degraded ECMs under glucose starvation condition, 
but this was not required for cell growth. MDA-MB-231 cells were plated under 0mM glucose (Glc 
free), 2.5mM Glc or complete (Com) media on dishes coated with NHS-fluorescein labelled (A) 1mg/ml 
collagen I, (B) 3mg/ml Matrigel or (C) 3.5mg/ml laminin/entactin for three days, in the presence of the 
lysosomal inhibitor E64d (20µM) or DMSO (control). Cells were fixed and stained for actin and nuclei. 
Images were collected by Nikon A1 confocal microscope. MDA-MB-231 cells were seeded on (D) 
untreated (control) or cross-linked 2mg/ml collagen I or 3mg/ml Matrigel or (E) normal and cross-
linked (X-linked) CAF-CDM under Glc starvation. Cell proliferation were measured by Hoechst nuclei 
staining.  Images were collected by ImageXpress micro and analysed by MetaXpress software. Values 
are mean ± SEM and are representative of three independent experiments. Graphs in A, B and C are 
representative of around 150 cells per condition (the bigger dots represent the mean of individual 
experiments).   ***p<0.001 **** p<0.0001 ANOVA test.    
 
 
We previously showed that mTORC1 activation is required for cell growth, and mTORC1 
pathway has been shown to upregulate MMP expression (Chen et al., 2009). Therefore, we 
wanted to investigate whether extracellular ECM degradation was required for cell growth 
under Glc starvation. To do this, we treated cells with matrix metalloproteinase inhibitors 
(GM6001) under complete and Glc depleted media. Our data revealed that inhibition of 
extracellular degradation of collagen I and Matrigel did not affect cell growth as cell number 
was similar between control group and cells treated with the broad MMP inhibitor, GM6001, 
under Glc starvation (Figure 6.15A-C). Taken together, our data suggest that under Glc 






Figure 6.15. MMP inhibition did not affect cell growth under glucose starvation. MDA-MB-231 were 
seeded on (A) 2mg/ml collagen I, (B) 3mg/ml Matrigel, or (C) plastic under complete or Glc depleted 
media. GM6001 (10µM) or DMSO (control) were added to the cells every two days. Cell proliferation 
was measured by DRAQ5 nuclear staining quantification with the Licor Odyssey system on day six. 
Values are mean ± SEM and are representative of three independent experiments (the black dots 
represent the mean of individual experiments).  
 
6.2.11 FAK activity was required for cell growth on Matrigel and CDM under 
glucose starvation. 
Our data previously revealed that even though cells can uptake ECM under Glc starvation, 
ECM internalization was not required for cell growth (Figure 6.14D-E). Therefore, we 
hypothesized that there might be another mechanism controlling ECM-dependent cell growth 
under Glc deficiency. FAK is a non-receptor kinase located in the FAs. Recent studies 
demonstrated that binding of ECM to integrin receptors trigger downstream signalling 
pathways mediated by FAK to regulate cell proliferation, migration, and survival (Aboubakar 
Nana et al., 2019).  To test whether the inhibition of focal adhesion signalling affected cell 
growth under Glc starvation, MDA-MB-231 cells were treated with the FAK inhibitor, 
PF573228. We previously showed that treating cells with PF573228 in complete media did 
not change their proliferation rate on collagen I or Matrigel (Chp3 figure 6C). Here, our results 
revealed that treatment of cells with FAK inhibitor significantly reduced cell growth on 
Matrigel and CAF-CDM, but not on collagen I, under Glc starvation. (Figure 6.16). Taken 
together, these data suggest that the presence of Matrigel and CAF-CDM triggers FAK-
dependent signalling pathways which could promote invasive breast cancer cell growth under 





Figure 6.16. FAK inhibition reduced cell growth on Matrigel and CAF-CDM under glucose starvation. 
MDA-MB-231 cells were seeded on either (A) 2mg/ml collagen I, 3mg/ml Matrigel or (B) on CAF-CDM 
for six days under Glc starvation. Cells were treated with 0.5μM PF573228 (FAKi) or DMSO (control) 
every two days. Cell proliferation was measured by Hoechst nuclei staining.  Images were collected by 
ImageXpress micro and analysed by MetaXpress software. Values are mean ± SEM and are 
representative of three independent experiments. **p<0.01 and ****p<0.0001 ANOVA test. 
 
6.2.12 Cells on plastic internalized more glucose compared to the cells on 
ECM. 
We have shown that the presence of ECMs partially rescued the growth of invasive breast 
cancer cells under Glc starvation (Figure 6.8). In addition, mTORC1 activity was enhanced by 
collagen I and Matrigel under starvation (Figure 6.13A-B). ECM proteins are heavily 
glycosylated, therefore we hypothesised that the ECM could provide an alternative source for 
sugars. Hence, cells on ECM might take up less Glc when being re-expose to it after starvation. 
To investigate this, MDA-MB-231 cells were seeded either on collagen I, Matrigel or plastic, 
under Glc starvation for six days and treated with 2-NBDG, a fluorescent tracer for Glc, for 
1hr.  The percentage of cells positive for 2-NBDG was higher under glucose starvation 
compared to the complete media, regardless of the type of substrate they were growing on 
(Figure 6.17A and C). Under glucose depleted media, a higher percentage of cells on plastic 
internalized 2NBDG compared to the cell on collagen I, but not on Matrigel (Figure 6.17A and 
C). However, the amount of 2-NBDG being accumulated inside the cell was remarkably higher 
in cells on plastic under Glc deficiency compared to collagen I and Matrigel (Figure 6.17B and 
D). Altogether, these data suggest that presence of ECM could decrease the dependence of 




Figure 6.17. The presence of ECM reduced 2-NBDG uptake under glucose starvation. MDA-MB-231 
cells were plated either on plastic or plastic coated with (A and B) 2mg/ml collagen I or (C and D) 
3mg/ml Matrigel under complete media (Com) or glucose starvation (Glc) for six days. Cells were 
incubated with 100μM 2-NBDG for 1 hr, were fixed and stained for nuclei.  Images were collected by 
ImageXpress micro and analysed by CME software. Values are mean ± SEM and are representative of 
three independent experiments (the black dots represent the mean of individual experiments).   
*p<0.05, **p<0.01, **** p<0.0001 ANOVA test. 
 
6.2.13 Cells on Matrigel had higher ATP content under glucose starvation. 
Our previous results showed that cells on ECM internalized a lower amount of 2-NBDG under 
Glc starvation compared to the plastic suggesting that the ECM could compensate for the 
absence of Glc in the environment (Figure 6.17). We then wanted to investigate whether ECM 
could facilitate energy production in breast cancer cells and whether the glycolysis/OXPHOS 
ratio was changed on ECM under starvation. To assess whether the presence of ECM affected 
ATP content of cells, MDA-MB-231 were seeded either on collagen I, Matrigel or plastic under 
complete or Glc depleted media. To quantify cellular ATP content, MDA-MB-231 cells were 
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incubated with bio-tracker ATP-red live cell dye for 15mins, after 1 hr of incubation with the 
OXPHOS inhibitor Oligomycin A (for further details please check section 4.2.7). ATP content 
of cells treated with oligomycin A was considered as the product of glycolysis. ATP from 
OXPHOS was measured by subtracting the ATP content of cells treated with oligomycin A from 
the ATP content of the control group, as described in Davis et al (2020). Our data showed that 
three days post Glc starvation, cells on Matrigel had a remarkably higher content of ATP 
compared to the cells on collagen I and plastic. Cells on Matrigel under complete media and 
on collagen I under Glc depleted media relied more on glycolysis for their ATP production 
compared to OXPHOS (Figure 6.18A). However, after six days of starvation, ATP contents of 
cells were equally the result of glycolysis and TCA cycle. Cells on Matrigel still had higher ATP 
content under Glc starvation compared to the cells on plastic. In contrast, cells on collagen I 
under Glc starvation did show a small but not statistically significant increase in their ATP 
content. Moreover, on day six, cells under Glc starvation on ECMs showed higher ATP content 
compared to the cells on ECMs under the complete media (Figure 6.18B). Taken together, our 
data suggest that ECMs induced the accumulation of ATP inside the cells under Glc starvation.   
 
Figure 6.18. Cells on Matrigel had higher ATP content under starvation. MDA-MB-231 cells were 
plated either on plastic or plastic coated with collagen I (2mg/ml) or Matrigel (3mg/ml) under 
complete media (Com) and glucose starvation (Glc). Cells were incubated with 126.4μM oligomycin A 
at 37oC and 5% CO2 for 1 hr at day (A) three or (B) six-day post starvation. Cells were stained with 
10μM BioTracker ATP-Red Live Cell Dye at 37oC and 5% CO2 for 15 min.  Live cell images were collected 
by ImageXpress micro and analysed by CME software. Values are mean ± SEM and are representative 
of three independent experiments.   *p<0.05, **p<0.01, *** p<0.001 and **** p<0.0001 ANOVA test.  
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6.2.14 The presence of Matrigel did not change the metabolite content of 
cells under glucose starvation. 
We previously showed Matrigel rescued cell growth and mTORC1 activation under Glc 
starvation. Moreover, cells growing on Matrigel had higher ATP content compared to the cells 
on plastic in the absence of Glc (Figure 6.18). Therefore, in order to highlight changes in 
metabolite content of cells, we use a non-targeted metabolomic approach in MDA-MB-231 
under Glc starvation. Cells were seeded either on Matrigel or plastic for six days in Glc 
depleted media. Metabolites were collected from the cells and examined via direct infusion 
mass spectrometry (DI-MS). Our data show that there was no significant difference in 
metabolite content of cells between plastic and Matrigel under Glc starvation (Figure 6.19).  
 
 
Figure 6.19. The presence of Matrigel did not affect cellular metabolite content under glucose 






6.3.1 Serum starvation 
In this study we showed TIF-CDM, and to a lesser extent collagen I and CAF-CDM, partially 
rescued the growth of invasive breast cancer cells, but not normal mammary epithelial cells 
or non-invasive breast cancer cells, under serum starvation. Moreover, collagen I was the only 
type of ECM able to support mTORC1 activity in serum-starved cells. 
In terms of invasive breast cancer cell growth under serum starvation, MDA-MB-231 cells had 
a higher growth rate on collagen I compared to the plastic under serum depletion condition, 
while Matrigel and laminin did not affect the growth at all. We also observed an increase in 
cell number on both TIF-CDM and CAF-CDM compared to the plastic. However, differences in 
cell number on CAF-CDM were mostly due to a more profound reduction of cell numbers on 
plastic, rather than a significant increase of cells growing on CAF-CDM. This suggests that CAF-
CDM promoted cell survival, rather than stimulating cell growth. Consistent with our data on 
plastic, there are studies showing that serum starvation induces apoptosis in cancer cells, 
including adenocarcinoma and colon carcinoma (Braun et al., 2011, Levin et al., 2010). There 
was also some evidence that serum starvation could trigger senescence in cells, as a 
senescence marker, SA-β-gal, was shown to be increased after serum depletion (Yurube et 
al., 2019). Another study demonstrated that addition of albumin to serum depleted cells 
induced PI3/Akt signalling pathway and inhibited apoptosis (Liu et al., 2012). Consistently, we 
showed that collagen I could partially rescue the growth of MDA-MB-231 cells under serum 
starvation. Further work is required to assess whether this is mediated by an inhibition of 
apoptosis.  
Serum is the main source of GFs for the cells growing in vitro. Analysing the composition of 
the FBS we used revealed that it contains IFG-1, TGF-β1 and FGF-2 
(https://static.thermoscientific.com/images/D22225~.pdf). There is also growing evidence 
that the ECM works as a GF reservoir. Different types of GFs including FGF, PDGF, TGF-β can 
associate to the ECM via GF binding sites (Hynes, 2009, Zhu and Clark, 2014). Thus, we 
hypothesize that TIF-CDM could promote cell growth under serum starvation because of the 
presence of GFs in the matrix. The composition of TIF- and CAF-CDM has been analysed by 
mass spectrometry (Hernandez-Fernaud et al., 2017), showing that that fibroblast growth 
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factor 2, Insulin-like growth factor-binding protein 3 and 5 were slightly reduced in CAF-CDM 
compared to TIF-CDM; whereas some other GFs such as connective tissue growth factor, 
transforming growth factor beta-2, and insulin-like growth factor-binding protein 7 were 
upregulated. Therefore, more studies are required to elucidate the reason why TIF-CDM, but 
not CAF-CDM rescued cell growth and whether this was mediated by presence of specific GFs 
in TIF-CDM. It is important to note that other factors, such as ECM structure or stiffness, might 
contribute. 
We also assessed the effect of serum starvation on normal mammary epithelial cells and non-
invasive breast cancer cells. Our data revealed that serum starvation did not affect the cell 
number of normal epithelial cells and non-invasive breast cancer cells. While Matrigel 
partially rescued their growth rate. Consistently, another study showed that laminin 
internalization rescued normal mammary epithelial cell growth under serum and GF 
starvation (Muranen et al., 2017). Therefore, it is possible that we observed higher growth on 
Matrigel compared to collagen I because of the presence of laminin as a Matrigel component. 
Moreover, our data showed that non-invasive breast cancer cells and normal mammary 
epithelial cells were less dependent on serum for their growth compared to invasive breast 
cancer cells. A study showed that the response to the serum starvation is different between 
adenocarcinoma cells and glioma cells. Under serum starvation, glioma cells stop apoptosis 
via increasing antiapoptotic proteins such as Bcl2, Bcl-xl and Bax. Glioma cells also decrease 
p53 expression to hinder p53 dependant apoptosis. In contrast, adenocarcinoma cells under 
serum starvation increase the level of p53 and decrease the Bcl-xl (Levin et al., 2010). 
Therefore, differences in response to the serum starvation in our cell lines might be because 
normal mammary epithelial cells and non-invasive breast cancer cells switch on signalling 
pathways to promote their survival.  
Assessing the rate of cell division showed that the presence of ECM did not increase cell 
proliferation under serum starvation, indicating that the increase in cell number observed on 
collagen I was not driven by an induction of cell proliferation. In addition, collagen I was the 
only ECM that could enhance mTORC1 activity under starvation, suggesting that higher 
mTORC1 activity might be the reason why collagen I could partially rescue cell growth. It was 
previously shown that laminin uptake and lysosomal degradation under serum and GF 
starvation increased the cellular AA content, inducing mTORC1 activity in mammary epithelial 
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cells (Muranen et al., 2017). However, in our study, we did not detect collagen I lysosomal 
degradation under serum starvation. In addition, even though cells were able to degrade 
Matrigel, the presence of Matrigel did not rescue invasive breast cancer cell growth. 
Therefore, positive effects of collagen I on cell growth might not be linked to collagen I-
derived alternative nutrients. It was shown that albumin has an anti-oxidative effect under 
serum starvation. Presence of albumin inhibits nicotinamide adenine dinucleotide phosphate 
(NAPDH) oxidase (NOX) activation, ROS generation and eventually hinders mitochondrial 
apoptosis (Liu et al., 2012). Therefore, more studies are required to define whether collagen 
I has an anti-apoptotic role in invasive breast cancer cells.  
6.3.2 Glucose starvation 
In this study we showed that the presence of ECM partially rescued invasive breast cancer cell 
growth and promoted mTORC1 activation under Glc starvation. Interestingly, non-invasive 
breast cancer and normal mammary epithelial cells did not grow under Glc starvation 
regardless of the presence of collagen I or Matrigel.  Moreover, ECM internalization was not 
required for invasive breast cancer cell growth under Glc starvation, while treatment with a 
FAK inhibitor significantly reduced their growth, suggesting that presence of ECM promoted 
cell growth through the activation of adhesion signalling under Glc starvation. 
A recent study revealed that Glc starvation causes selective turnover of lysosome membrane 
proteins in MCF10A cells (Lee et al., 2020), suggesting that full depletion of Glc from the media 
might disrupt lysosome function. This would in turn prevent ECM degradation. However, this 
was not the case in our study, as we observed a significant increase in the ECM intracellular 
content upon inhibition of lysosomal proteases under full Glc starvation.  In addition, it was 
shown that extraction of proline from collagen partially rescued the survival of pancreatic 
cancer cells under low Glc but not in fully Glc depleted media (Olivares et al., 2017). On the 
contrary, our data clearly demonstrated that in invasive breast cancer cells the ECM had a 
more profound effect on cell growth under complete Glc starvation, rather than low Glc 
concentrations. Moreover, we showed that normal mammary epithelial cells were dying 
under Glc deficiency regardless of the substrate they were growing on, while non-invasive 
cancer cell growth was partially rescued on Matrigel but not collagen I.  As we previously 
mentioned, non-invasive breast cancer cells reside inside the mammary duct and with direct 
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contact to the BM (Muschler and Streuli, 2010). Since Matrigel is a BM extract, it could more 
closely recapitulates the TME surrounding non-invasive breast tumours (Muschler and Streuli, 
2010). This indicates that invasive cells can benefit more from the presence of ECM to support 
their survival under Glc starvation. However, our data demonstrated that there was no 
difference in invasive breast cancer cell proliferation, measured by EdU incorporation, when 
comparing ECM and plastic, suggesting that the higher cell number on ECM was not due to 
higher cell division. Similarly, there was no significant difference in the apoptosis rate of cells 
under Glc starvation on collagen I, Matrigel or plastic. Our data revealed that the apoptosis 
rate increased between day three up to day six post starvation, which is consistent with other 
study showing that Glc starvation induced apoptosis in MDA-MB-231 and MCF7 cells via 
increasing ROS generation and mitochondria dysfunction (Raut et al., 2019). It is important to 
note that cells under Glc deficiency can face other types of cell death such as autophagic cell 
death (Chiodi et al., 2019) or entosis (Hamann et al., 2017), which we did not assess in our 
study.  
Lack of Glc has been shown to affect mTORC1 activity via the activation of AMPK (Kim et al., 
2013a). There are conflicting pieces of evidence in the literature regarding the role of ECM 
internalisation in supporting mTORC1 activation under Glc starvation. It has been shown that 
the inhibition mTORC1 activation, via complete Glc depletion, induces fibronectin 
internalization in ovarian cancer cells (Rainero et al., 2015a); while collagen I and IV 
endocytosis did not affect mTORC1 downstream signalling under Glc free condition in 
pancreatic cancer cells (Olivares et al., 2017). In our study collagen I, and to a lesser extent 
Matrigel, induced mTORC1 activity under Glc starvation, suggesting that the role of the ECM 
in supporting mTORC1 activation could be cancer type specific. It was previously 
demonstrated that accumulation of AAs inside the lysosome induces a signal transferred to 
Rag GTPases via the v-ATPase–Ragulator interaction leading to mTORC1 lysosomal 
recruitment and activation (Zoncu et al., 2011a). In agreement with this, v-ATPase inhibition 
prevented ECM-dependent mTORC1 activation and cell growth, suggesting that the ECM 
could promote cell growth under Glc starvation by promoting mTORC1 activity. However, 
further work is needed to confirm that this is the case. Our data also showed that under Glc 
starvation cells were able to internalize and degrade the ECM. However, inhibiting ECM 
internalization did not have any impact on cell growth. These data indicate that cell-ECM 
192 
 
interaction, but not ECM uptake, might promote cell survival under Glc starvation. In parallel, 
our data showed that inhibition of FAK significantly reduced cell growth on Matrigel and CAF-
CDM, but not collagen I. In addition, our data showed that there was no difference in cellular 
metabolite content between cells growing on Matrigel or plastic. Due to technical difficulties, 
we could not perform metabolomics on collagen I under Glc starvation. It would be 
informative to elucidate whether the presence of collagen I resulted in changes in metabolic 
pathways in the cells under Glc starvation, since we observed higher mTORC1 activity 
compared to Matrigel. Taken together these data suggest that the ECM mechanism of action 
to induce survival of cells under Glc starvation is mostly due adhesion-dependent signalling 
rather than a metabolic effect caused by ECM internalisation and lysosomal degradation, as 
we reported in the case of AA starvation (chapter 3). It was previously shown that the addition 
of collagen I and IV to PDAC cells under Glc starvation induced extracellular signal-regulated 
kinase-1/2 (ERK1/2) signalling pathway to increase the survival rate (Olivares et al., 2017).  It 
has been reported that interaction of β1 integrin with collagen IV triggers FAK and 
downstream ERK1/2 signalling via Ras activation. It was also shown that ERK1/2 activation 
induces invasion in pancreatic cancer cells with no significant effect on apoptosis (Sawai et 
al., 2005). Therefore, stimulation of ERK1/2 downstream of ECM-dependent FAK activation 
could be a candidate signalling pathway promoting cell growth/survival under Glc starvation. 
Thus, further experiments are needed to determine this.  
Interestingly, we found that the presence of ECM changed Glc uptake and ATP content of cells 
under Glc starvation. Our data revealed that the cells growing on collagen I and Matrigel 
internalize a significantly lower amount of Glc compared to the plastic, when exposed to a Glc 
tracer after six days of Glc starvation. These data suggest that the presence of ECM might 
decrease the need of cells to Glc after starvation. It was recently reported that metastatic 
cancer cells have the ability to switch between different metabolic pathways and can 
compensate for lack of glycolysis by upregulating glutaminolysis to feed the TCA cycle 
(Méndez-Lucas et al., 2020). We also showed that cells had higher ATP content on collagen I 
(slightly) and on Matrigel (significantly) compared to the plastic under Glc starvation, 
suggesting that they could rely on different metabolic pathways for energy production. It has 
been shown that macropinocytosis of yeast proteins increased the survival rate of Glc-
independent lung cancer cells under serum and Glc deficiency. Degradation of internalized 
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proteins produced AAs, like alanine, which fed into the TCA cycle and glucogenesis via the 
conversion of alanine to pyruvate. Interestingly, they showed that Glc-dependent lung cancer 
cells did not have this ability and the addition of soluble proteins did not rescue their growth 
(Hodakoski et al., 2019). Even though in our study we showed that breast cancer cells did not 
need ECM internalization to rescue their growth, the presence of ECM might make them 
glucose-independent and enable them to use AAs in the media to support glucogenesis. The 
fact that our non-targeted metabolomics data did not show any difference suggests that more 
subtle changes could be behind this, and more detailed analysis are need. For instance, using 
13C-labeled AA could help us to track journey of AAs inside the Glc starved cells on plastic and 
ECM. In addition, it was shown that invasive breast cancer cells are more glycolytic on stiff 
matrices and glass; while they mainly produce energy via OXPHOS on soft ECMs (Mah et al., 
2018). Therefore, one reason why MDA-MB-231 cells produce higher ATP on Matrigel 
compared to plastic might be mediated by their metabolic shift toward OXPHOS due to 
changes in the stiffness. However, in our study, we did not see any difference between the 
level of ATP produced by OXPHOs or glycolysis. More studies are needed to assess the ATP to 
ADP conversion, as it is possible that higher ATP content is due to lower energy consumption. 
In addition, on plastic, cells were treated with the OXPHOS inhibitor (Oligomycin A) could still 
produce ATP under Glc starvation. This result brings this question that how cells with no 
access to Glc and under Oligomycin A can still produce ATP. To complement these data and 
assess whether the ECM affects metabolic plasticity, 13C isotope-assisted methods for Gln 
tracing could be performed by mass spectrometry. Moreover, using the Seahorse XF 
technique to measure oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) of live cells on Matrigel and collagen I under Glc starvation could allow us to establish 
whether different ECM components affect cell metabolism. Taken together, our data suggest 
that the presence of ECM can direct cells toward a glucose-independent metabolic pathway 
for energy production, to compensate for lack of Glc. 
In conclusion, our data suggest that the presence of ECM can trigger signalling pathways 
downstream of FAK activation inducing cell survival. Concomitantly, the ECM might promote 
cancer cell ability to switch to different metabolic pathways independent of glucose. 
Therefore, further studies are needed to characterise which signalling pathways downstream 
of FAK induce cell survival on ECM under Glc starvation. This could be followed by assessing 
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whether these signalling pathways affect cell metabolism either via enhancing mTORC1 
activity, activating specific metabolic pathways such as OXPHOS or increasing the transport 



















Chapter 7. General discussion 
7.1 Summary 
Using extracellular proteins as a substitute source of food during starvation is a mechanism 
cancer cells benefit from to survive (Commisso et al., 2013, Muranen et al., 2017, Olivares et 
al., 2017, Palm et al., 2015). ECMs are a major component of the TME and they are in direct 
contact with tumour cells. Increased secretion of ECM is linked to higher tumour initiation, 
adhesion, sprouting, invasiveness, and survival of breast cancer cells (Kim et al., 2014, Yao et 
al., 2007, Chang et al., 2015). In this study, we investigated the role of ECM components in 
controlling breast cancer cells growth under different starvation conditions. We 
demonstrated that the presence of ECM under AA starvation induced cell proliferation, 
enhanced mTORC1 activity and upregulated AA content of cells, suggesting that cells could 
extract AA from ECMs to compensate for the AA deficiency. Under serum starvation, only 
collagen I, TIF-CDM and CAF-CDM could partially rescue cell growth. Presence of collagen I 
did not increase the division rate but it significantly enhanced mTORC1 activity under serum 
starvation. TIF-CDM has the strongest effect on cell growth under serum starvation implying 
that it might provide GFs for serum starved cells. Under Glc starvation, ECMs enhanced 
mTORC1 activity. However, after an initial increase in cell proliferation after Glc starvation, 
cell growth was not sustained and at a later point there was no difference in cell division. In 
addition, there was no substantial difference in the metabolite content of cells on ECM 
compared to plastic. Interestingly, inhibiting focal adhesion signalling adversely affected the 
growth on ECM in Glc starved cells. Hence, we hypothesized that under Glc starvation, 
presence of ECM trigger signalling pathways downstream of FAK to induce cell 




Figure 7.1. Mechanism of cell ECM interaction under different starvation conditions. (A) Under AA 
starvation, invasive breast cancer cells internalize ECM and extract AA via lysosomal degradation. 
Upregulation AA content enhances phenylalanine and tyrosine metabolism pathway and mTORC1 
activity. ECM internalization might happen via macropinocytosis or receptor mediated endocytosis. 
(B) Under Glc starvation, interaction of ECM with integrin receptors triggers signalling pathways 
downstream of FAK that result in higher cell growth. (C) Under serum starvation, we propose that cells 
might use the ECM as a GFs reservoir to induce their growth/survival.     
 
7.2 ECMs partially rescued cell growth under different starvation conditions. 
Under Gln and AA starvation, the presence of collagen I, Matrigel, laminin and CAF-CDM 
rescued breast cancer cell growth. Cells on TIF-CDM promoted cell growth under Gln but not 
AA depleted media. Analysing the rate of cell division via EdU labelling also revealed that the 
number of MDA-MB-231 cells positive for EdU is significantly higher on ECM compared to the 
plastic in AA starved cells. Consistently, under NEAA starvation, cells had higher cell growth 
on Matrigel, collagen I and CAF-CDM compared to the plastic. Under Glc starvation, all types 
of ECM partially rescued cell growth up to day eight. However, from around day four onwards 
the graph representative of cell growth on ECM showed plateau on collagen I, Matrigel and 
laminin (Table 7.1). Cell growth on CDM data was collected on day eight. Therefore, it was 
not possible to assess whether cell growth ceased after the first four days or not. We could 
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detect a similar amount of extracellular ECM under all starvation conditions, it is unlikely that 
cell growth was prevented under Glc deficiency because of lack of ECM. Taken together, our 
data suggest that under Glc starvation the presence of ECM might be sufficient to enhance 
invasive breast cancer cell survival, but not their proliferation in the long term. Under serum 
starvation, only collagen I, TIF-CDM and CAF-CDM enhanced invasive breast cancer cell 
growth. Among them, TIF-CDM had the greatest effect. However, none of the matrices tested 
could increase cell division rate. The CDM is composed of many different components. In vivo 
characterization of normal and tumour ECMs revealed that the core matrisome includes 
around 300 genes. 35 genes for proteoglycans, 43 genes for collagens and the rest are for 
glycoproteins including fibronectin, laminin, tenascins, thrombospondin. Matrisome-
associated proteins include around 778 genes subcategorized to ECM regulators such as 
MMPs and LOX, and secreted factors including cytokines and GFs (Naba et al., 2012). 
Therefore, it is important to consider that more than one factor could potentially enhance 
cell growth under serum starvation on CDM. There is growing evidence that the ECM works 
as a GF reservoir. Different types of GFs including FGF, PDGF, TGF-β can associate to the ECMs 
via their specific GF binding sites (Hynes, 2009, Zhu and Clark, 2014). In addition, CDMs can 
show different mechanical properties due to different levels of remodelling and cross-linking, 
mediated by MMPs and LOX enzymes. Higher ECM stiffness has been linked to the integrin 
clustering, resulting in activation of FAK and PI3K and eventually breast malignancy (Levental 
et al., 2009).  So far, we can hypothesize that upregulation of signalling pathways linked to 
cell proliferation, such as PI3K, could promote on CDM either via GFs or CDM-dependent 
signalling pathways due to their mechanical properties.  
 
Table 7.1. Effect of different matrices on MDA-MB-231 growth under various starvation 
conditions. 
Starvations Collagen I Matrigel Laminin TIF-CDM CAF-CDM 
Amino acid + + + - + 
Nonessential 
amino acids 
+ + NA NA + 
Glutamine + + + + + 
Glucose + + + + + 
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serum + - - + + 
(+) matrix can partially rescue cell growth. (-) no difference in cell growth between matrix and plastic. 
(NA) it was not tested. 
7.3 Normal mammary epithelial cells and non-invasive breast cancer cells 
behaved differently on ECM under different starvation conditions. 
To investigate whether the ability to take advantage of the ECM to promote cell growth under 
starvation is a common feature of mammary epithelial cells or is acquired during carcinoma 
progression, we examined the growth rate of normal mammary epithelial cells (MCF10A) and 
non-invasive breast cancer cells (MCF10A-DCIS). Under Glc and AA starvation, the growth rate 
of MCF10A and MCF10A-DCIS was not changed on collagen I and Matrigel compared to the 
plastic. Alongside, it has been shown that deprivation of arginine induced cell cycle arrest in 
both MCF10A cells and MCF7 (invasive breast cancer cells). However, addition of arginine to 
the media after 5 days of starvation rescued cell growth for invasive breast cancer cells while 
normal mammary epithelial cells were not responsive to it, as arginine starvation induced 
irreversible senescence in normal mammary epithelial cells (Chiaviello et al., 2012). In our 
study, we showed that arginine biosynthesis pathway is upregulated in AA starved invasive 
breast cancer cells on collagen I compared to the plastic. Since ECM proteins contain arginine, 
it is possible that invasive breast cancer cells, but not normal mammary epithelial cells, could 
support their growth under AA deficiency by extracting arginine from internalised ECM 
components.  In contrast, the presence of Matrigel, but not collagen I, was able to rescue 
MCF10A-DCIS and MCF10A growth under Gln and serum starvation, respectively.  Non-
invasive breast cancer cells reside inside the mammary duct and in contact with the BM 
(Muschler and Streuli, 2010). Hence, the reason why cells have better growth on Matrigel 
under Gln starvation could be because Matrigel more closely recapitulates the BM 
environment. It has been shown that under 24hrs serum starvation followed by 2hrs AA 
starvation, laminin supported the growth of MCF10A cells (Muranen et al., 2017). Since 
Matrigel contains laminin, this could be the reason why MCF10A cells have better growth on 
Matrigel under serum starvation. Taken together, our data reveal that the ECM did not rescue 
the growth of non-invasive breast cancer cells and normal mammary epithelial cells under AA 
and Glc starvation, suggesting that invasive breast cancer cells have acquired the ability to 
use ECM to overcome nutrient scarcity. Further studies are needed to characterise how this 
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is developed during carcinoma progression. Our data showing a significantly higher growth 
rate of non-invasive breast cancer cells on Matrigel under Gln starvation suggest that they 
achieve this ability on their way to becoming invasive.  
7.4 The ECM promoted cell growth via different mechanisms under various 
starvation conditions.  
Our data demonstrate that the presence of ECM supports cell growth via different 
mechanisms under different starvation conditions. In general, cells respond to Glc and AA 
deficiency by activating distinct signalling pathways. Therefore, it is possible that these in turn 
could determine how cells take advantage of the ECM. Under Glc starvation, liver kinase B1 
(LKB1)-adenosine monophosphate-activated kinase (AMPK) signalling plays an important role 
in sensing nutrient stress and controlling energy homeostasis via different mechanisms. 
Excessive level of ROS inside the cells triggers LKB1/AMPK to promote cell survival during Glc 
deficiency via (1) decreasing consumption of NADPH to prevent ROS accumulation (Jeon et 
al., 2012); (2) activation of p53, which is a cell cycle checkpoint and induces senescence (Jones 
et al., 2005), or (3) activation of an mTORC1 inhibitor, TSC1/2, leading to reduction of protein 
translation and induction of autophagy (Corradetti et al., 2004). It was also shown that the 
activation of LKB1/AMPK induces the expression of Nrf1, a transcription factor resulting in 
higher expression of MMP-9 and cell invasion (Endo et al., 2018). Future work will determine 
how the presence of ECM impinges on Glc sensing and whether this in turn affect cell-ECM 
interaction. 
AA deficiency is sensed by the integrated stress response and has been shown to trigger 
activation of eIF2a-kinases, such as General Control Non-depressible 2 (GCN2), promoting 
eukaryotic Initiation Factor 2α (eIF2α). eIF2α induces the translation of transcription factors, 
C/EBP-homologous protein (CHOP) and transcription factor 4 (ATF4), responsible for the 
transcription of different sets of genes controlling autophagy (B'Chir et al., 2013). AA starved 
cells could also induce autophagy and inhibit anabolic processes via mTORC1 inactivation. AA 
deficiency causes Rag inactivation, to induce mTORC1 release from lysosome via two 
independent mechanisms. First, Rag reduces its binding to mTORC1. Second, it recruits TSC2 
on the lysosomes, which inhibits Rheb and consequently induces mTORC1 release to the 
cytoplasm (Demetriades et al., 2014). However, it was shown that cells adopt different 
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mechanisms for their survival in long-term AA depletion compared to the short-term 
starvation. Cells able to tolerate long-term AA deficiency did not show any difference in 
mTORC1 and GCN2/elf2α activity, compared to cells in which AA starvation induces apoptosis. 
In contrast, cells with higher tolerance to AA starvation had lower ATF4 activity, which 
prevents apoptosis (Mesclon et al., 2017). Future work will address whether ATF4 activity is 
linked to ECM-dependent cell growth under AA starvation and whether the integrated stress 
response promotes ECM internalisation and/or degradation.  
7.4.1 Assessing rate of cell division and apoptosis on different ECMs and starvation 
conditions. 
Under AA starvation, ECMs enhanced cell division while under Glc and serum starvation the 
percentage of cells positive for EdU was similar on ECM and plastic. There are few studies 
showing that ECPs can enhance cell growth under full AA deficiency (Kamphorst et al., 2015), 
5% EAA (Palm et al., 2015) or Gln depleted conditions (Olivares et al., 2017). In contrast, in 
full Glc deficiency cells did not show higher growth in the presence of albumin (Palm et al., 
2015) or collagen (Olivares et al., 2017). Those studies were mostly performed adding soluble 
proteins, while our work uses polymerised ECMs. It is possible that only assembled ECM (and 
not soluble components) are able to support cell growth under Glc starvation. Therefore, we 
can hypothesize that the reason why under Glc starvation cells on ECM have higher cell 
numbers could be due the ECM signalling downstream of the interaction with their plasma 
membrane receptors.  
We examined whether the presence of collagen I and Matrigel can have anti-apoptotic 
effects. Our data revealed that Glc starvation enhanced apoptosis regardless of the substrate 
the cells were growing on and cells on ECM did not reduce apoptosis rate. In parallel, another 
study revealed that Glc starvation induces apoptosis in MDA-MB-231 and MCF7 cells via 
increasing ROS generation and mitochondria dysfunction (Raut et al., 2019). Taken together, 
the ECM function to increase cell number under Glc starvation is not an anti-apoptotic 
mechanism.  
Our data demonstrated that CAF-CDM, but not TIF-CDM, supported MDA-MB-231 cell growth 
under AA starvation, while TIF-CDM had a stronger growth promoting effect under serum 
starvation. It was previously shown that CAF-CDM is denser with more uniform collagen and 
201 
 
FN fibres compared to TIF-CDM. Mechanically, CAF-CDM is stiffer than TIF-CDM, which could 
influence cancer cell proliferation. It was demonstrated that TIF-CDM has an anti-proliferation 
effect on breast cancer cells. Low stiffness of TIF-CDM enhances histone demethylase, 
JMJD1a, translocation from the nucleus to the cytoplasm. Lack of JMJD1a activity 
downregulates Yap/Taz transcription resulting in lower proliferation. CAF-CDM, in contrast, 
does not change Yap/Taz activity and proliferation rate. On CAF-CDM, JMD1a is localized in 
the nucleus resulting in Yap/Taz upregulation and proliferation (Kaukonen et al., 2016). In our 
study, MDA-MB-231 cells under complete media did not show any lower growth rate on TIF-
CDM compared to the plastic. However, it has been shown that under nutrient stress such as 
Glc deficiency, Yap/Taz activity could be inhibited (DeRan et al., 2014). Or, in nutrient limited 
conditions when AA starved cells just have access to Gln and leucine, Yap/Taz enhanced 
transcription of leucine transporter results in higher mTORC1 activity and proliferation 
(Hansen et al., 2015). Therefore, different cell behaviour on TIF-CDM and CAF-CDM in our 
study could be the result of interplay between mechanosensing and metabolism which needs 
to be investigated further. A study demonstrated that in higher density collagen, cells rely 
more on the contribution of Gln to the TCA cycle; whereas, on low density collagen, they 
mostly use Glc to feed the TCA cycle (Morris et al., 2016). It was also shown that collagen 
stiffness enhances the shift of breast cancer cells metabolism from OXPHOs to glycolysis (Mah 
et al., 2018). Taken together, we can hypothesize that the higher growth rate of invasive 
breast cancer cells on CAF-CDM, but not -TIF-CDM, under AA starvation might be because (1) 
cells rely on Glc and glycolysis to produce energy and feed the TCA cycle because of the higher 
stiffness of CAF-CDM, (2) mechanosensing signalling pathways, like Yap/Taz, are upregulated 
because of the mechanical properties of CAF-CDM, resulting in higher proliferation and/or 
mTORC1 activity, or (3) cells can internalise and extract AAs more efficiently from CAF-CDM. 
In contrast, under serum starvation cells had better growth on TIF-CDM compared to CAF-
CDM. Since CAF-CDM provides more favourable environment in terms of mechanosensing 
related signalling pathways resulting in higher proliferation (Kaukonen et al., 2016), we can 
hypothesize that specific structure/composition of TIF-CDM might make the GFs more 
available compared to the CAF-CDM. However, further studies are required to find whether 




7.4.2 Potential mechanisms controlling mTORC1 activity on ECMs under different nutrient 
conditions. 
Our data showed that under AA starvation collagen I and Matrigel, but not laminin, enhanced 
mTORC1 activity compared to the plastic. Even though mTORC1 is enhanced on specific ECMs 
under Glc and AA starvation, all the ECMs promoted cell growth. Thus, mTORC1 activation 
might not be the only reason for the greater growth rate. A study revealed that under EEA 
starvation, albumin scavenging can rescue mTORC1 activity via providing AA (Palm et al., 
2015). Similarly, we also showed that under AA starvation cells can internalize and degrade 
collagen I and Matrigel inside the lysosomes, which might provide AAs leading to the 
activation of mTORC1. Under Glc and serum starvation, however, only the presence of 
collagen I, but not Matrigel or laminin, could rescue mTORC1 activity. All the tested ECMs 
were shown to be internalised and degraded in lysosomes in the absence of Glc, suggesting 
that the mechanism through which collagen I support mTORC1 activation is independent from 
the generation of nutrients in the lysosomes. Similarly, no collagen I intracellular degradation 
was observed under serum starvation, suggesting that collagen I-dependent signalling might 
promote mTORC1 activation. 
In addition to lysosomal degradation, there were other variables that could have affected 
mTORC1 activity. We used different concentrations of the different ECMs (in order to 
polymerise them correctly), and the matrices might have different stiffnesses and 
morphologies. Moreover, different ECM components can interact with different receptors. It 
was previously shown that interaction of stiff ECM with β1 and β3 integrin stabilizes insulin 
receptors (IR) and results in activation of IR/Akt/mTORC1 pathway. It was also shown that 
engagement of integrin with stiff ECM reinforces this pathway, via inhibiting IR lysosomal 
degradation (Bui et al., 2019). It was also demonstrated that inhibition of FAK in mammary 
tumours results in downregulation of Akt/mTORC1 pathway, inducing apoptosis (Paul et al., 
2020). FAK can also activate Ras/Raf/MEK/ERK1/2 pathway, which could enhance mTORC1 
activity via TSC1/2 inhibition. Taken together, our data and previous studies suggest that cells 
might benefit from different mechanisms downstream of cell-ECM interaction to compensate 
for nutrient starvation and induce mTORC1 activation. In addition, these mechanisms might 
vary under different starvation conditions. We can hypothesize that under AA starvation cells 
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might rely on AA extraction while under Glc starvation signalling pathways downstream of 
integrin-FAK activation might result in enhanced mTORC1 activity (Figure 7.1).  
7.4.3 Does the presence of ECM have signalling or metabolic impact? 
It was previously shown that cancer cells rely on scavenging extracellular proteins and 
extracting AAs from them under starvation to maintain their survival and growth (Olivares et 
al., 2017, Commisso et al., 2013). We showed that under both AA and Glc depleted media, 
MDA-MB-231 cells internalize ECM followed by lysosomal degradation. However, inhibition 
of ECM internalisation opposed cell growth under AA starvation, but not Glc starvation. In 
addition, FAK inhibition did not affect cell growth under AA starvation on ECMs while it 
reduced cell growth on Matrigel and CAF-CDM for Glc starved cells. Taken together, since cell 
growth on ECM was dependent on FAK activation but not ECM uptake under Glc depleted 
media, we conclude that ECMs partially rescue cell growth via triggering signalling pathways 
downstream of FAK. It was previously shown that addition of collagen I and IV under Glc 
starvation enhances ERK1/2 signalling pathway to increase survival rate of cancer cells 
(Olivares et al., 2017).  Interaction of β1 integrin with collagen IV triggers FAK ERK1/2 
activation, resulting in higher invasion in pancreatic cancer cells (Sawai et al., 2005). 
Alongside, in fibroblasts, binding of collagen I, but no FN, to α11 integrin increases focal 
adhesion formation, followed by FAK/ERK activation and cell proliferation (Erusappan et al., 
2019). Therefore, it is possible that matrix-specific or integrin isoform-specific adhesion 
signalling promotes cell growth.  Thus, further studies are needed to identify which signalling 
pathways downstream of FAK are being activated in this situation. However, we can 
hypothesize that binding of the ECM to an integrin receptor might activate ERK1/2 signalling, 
resulting in higher resistance to Glc starvation in invasive breast cancer cells. It is also 
important to test whether this solely relies on a signalling pathway downstream integrins 
located in plasma membrane or there is also a contribution from signalling from endosomes, 
since we could detect ECM internalization under Glc starvation. It was previously shown that 
Integrin-ECM located in EEs cause the assembly of FAK-containing signalling complexes on the 
endosomal surface, resulting in anoikis resistance and cell growth (Alanko et al., 2015, Nader 
et al., 2016).  
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The observation that inhibition of ECM internalization adversely affected cells growth under 
AA depleted media while FAK inhibition did not suggest that that ECM has different 
mechanisms of action under AA starvation compared to the Glc depletion.  In parallel, our 
non-targeted metabolomic data revealed that the presence of both collagen I and Matrigel 
significantly changed the cellular metabolite content compared to the plastic in AA starved 
cells. Cells on both collagen I and Matrigel had higher AA content, suggesting that the ECM 
supports breast cancer cell growth by providing an alternative source of AA. Several studies 
showed that scavenging ECPs can upregulate AA content in AA starved cells. It was shown 
that addition of yeast protein to the cells increases AA content which feeds into TCA cycle and 
cause lactate, and pyruvate production (Commisso et al., 2013). It was also revealed that 
addition of albumin to AA starved cancer cells can increase EAAs cellular concentration more 
than the complete media (Kamphorst et al., 2015). In vivo study also observed significantly 
higher AA extracted from heavy carbon labelled albumin in pancreatic cancer cells compared 
to adjacent healthy tissue (Davidson et al., 2017).  
In this study, we used an RNAi screening approach to identify vesicular trafficking regulators 
potentially involved in controlling ECM-dependent cell growth under NEAA starvation. We 
found silencing of three genes, AP3, JIN3 and RIN3, can substantially reduce cell growth under 
starvation on Matrigel and collagen I. These data suggests that these genes are involved in 
ECM trafficking and their silencing might result in lack of ECM internalization and/or 
lysosomal degradation and impede the access of cells to AA from ECMs (Peden et al., 2004, 
Williamson and Donaldson, 2019, Kajiho et al., 2003). In addition, JIN3 could also be important 
in Glc starvation due to its role in adhesion signalling (Takino et al., 2002). 
7.5 Metabolic pathways were enhanced on ECMs in AA starved cells. 
Our non-targeted metabolomic approach showed the upregulation of different metabolic 
pathways under AA starvation in the presence of ECM, including phenylalanine and tyrosine 
metabolism. This leads to the production of fumarate, working as TCA cycle intermediate. Our 
data showed that the downregulation of HPDL, but not HPD, completely opposed ECM-
dependent cell growth under AA starvation, suggesting that HPDL might specifically be 
activated in metabolic pathways downstream of ECM degradation. Further studies are 
required to find whether HPDL activation is related to the presence of ECM. In addition, it will 
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be important to confirm that the lack of growth upon HPDL KD is related to phenylalanine and 
tyrosine metabolism dysfunction, as it was shown that HPDL could also have a role in 
mitochondria metabolic functions (Ghosh et al., 2020). Interestingly, we found other 
metabolic pathways potentially being upregulated on ECM compared to the plastic in AA 
starved cells, including arginine biosynthesis, purine metabolism and valine, leucine, and 
isoleucine biosynthesis. It was previously shown that lack of arginine in the media causes cell 
cycle arrest in invasive breast cancer cells which can be reverted by the re-addition of arginine 
(Chiaviello et al., 2012). Valine, leucine, and isoleucine are all branched chained AAs (BCAAs). 
BCAAs are upregulated in both plasma and tissue of breast cancer patients. Catabolism of 
BCAAs in breast cancer cells is mediated by branched-chain AA transaminase 1 (BCAT1). 
BCAT1 expression is elevated in breast cancer cells and has a role in enhancing mitochondria 
biogenesis, ATP production and mTORC1 activation, resulting in cell growth and colony 
formation (Zhang and Han, 2017). In terms of purine metabolism, in hepatocellular carcinoma 
(HCC) enhanced purine metabolism was shown in vitro, in mouse models and patient tissues. 
Purine metabolism is linked to tumour grade and prognosis while KD of the enzymes 
participating in this process reduce cell proliferation and tumour burden (Chong et al., 2020). 
Taken together, upregulation of all these metabolic pathways on ECM could potentially assist 
cell growth. Further studies are needed to define how the presence of ECM enhances these 
metabolic pathways and whether it is related to AA starvation or not.  
These data raise the possibility that ECM proteins could provide AA for AA starved invasive 
breast cancer cells to promote cell proliferation and energy production by upregulating 
metabolic pathways that could also feed TCA cycle. It has been previously shown that the 
level of nutrients that tumour’s cells have access to is different from normal tissues. Cells 
receive the nutrients via the vasculature that releases the nutrients from the circulating 
system into the interstitial area of tissues. Nutrient and waste exchange happens between 
the interstitial fluid (IF) and capillaries and lymph system (Sullivan et al., 2019). However, 
tumour blood vessels are highly branched, leaky, enlarged with inconsistent blood flow (Nagy 
et al., 2010, Baluk et al., 2005). Therefore, the nutrient content of the IF is different from the 
plasma. In vivo study of PDAC and lung tumours in mice showed that nutrient composition of 
IF varies by the tumour location, tissue of origin and diet. The nutrients that tumour cells rely 
on are mostly depleted in IF compared to the plasma. For instance, in PDAC the amount of 
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Glc, arginine, tryptophan and cysteine were lower in IF compared to the plasma (Sullivan et 
al., 2019). Thus, it is essential to know what metabolites cancer cells rely on and whether it is 
possible to reduce their access to them via changing the diet. However, focusing on the diet 
alone might not be enough. In our study we showed that even under complete AA depletion, 
invasive breast cancer cells had higher phenylalanine and tyrosine metabolism on ECM 
compared to the plastic. It was previously demonstrated that phenylalanine and tyrosine 
metabolism is higher in invasive breast cancer tissue compared to the non-invasive and 
normal mammary epithelial cells suggesting that they rely on this metabolic pathway for AA 
or energy production (More et al., 2018). Taken together, this suggests that even in low AA 
levels in IF, cancer cells can rely on alternative sources of AA like ECM. Therefore, diet 
restriction might not be a viable approach to induce tumour starvation. Since it is unlikely that 
in vivo cells are under full Glc or AA starvation, we used diluted Plasmax media to reduce up 
to 75% the accessibility of all the nutrients compared to the plasma. The presence of ECM 
partially rescued invasive breast cancer cell growth under diluted Plasmax, suggesting that 
ECM can promote cell growth under starvation in a more physiological environment as well. 
However, further studies are needed to determine whether cell growth is ECM 
internalisation- or signalling dependent. In addition, HPD and HPDL KD on collagen I Under 
Plasmax (data not shown) showed similar effect as in AA starved cells implying that they might 
rely on common pathways to compensate their growth. Therefore, in addition to the level of 
nutrients in IF, plasma, or diet, it is very important to consider accessibility of cells to ECM 
while metabolic conditions of tumours are assessed.  
7.6 Conclusion and future directions 
Overall, the data presented in this thesis highlights that under different starvation conditions, 
invasive breast cancer cells can benefit from the presence of ECM. However, the ECM 
mechanism of action is different depending on the starvation condition. In this thesis we 
showed that under Glc starvation, cells have higher survival rate on ECM compared to plastic, 
which might be the result of signalling pathways being triggered downstream of ECM-integrin 
binding and FAK activation. In contrast, under AA starvation, cells need ECM uptake to 
enhance their proliferation. We showed that ECM internalization is followed by lysosomal 
degradation and AA extraction, eventually feeding into the TCA cycle. Several studies revealed 
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that normal tissue stroma is transformed into a very dense and fibrotic stroma in breast (Kim 
et al., 2014), lung, pancreatic (Neesse et al., 2015) and colon (Brauchle et al., 2018) tumours, 
and this correlates with cancer formation and progression. Therefore, the findings of this 
study could potentially be generalized to other highly fibrotic cancers, although further 
studies are needed.  
This study has raised many questions about the mechanism of cell-ECM interaction under 
starvation which are interesting for future investigation. Here is a summary of the main 
questions which could be addressed in the future: 
● Elucidate the mechanism through which TIF-CDM partially induces cell growth under 
serum starvation. Is it because the CDM works as a GF reservoir or does ECM-integrin 
interaction trigger signalling pathways that induce growth/survival?  
● Characterise the signalling pathway(s) downstream of FAK activation under Glc 
starvation on ECM and define whether this signalling pathway occurs via activation of 
integrins at plasma membrane or on endosomes.  
● Perform phenylalanine and tyrosine metabolic tracing to assess whether they are fed 
into TCA cycle under AA starvation on ECM. 
● Compare activity of phenylalanine and tyrosine metabolism pathway between 
invasive breast cancer cells and normal mammary epithelial cells. 
● Define the molecular mechanisms controlling ECM internalization in AA starved cells. 
● Use the Seahorse XF technique to define the metabolic status of cells on different 
ECM and starvation conditions. 
● Expand this study to include different cancer cell lines, to establish whether the ability 
to use ECM to support cell growth under starvation is a common feature of different 
cancer types.  
This study reinforces the need for a better understanding of the impact of the ECM on breast 
cancer cell growth/survival under different starvation conditions. It strengthens the idea that 
during the study of cancer cell metabolism, the effect of the TME and especially the ECM 
should be considered. I hope the findings in this thesis will be beneficial for developing 
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